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SUMMARY 
A large number of protein-based medicines have successfully improved the treatment and quality life 
of patients in diverse therapeutic areas (1). Due to the typically chronic and frequent administration 
regimens, in many cases the subcutaneous route of administration is preferred. This modality 
facilitates self-administration and prevents the necessity of professional health assistance. However, as 
the maximum volume that the area between skin and muscle can support is < 2 mL, highly 
concentrated formulations have to be developed in order to reach the required large doses of several 
mg/mL/Kg-bodyweight (2). From a pharmaceutical technology perspective, the main associated 
implications are high viscosity (3, 4) and increased protein aggregation tendency (5, 6) that typically 
characterize protein formulations.  
Both aspects represent new challenges to the pharmaceutical development field (7, 8). For example, 
despite the proven safety and efficacy of biotechnological products, some publications have suggested 
that the particulate matter present in liquid formulations has immunogenic properties (9-11). Thus, 
there is an increasing interest to research and characterize protein particles beyond the limits of current 
USP applications of Chapter <787> (12) had appeared in the recent years. A number of analytical 
techniques have emerged for the characterization of particles size between the upper size limit of 
chromatography techniques and the lower size limit of the compendial light obscuration method (6, 
13-16). Although this represents an instrumentation achievement, the analytical performance of such 
tools is unknown.  
This present Doctoral research aims to evaluate the applicability of the new techniques in the analysis 
of biotechnological products including deeper understanding of their principles as well as the 
comparative evaluation with the compendial light obscuration method. 
As a starting point, stability study was performed using a representative Biotech product (Chapter 1). 
Particle numbers were followed using a broad analytical toolbox that covered particle sizes from nano 
to micrometers. This research revealed a series of inconsistencies not only between the different 
instruments but also between the different time points. Whereas some instruments showed no 
significant changes over the 13 week duration of the study, other methods reported a decrease in the 
number of particles even when a stress condition was applied. These results clearly exemplified the 
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complexity of particle characterization. Whether these trends were meaningful or not, or if they were 
just artefacts resulting from sample unsuitability, becomes a main concern for results interpretation. 
Hence, a detailed study on the analytical performance of the instruments was undertaken. Although 
certain information was available from vendor suppliers, no information was found about precision 
and accuracy assessment in the frame of Biotherapeutics. It was also clear that different factors might 
be involved as the results from the stability study did not reproduce vendor information.  
The first part related to precision is studied in Chapter 1, where repeatability and intermediate 
precision experiments are presented. The use of both, protein particle suspension and polystyrene 
beads – the later typically used as calibration standard material, - revealed interesting differences 
inherent to the nature of the sample. Whereas measurements of standard solutions representing a size-
monodisperse system showed good precision, the performance of the instrument when measuring 
protein polydisperse samples showed deficiencies for particle sizes that were underrepresented in the 
sample. More importantly, the amount of sample measured was determined to be a critical factor for 
the precision performance of the methods. The smaller the sample volume to analyse, the less precise 
the measurement was. This important extrapolation factor effect appeared to influence mainly the 
submicrometer methods, thus limiting their applicability. 
The second part of the instrument performance evaluation was investigated in Chapter 2. It included 
accuracy and linearity studies. In this part of the work, not only the standards and protein particles 
were included, but also different morphologies of such protein particles. This approach succeed in 
showing that besides sample composition, sample morphology can influence method accuracy. 
Interestingly, as well as in the precision study, the relative size composition of the samples was found 
to impact the counting accuracy. Three categories were identified: i) good accuracy irrespectively of 
particle size, ii) better accuracy for those particles sizes that were mainly represented and iii) poor 
accuracy. In terms of accuracy sizing, a general overestimation in the lower size limit of the 
instruments was found. In contrast, an underestimation occurred towards the upper size limit. 
Similarly to precision, the linearity assessment of submicrometer methods had greater difficulty in 
providing accurate measurements as compared to the micrometer ones. Chapter 2 also provides a 
detailed analysis on the instrument-to-instrument correlation in those cases on which a size overlap 
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exist. The particle morphology and concentration variables were found to be the most important 
factors for obtaining consistent particle numbers among different methods at a given size. An extra 
value of this experimental approach is that it proved to be effective in defining practical limits for 
particle quantification in a product and instrument specific mode.  
Together, Chapter 1 and Chapter 2 provide a highly integrative understanding of the strengths and 
weaknesses of the available techniques for protein particle characterization in Biotechnological 
products. The results presented in these chapters suggest that the newer methodologies still require 
more development in order to be considered reliable analytical techniques. This knowledge was then 
applied to generate tools that could improve the actual status of the analytical instruments. 
Instrumental, operational and data analysis approaches are described in Chapters 3 to 4.  
Light obscuration method is the focus of Chapter 3. This particle counting method has been part of 
the US Pharmacopeia since 1985 (USP XXI) and together with the membrane method is the only one 
stipulated and harmonized in all parenteral-related legislation. However, with the emergence of 
Biotechnological products, some shortcomings of the technique had been exposed. For example, 
protein particles are in general highly translucency and irregular in shape. For the light blockage 
principle, this represents potential misleading sizing assessments, especially for particles in the lower 
size range of the technique (1-2 µm). In order to overcome this scenario, an innovative instrumental 
modification was evaluated in Chapter 3. Whereas the standard principle is based on the measurement 
of the height of the voltage signal; this instrumental approach examines on the benefits of measuring 
the width of the peak instead. The new method was named Time Resolved Light Obscuration and it 
demonstrated improvements in the accuracy of the technique when measuring highly translucent 
protein particles around 1-2 µm. 
In Chapter 4 an empirical approach was applied to the study of the performance of the Nano Tracking 
Analysis technique. From Chapters 1 and 2, this technique appeared to be the least robust and the most 
affected by user-defined settings. Hence a detailed study on the variables that can impact the 
measurements was conducted. Both, sample- and instrument-related aspects were considered. For 
some samples the measurement was not possible due to the high presence of scattering oligomeric 
species. The effect of dilution, a common practice to reduce that noise signal, together with the study 
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of various combinations of camera levels showed the broadness of the possible results. Such high 
variability was worse in the case of the concentration assessments. This suggested that the Nano 
Tracking Technology is more suited for size distribution assessments. 
Altogether through the findings outlined in the present Doctoral thesis a better understanding of the 
particle characterization techniques can be obtained. An additional value of the research is that it 
considers realistic (sample types and concentration burdens) and highly integrative (complete and 
broad set of analytical tools included) scenarios in the frame of Pharmaceutical Industry. This allowed 
for the detection of inherent instrument-to-sample incompatibilities that constrain the applicability of 
the techniques to rather narrow size and concentration ranges. In some cases such ranges were not 
relevant considering the likely particle burden of Biotherapeutic products. Sampling efficiency was 
found to be the most important factor affecting instrument performance. In terms of precision, this was 
reflected mainly in the case of submicron methods due to the tiny samples volumes that are measured. 
In terms of accuracy, the same effect was encountered for the least represented sizes within the 
sample. Furthermore, the collected research findings pointed to the necessity of sample-specific 
method development and, in most cases, the severe immaturity of the techniques as demonstrated by 
the high variability of the results. Whereas research tasks can profoundly benefit from these new 
methodologies due to their high flexibility and new capabilities, apart from the compendial Light 
Obscuration technique any other should remain as supportive tool. Nevertheless, their performance 
can be improved by applying the concepts here described. 
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I INTRODUCTION 
“Biotherapeutic” is a term that encompasses therapeutic proteins (medicinal products, therapeutics, 
prophylactics and in vivo diagnostics) with active agents inherently biological in nature and 
manufactured using biotechnology (1). The emergence of this type of medicinal products dates to 
1970’s when the increasing demand of insulin for the treatment of diabetes urged scientists to look for 
other sources of production rather than animal models (2). As a result, DNA recombinant technologies 
emerged, allowing the successful expression of human insulin in bacteria models in laboratory 
conditions followed by commercial scale and industry production (3, 4). Nowadays not only the 
treatment of diabetes and other endocrine diseases benefit from this technology but also inflammatory, 
immune, cardiovascular, infectious and respiratory diseases as well as oncology (5-7) (see Table I.a). 
The polymeric nature and highly ordered structure that are characteristic properties of proteins make 
their formulation much more challenging than that of (small) chemically synthetized molecules. 
Several strategies can be applied to improve protein chemical stability e.g. use of additives like salts,  
 
Table I.a Examples of Biopharmaceuticals approved during 2013-2014 in Europe and United States of 
America. Extracted from reference (1) 
Category  Product  Company  Therapeutic indication 
Recombinant 
blood factors 
 Nuwiq  Octapharma AB   Hemophilia A 
 Alprolix  Biogen Idec  Hemophilia B 
 Jetrea  ThromboGenics   Symptomatic vitreomacular adhesion 
Recombinant 
hormones 
 Afrezza  MannKind   Diabetes mellitus 
 Tresiba  Novo Nordisk  Diabetes 
 Somatropin  BioPartners   Growth hormone deficiency 
 Ovaleap  Teva Pharma   Infertility/subfertility 
 Elonva  Merck Sharp Dohme   Controlled ovarian stimulation 
 Myalept  AstraZeneca   Some forms of lipodystrophy 
 Grastofil  Apotex   Neutropenia 
 Lonquex  Teva Pharmaceuticals   Neutropenia 
 Plegridy  Biogen Idec   Multiple sclerosis 
Recombinant 
vaccines 
 Bexsero  Novartis  Against invasive meningococcal disease 
 Flublok  Protein Sciences   Against influenza 
 Provenge  Dendreon   Prostate cancer 
Monoclonal 
antibody based 
products 
 Sylvant  Janssen Biotech   Multicentric Castleman’s disease 
 Cyramza  Eli Lilly  Gastric cancer 
 Gazyva  Roche (Genentech)/ Roche  Chronic lymphocytic leukemia 
 Kadcyla  Roche (Genentech)/ Roche  Breast cancer 
 Perjeta  Roche (Genentech)/ Roche  Breast cancer 
 Simponi Aria  Janssen Biotech  Rheumatoid arthritis 
Recombinant 
enzymes 
 Vimizim  BioMarin   Morquio A síndrome 
 Krystexxa  Savient   Gout 
Gene therapy  Kynamro  Sanofi/Isis   Familial hypercholesterolemia 
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polyalcohol compounds or detergents; the replacement of specific residues of the primary protein 
sequence to remove reactive sites or chemical modifications to prevent their reactivity (8-11). On the 
other hand, the physical stability can be enhanced by stabilizing the native conformation of the protein 
e.g. using certain sugars (12-14) or by reducing the molecular collisions and limiting protein mobility 
through the lyophilisation process (15, 16). However, both, chemical (17) and physical (18) 
denaturation pathways (see Table I.b) can take place at different stages of the production procedure 
starting from cell culture up to final container filling or even upon storage conditions (19). 
Additionally, the poor bioavailability due to the many degradation pathways that proteins can 
undertake (20, 21) triggers the necessity of intravenous or subcutaneous administration routes as well 
 
Table I.b Examples of instabilities that can take place in biotherapeutics. Extracted from reference (2) 
 
 
Definition 
 
Causes 
 
Type 
 
Description 
 
Examples of 
consequences 
C
h
em
ic
a
l 
in
st
a
b
il
it
y
 
 
Modification 
or alteration 
of the 
aminoacid 
residues 
 
Protein 
intrinsic 
reactivity 
 
Deamidation 
 
Hydrolysis  of the 
side chain amide 
linkage of Gnl or 
Asn to form a free 
carboxylic acid 
 
Loss of biological 
activity (3) 
possible 
participation in 
immunogenicity 
(4) 
   
Oxidation  
 
Side chains of 
aromatic 
aminoacids to 
radiolysis in the 
presence 
of oxygen. 
 
Generation of 
micron-sized 
aggregates, 
secondary 
structure changes 
and  immune 
resistivity 
breakage (5, 6) 
   
Proteolisys 
 
Intramolecular 
catalysis by a 
carboxyl group of 
the Asp residue 
 
Loss of enzymatic 
activity (7) 
   
Disulfide 
scrambling  
Formation of 
sulfhydril groups 
and disulfide bons 
using Cys residues 
 
Covalent 
aggregation via 
cross linking (8) 
   
Racemization / 
Beta elimination  
Deprotonation of 
the hydrogen of 
the alfa carbon 
 
Aggregation 
susceptibility upon 
freezing (9) 
P
h
y
si
ca
l 
in
st
a
b
il
it
y
 
 
Modification 
or alteration 
of the native 
spatial 
arrangement 
of the 
protein 
 
Environmental 
factors like 
e.g.temperature
; pH; ionic 
strength; air 
exposure; 
surface 
interactions 
 
Adsorption 
 
Adhesion to 
biomaterials of 
primary containers  
 
Fogging 
phenomena after 
lyophilization (10)  
   
Aggregation 
 
Accumulation of 
proteins in a non-
native state 
forming 
agglomerates 
 
Possible 
participation in 
immunogenicity 
(11) 
I INTRODUCTION 3 
1 
APPLICATION OF NOVEL TECHNIQUES FOR CHARACTERIZATION OF SUB-VISIBLE AND SUB-MICRON 
PARTICLES IN BIOPHARMACEUTICAL PREPARATIONS 
 
as high concentrated formulations (e.g. Cimzia, Pharma/UCB is formulated at 200 mg/mL). This 
represents another possible cause of instability as protein-protein interactions are enhanced, likely 
triggering the formation of protein aggregates and particles (22).  
On the other hand, in cases where sub cutaneous administration is preferred, a pre-filled syringe 
primary container is typically used (23, 24). The silicon oil layer in the internal face of the glass barrel 
can migrate into solution adding a second particulate population (25-27). Furthermore, it has been 
proposed those oil droplets likely serve as nucleation template and initiate protein aggregation 
processes (28-31). For the device development area, this is an active topic of research and some efforts 
have been made to produce silicon-oil free prefillable syringe systems demonstrating lower particle 
counts in solutions (32). 
 
Table I.c Classification of protein aggregates Summarized/modified from reference (12) 
Category  Classification  Description 
Size 
 Monomer  Smallest existent and/or functional unit 
 
Aggregate  
> 100 µm 
1-100 µm 
100 - 1000 nm 
< 100 nm 
 
Oligomer  
Any aggregate that contains more than one 
monomeric unit in a non-native state 
Reversibility 
 
Reversible  
Aggregates that exist in equilibrium with 
the native monomeric subunit. Might be 
accompanied with the time scale of the 
observation  
 
Dissociable  
Recovery of the monomeric specie is 
possible applying certain conditions 
 Irreversible  Aggregation state is not dissociable 
Conformation 
 
Native  
Conformation of non-aggregated active 
protein in which the protein originates 
 
Partially unfolded  
Changes can be detected but native 
structure still remains 
 
Misfolded  
Different three dimensional conformation 
as the native protein 
 
Unfolded  
Protein condition after strong denaturation 
procedure e.g. guanidine 6M 
 
Inherently disordered  
No defined three dimensional is associated 
with the functionality of the protein 
 Amyloid  Cross- β diffraction pattern is exhibit 
Chemical 
modification 
 
Cross linked  
Formation of covalent non-reducible new 
bonds intra o intermolecularly 
 
Site directed  
Modification of specific residues on the 
primary sequence 
Morphology 
 
Physical  
Aspect ratio, diameter, perimeter, surface 
roughness etc. 
 Optical   Refractive index and transparency/intensity 
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Protein particles can be classified as intrinsic or extrinsic. Intrinsic if their source can be explained as 
naturally formed through any mechanism related with the nature of the formulated protein itself and 
described in Table I.b. Extrinsic when it is non-related with the product or its production process. A 
more detailed classification of particles considers aspects like size; reversibility; conformation; 
chemical modification and morphology (see Table I.c). The previously described possible causes and 
sources of protein instability and particles explain why the presence of particulate matter in parenteral 
pharmaceutical formulations can be considered a common finding (33). This represents an important 
quality control attribute. Thus, not only the formulation strategies had to be adapted as already 
mentioned but the compendial and regulatory aspects around parenteral products as well.  
The historical development of the topic can be appreciated by following the evolution of the USP 
editions (see Table I.d). Starting in 1936, edition 11th established the concept of clearness for 
parenteral formulations. Later, edition 14th in 1946 changed from clearness to a substantially free 
definition. More specificity was included in 1984 when instrumentation developments helped to 
establish quantitative limits for those particles that could not be detected by the naked eyes. In that 
edition light obscuration and membrane methods were defined as compendial for the evaluation of 
particulate matter of sizes > 10 µm (limit 6000 particles/mL) and > 25 µm (limit 600 particles/mL). At  
 
Table I.d Historical development of particle-related regulations in parenteral formulations 
Extracted from reference (13) 
Period  Events 
Cognitive 
 1905 Parenteral solutions are included as compendial drug 
 
1936 Parenterals must have clearness and be “substantially free” of 
precipitates; cloudiness or turbidity 
Latent 
 1946 Frist medical events related to particles are reported 
 1949 Individual visual inspection is established 
 1965 Development of the first type of particulate standard in Austria 
Definitive 
 1966 First symposium on safety of large volume parenterals 
 1975 Membrane test is stablished for large volume injections 
 
1984 Membrane microscopic and light obscuration methods are defined for 
large and small volume parenterals, respectively 
 1985 A method for small volume parenterals is added 
Evaluative 
 1995 Light obscuration is the preferred method over membrane microscopy 
 2004 Ophthalmic solutions are included in a special chapter 
Harmonization 
 2007 USP, EP and JP agreement on method definitions and limits 
 
2014 Particulate matter in therapeutic protein injections is included in a 
special chapter. 
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present (mostly triggered by technical developments), the status of this topic is facing a new era. The 
USP chapter <788> for Particulate Matter in Injections establishes the quality control criteria that 
parenteral products should meet. Given the special characteristics of biotechnological products, this 
chapter had to be adjusted and special recommendations for sample preparation are established in 
Chapter <787>. Furthermore, discussions about the necessity of monitoring sub visible particles ≤ 
10µm over the already well standardized control of particles >10 and >25 µm (USP <788>) are taking 
place (34, 33). Such motivation is based on the alleged immunogenic properties of small particulate 
matter. As consequence, in addition to the traditionally used and compendial light obscuration method, 
many other techniques have been emerged or been re-adapted. The aim is to fulfil the necessity of a 
more complete size-wise particle characterization of biotechnological products. It is then of the highest 
importance to build a sound base knowledge of such analytical tools.  
This area of instrumentation development has become very active and in a relatively short period of 
time, new instruments and/or several new versions of them have appeared on the market. Instruments 
can be grouped in submicron and micron categories depending on the particle size range on which 
they can be used for characterization. For the assessment of particles between 100-1000 nm size 
(submicron range), Nanoparticle Tracking Analysis, (NTA) and Resonant Mass Measurement (RMM) 
instruments can be used. For the assessment of particles between 1-100 µm size (micron range), 
Coulter Counter (CC); Flow Microscopy (Micro Flow imaging (MFI) and Flow Cam (FC)) and the 
compendial Light Obscuration (HIAC) are available. In the following paragraphs, each methodology 
is described together with some pharmaceutical applications. 
NTA is a technique which combines laser light scattering microscopy and a video imaging system for 
real time sizing of particles suspended in liquids. This technique is based on the video recording of the 
light scattered by particles under Brownian motion as they interact with a laser beam that illuminates a  
sample area of approximately 8x10-8 cm3. Such movement is possible to track using the charged 
couple device principle connected to a microscope (20x amplification) and a high speed camera (30 
frames per second) combination. This allows for individual and simultaneous visualization of particles 
that can be analysed using the instrument software. Some user defined parameters are needed as 
follows: i) threshold value for a particle to be differentiated from the background signal ii) pixel area 
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to be sum around a particle centre iii) probabilistic distance that a particle can travel from one frame to 
another and iv) number of continuous frames on which a given particle can be encountered. The two 
dimensional distance that each particle moves allows for the calculation of the diffusion coefficient of 
the particles. Finally the hydrodynamic diameter is calculated by the Stokes-Einstein equation. NTA 
has general size capabilities from 30 to 1000 nm, but refractive index properties can tighten this range. 
In terms of concentration, 10^7 to 10^9 particles per mL is recommended by the vendor. In 
comparison with similar methodologies, also based on light scattering NTA offers some advantages. 
For example, NTA has less interference of larger particles than can possible obscure the intensity 
fluctuations of smaller particles. Hence, the image analysis offers better determinations when z-axis 
collocation occurs as compared with the analysis of time-dependent fluctuations. However, other 
factors related with inter-particle distance and to two dimensional dynamics become important in 
avoiding erroneous particle sizing (35). 
In the RMM instrument, particles move in their native suspensions through a Micro Electro 
Mechanical Systems fabricated microfluidic channel that resonates mechanically. The presence of a 
particle adds to the total mass and shifts the sensor resonant frequency. The shifts are measured as 
each individual particle passes through the sensor. The RMM device offers an excellent tool for 
differentiation between protein and silicon population. This instrument is based on the differential 
vibration frequency that a resonator will present due the different densities of silicon oil and protein 
particles with respect to the liquid in which they are immersed.  
The CC instrument relies on the Electrical Sensing Zone principle. The device is equipped with a glass 
tube with a known diameter aperture which is then immersed in the conductive sample. A current is 
applied using electrodes placed inside and outside of the tube. A particle passing through the aperture 
causes a short-term increase in resistance. The magnitude of the resistance change depends on the 
volume of the particle. The particle size (calculated by volume) and particle counts are obtained based 
on the change in the electrical resistance.  
In the FI techniques bright-field images are captured in successive frames as a continuous sample 
stream passes through a flow cell positioned in the field of view of a microscopic system. The digital 
images of the particles present in the sample are processed by image morphology analysis software 
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that allows their quantification in size and count. Micro flow imaging allows not only enumerating the 
subvisible particles present in the sample, but also a visual examination of the images of all the 
captured particles as well as identification of contaminants like silicone oil droplets, for example. 
Finally, LO bases the determination of particle size and counts on the blockage of a constant source of 
light and the measurement of the consequent drop in voltage. Such response is caused by particles 
suspended in liquids as they go through a channel of defined diameter at a constant flow rate. Data 
analysis implies the comparison of the registered drop with a preloaded calibration curve built with 
particles of certified size. Interpolation allows the translation of voltage changes into particle size. The 
number of signals recorded is related to the user-defined analysed volume to determine the cumulative 
particle concentration per millilitre. 
The previously described analytical tool box is a complex one with a rather new set of technologies 
that can support the characterization of subvisible and submicron particles. Partial and limited attempts 
have been made to characterize and understand the number of factors governing the analytical 
performance of all those techniques (36-58). Some interesting findings and exciting applications as 
well as some limitations and shortcomings have been already reported (59-61). However, some aspects 
require further research, especially in terms of basic analytical evaluation and guidelines for method 
development. Thus, the study and thorough understanding of how they work and the factors that affect 
their functionality constitutes the main objective of this dissertation. 
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II SCOPE 
The present Doctoral thesis was motivated by the increasing interest in subvisible and submicron 
protein particles present in biotechnological products. In view of the potential biological consequences 
of such particulate matter, especial attention was given to the analytical instrumentation used to 
characterize protein particles.  More specifically, this dissertation was focused on those that measure 
particles suspended in liquids. Four main groups were included: light obscuration (HIAC and 
SYRINGE); flow imaging (Micro Flow Imaging and Flow Cam); electro zone sensing (Coulter 
Counter) and nano-range technologies (Nano Tracking Analysis and Resonant Mass Measurement).  
Aiming to increase our knowledge about those new analytical tools the present dissertation was 
divided in 4 chapters. Broadly, in the first two chapters the aim was to present and identify general 
factors that govern instrument performance. In the last 2 chapters and using that experience, the focus 
was on the areas of opportunity in order to offer analytical tools that improve the current status of the 
subvisible particle analysis.  
It was the goal of Chapter 1 to expose the unclear aspects and main questions about the analytical 
toolbox performance. To achieve that objective an integrative and realistic stability study with a low 
concentrated biopharmaceutical product was conducted. Such a highly challenging configuration was 
chosen to illustrate a worst case scenario and hence allowed the identification of general instrumental-
related factors.  
The results of that stability study triggered the interest in a more profound research on the basics of 
instruments analytical operation. Chapter 1 focused on the precision and Chapter 2 on the accuracy 
and linearity performance. In each case, the fundament of each method was challenged using particle 
models in concentration, size, morphology and nature of interest for the Pharmaceutical Industry.  
Due to the fact that each sample might develop its own experimental method guidelines, to provide 
exact numbers for quantitation limits was not in the scope of this dissertation.  However, despite the 
individual instruments’ differences, it was the aim of Chapter 1 and Chapter 2 to establish some 
generalities to rationalize the strengths and weaknesses of the techniques.  
Once the specific effects that directly impact the analytical performance were identified,  the goal of 
Chapter 3 and Chapter 4 was to propose instrument and method improvements. 
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Since light obscuration technique is the most established one as indicated in the Pharmacopoeia, it was 
the aim of Chapter 3 to improve the applicability of the technique to the exigencies of 
Biotechnological samples. More precisely, by means of changing the measuring mode of the light 
obscuration sensor, the aims were to lower the detection limit to particles < 1 µm and to improve the 
detection of highly translucent particles.  
Finally, in Chapter 4 the aim was to identify and rationalize the artefacts that can affect the Nano 
Tracking-based technique and provide guidance for the development of product-specific analytical 
methods and for the proper results interpretation.  
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1.1 ABSTRACT  
The current study was performed to assess the precision of the principal subvisible 
particle measurement methods available today. Special attention was given to 
identifying the sources of error and the factors governing analytical performance. 
The performance of individual techniques was evaluated using a commercial 
biologic drug product in a prefilled syringe container. In control experiments, latex 
spheres were used as standards and instrument calibration suspensions. The results 
reported in this manuscript clearly demonstrated that the particle measurement 
techniques operating in the submicrometer range have much lower precision than 
the micrometer size-range methods. It was established that the main factor 
governing the relatively poor precision of submicrometer methods in general and 
inherently, is their low sampling volume and the corresponding large extrapolation 
factors for calculating final results. The variety of new methods for submicrometer 
particle analysis may in the future support product characterization; however, the 
performance of the existing methods does not yet allow for their use in routine 
practice and quality control 
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1.2 INTRODUCTION 
Due to concerns related to the hypothesis that proteinaceous particles may act as potential immune 
activators, significant attention has been focused on the protein particles sized between ca. 1 µm and 
100 µm, the “subvisible particles” (1-4). The high interest triggered by this topic has resulted in a 
number of scientific publications (5-9). As a result from the intense focus on subvisible particles over 
the last decade, several new analytical methods were developed and introduced in industry. At present, 
the “gold standard” for subvisible particle analysis is the light obscuration method. This method is 
often combined with additional characterization methods utilizing a different measurement principle, 
offering the possibility to extend the size range of analysed particles from 10 µm down to 30 nm. 
Thus, the apparent gap of measurable particle sizes (i.e. the “submicron gap”) can be closed (10, 11).  
The different measurement principles of the newly emerged methods can be summarized as follows 
(see Table 1.1): Nanoparticle Tracking Analysis (NTA) is a technique, which combines laser light 
scattering microscopy and a video imaging system for sizing and counting of particles. After recording 
a video of the sample, the NTA software identifies and tracks the particles which are moving under 
Brownian motion. The rate of diffusion of each individual particle captured on film is related to its size 
according to a modified 2-dimensional Stokes–Einstein equation. In the Resonant Mass Measurement 
(RMM) technique, particles in suspensions are pumped through a microfluidic channel that resonates 
mechanically. The presence of a particle in the resonator channel adds to the total mass and therefore 
shifts the sensor resonant frequency. These shifts are recorded as each individual particle passes 
through the sensor. Density differences between the particles and the fluid matrix, allows for particle 
categorization in positive or negative buoyant populations. The Coulter Counter (CC) instrument relies 
on the Electrical Sensing Zone principle. The device is equipped with a glass tube with an aperture of 
given diameter, which is immersed in the conductive sample. A current is applied between electrodes 
placed inside and outside of the tube. A particle passing through the aperture causes a short-term 
increase in resistance. The magnitude of the resistance change depends on the volume of the particle. 
Thus, the particle size (calculated by volume) and particle counts are derived based on a change in 
electrical resistance. In the micro flow imaging technique (MFI), bright-field images are captured in 
successive frames as a continuous sample stream passes through a flow cell positioned in the field of 
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Table 1.1 Instruments in scope  
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Tracking of Brownian 
motion of individual 
particles using a 
microscope and a video 
camera 
Hypothetical hard spheres that diffuse at the same speed of the tracked particles are 
assumed. The hydrodynamic diameter is obtained according to the 2D-modified Stokes-
Einstein equation. For count determinations the averaged particle abundance (average 
number of particles per frame) is divided by the estimated volume of the sample chamber 
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̴ 20-70 centers 
per frame 
R
es
o
n
a
n
t 
m
a
ss
 
m
ea
su
re
m
en
ts
. 
R
M
M
 Changes in frequency due 
to added mass as particles  
go through a micro 
resonator channel 
Shifts in frequency with respect to sensor baseline resonance are converted into buoyant 
mass using the sensor-specific sensitivity. Sensitivity is obtained using size standards as 
calibrators. Knowing the fluid and particle density, buoyant mass is converted into dry 
mass. Finally, assuming a sphere shape, particle diameter is calculated. Concentration is 
obtained relating the number of events (particles) registered with the volume of sample 
dispensed 
                     
< 8x106 
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Changes in resistance due 
to volume displacement as 
particles immersed in 
conductive solutions cross 
an aperture in a glass tube 
The impedance pulses generated as particles are pumped through an orifice in a glass tube 
are individually analyzed by the instrument electronic components. As the electrical 
current is constrained in the aperture orifice each pulse is directly proportional to the 
volume that the particle displaced and its size. Concentration is obtained relating the 
number of events (particles) registered with the volume of sample dispensed 
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< 5% 
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Viewing of single 
particles passing through a 
flow cell and are 
photographed with a high 
speed camera 
Digital images are analyzed by the instrument software. Following background 
comparison, intensity values are assigned to each activated pixel. Adjoining pixels below 
96% of the maximum brightness is grouped as particles. Internal algorithms are used to 
generate morphological descriptors per each particle. Concentration is obtained relating 
the number of events (particles) registered with the volume of sample dispensed 
                        
 < 9x104 
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 Drop in current due to the 
amount of light blocked as 
particles  cross the light 
source 
A calibration curve size-voltage is prebuild using calibration size standards. Particle size is 
obtained by direct interpolation in the calibration curve of the voltage recorded when a 
particle blocks the sensor. Concentration is obtained relating the number of events 
(particles) registered with the volume of sample dispensed 
                        
< 1.8x104 
* Size bins used in this study are presented in a discontinuous scale. Instrument actual measuring size ranges might be broader. 
** Maximum values as recommended for the supplier. 
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view of an optical system with a 5x magnification objective. The digital images of the particles present 
in the sample are processed based on image morphology and yields information on particle size and 
count. It should be noted that microscopic imaging supports morphological characterization of 
particles. Thus, silicone oil droplets and other particulate contaminants can be identified and excluded 
from protein analysis. Finally, the Light Obscuration (LO) method measures the drop in voltage 
consequence of the blockage of a constant source of light illuminating as particles pass through the 
flow-cell.  
Each individual method from the diverse collection described above utilizes a different measuring 
principle and therefore – presents its unique challenges. Although the recent literature provides a good 
overview of the latest analytical developments in the field of particle analysis (12-19), a systematic 
critical assessment and comparison of the individual methods is still missing. In particular, a detailed 
comparative evaluation of the analytical performance of the individual methods and most importantly 
– a qualitative understanding of the sources of error (both random and systematic) of these methods 
are not yet available.  
The aim of the present study was to conduct detailed assessment of analytical performance of particle 
measurement techniques currently available with respect to one of the main analytical performance 
attributes – method precision (including repeatability and intermediate precision). The most widely 
used analytical tools (Table 1.1) for subvisible particle measurements in liquids were evaluated in 
terms of precision and limitations leading to deviations between typically used (and NIST certified) 
polystyrene standard calibration samples and actual drug product samples. Microscopy techniques 
other than flow imaging microscopy (e.g. TEM or membrane microscopy) which include additional 
sample preparation steps like for example filtration, were out of the scope of this study. Furthermore, 
this study was focused on particle counting rather than on characterizing morphological attributes or 
particle identity. In this study, performance of instruments was verified using a commercial biologic 
drug product. In control experiments, latex spheres were used as standards and instrument calibration 
suspensions. 
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1.3 MATERIALS AND METHODS 
Polystyrene beads in a Count standard configuration (3000 particles/mL, COUNT CAL, Thermo 
Fisher 
Scientific) of 2; 5; 10 and 25 µm and RI of 1.59 were used for the precision assessment of micrometer 
methods (HIAC; MFI and CC).  
A therapeutic protein product  with a molecular weight in the range of 50 kDa  and concentration of 
0.36 mg/mL  were stored in stacked-in-needle Pre-Filled Syringes (PFS), (1mL syringe with 0.5 mL 
filled in volume) and type 1 glass vials (6 mL vial with 5 mL filled in volume), respectively. The study 
employed recommended storage conditions (2-8 °C), accelerated storage conditions (25 °C/60% r.h.), 
and a stress condition (40 °C/75% r.h.). Samples were analysed at selected time points (T) 0; 4; 8 and 
13 weeks (w). Protein formulation as well as placebo samples (i.e. formulation without protein) were 
included in the accelerated stability study. All samples were prepared in a particle-free environment, 
utilizing material extensively rinsed with particle free water. Water was treated by several filtration 
and degassing steps (Liqui-cel Membrane Contactors, Membrana Germany). Air used for drying was 
filtered (0.22 µm pore size Millex PES filter membranes, Millipore Ltd, Cork, Ireland). Sample 
pooling was done as follows: the content of syringes was homogenized by gently inverting them 20 
times in a vertical position. Solution was manually ejected into the glass vials within 20 to 25 seconds 
(s). Finally, before measurements, pooled solutions were manually homogenized by repeated 
inversions of the vials. The pool size was defined accordingly to instrument minimum sample 
requirements and experiment intent as described in following sections. 
Syringes containing protein formulation stored for 2 months at 2-8 °C were used for precision 
assessment (repeatability and intermediate precision) and container to container variability (pool size 
and pump speed) experiments. Repeatability was defined as the variability of the values of triplicate 
consecutive measurements of the same sample performed by the same analyst and was assessed by the 
magnitude of the associated standard deviation and coefficient of variance. Intermediate precision was 
defined as the variability of the values of triplicate consecutive measurements of identically prepared 
and independent samples performed by different analysts on different days and was assessed by the 
magnitude of the associated standard deviation and coefficient of variance.  
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Particle counts were reported per mL of sample and in the typically used cumulative size bins. Plots 
were constructed as the ratio of the standard deviation to the mean values (CV %) versus particle size 
using Origin 9.1 software. 
Light obscuration (HIAC) 
The light obscuration measurements were performed using a HIAC Royco counting System 9703 
equipped with an HRLD400HC sensor. Analyses were made with a flushing volume of 1 mL followed 
with a small volume method of 4 runs of 1 mL each. The first run was rejected and remaining runs 
were averaged to get particle counts per mL in the following size categories: ≥ 1, ≥ 2, ≥ 5, 10 and ≥25 
μm. Blank runs were performed before each sample allowing no more than 20, 5 and 1 particles/mL 
for sizes ≥2 µm; ≥5 µm and ≥10 µm, respectively. Suitability test per day of measurements involved 
the measurement of 2, 5, 10 and 25 µm count standards (Count-cal, Thermo Fisher Scientific, 
Fremont, USA) accordingly to supplier specifications. Intermediate precision and stability samples 
were prepared by pooling the contents of either 40 syringes or 4 vials (total sample volume of 20 mL) 
from which 3 aliquots of 5 mL were measured. Pool-to-pool variability was assessed by single 
measurements of six independent and identically prepared solutions, each obtained by pooling the 
contents of 10 syringes. 
Micro flow imaging (MFI) 
Flow microscopy analysis was performed using a DPA4200 MFI Flow Microscope System 
(ProteinSimple, Toronto, Canada). Method parameters were set to 1 mL sample volume as termination 
type, 0.2 mL as purge volume (analysed volume ~0.59 mL) and “edge particle rejection” as well as 
“fill particle” options activated. Light optimization step was performed with the correspondent 
filtrated sample matrix. Either single or 3 independent runs of the same dilution were performed for 
blanks and particle samples, respectively. Cumulative particle counts per mL were obtained in the 
following bins: ≥ 1, ≥ 2, ≥ 5, ≥10, and ≥ 25 μm using the software MVSS version 2 (ProteinSimple, 
Canada). Acceptance criteria for blanks was less than 100 particles per mL > 1µm. Suitability test per 
day of experiment involved 1) measurement of 5 µm count standards (Thermo Fisher Scientific) with 
acceptance limits of ± 10 % the reported concentration for particles > 3 µm and 2) measurement of 5 
µm size standard with acceptance limits of Equivalent Circular Diameter ECD mean of ± 25 % the 
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reported size and standard deviation <0.4. Intermediate precision and stability samples were manually 
prepared by pooling the content of 10 syringes for a total sample volume of 5 mL from which 3 
aliquots of 1 mL were measured. Bulk solutions were used directly from the initial vial container. 
Pool-to-pool variability was assessed by single measurements of six independent and identically 
prepared solutions, each obtained by pooling the contents of 1, 3, 6 and 10 syringes using an 
automated syringe pump (Harvard PHD Apparatus, 2000 infusion) at a rate of 1.5 mL/min (dispensing 
time 20 s) and collecting samples in individual glass vials. A modified method of 0.5 mL sample 
volume as termination type and 0.2 mL as purge volume was used (analysed volume was ~0.17 mL).  
Coulter counter (CC) 
A CC4 model of Beckman Coulter with a 20 µm aperture tube was used. Protein sample conductivity 
was ~17 mS hence used without further adjustments. For any other sample isotone (Beckman Coulter, 
Monheim, Germany) was used as matrix (~18 mS). Electrolyte jar was filled with the same buffer 
solution as that of sample matrix. Method parameters were set to: volume analysed 50 µl, runs 3, 
current 600 µA and gain 4. Aperture tube’s cleanness was verified in between every sample with blank 
(isotone or buffer) measurements allowing less than 1000 particles/mL. Instrument was daily 
calibrated using 3 µm size standards in the correspondent sample matrix. As sample container a small 
volume cuvette of 5 mL capacity (Beckman Coulter, Monheim, Germany) was used with especial 
attention into full electrode coverage. Intermediate precision and stability samples for T0 w, T4 w, and 
T13 w were prepared by pooling the content of 10 syringes. For T8 w, 24 syringes were pooled. From 
the respective final volumes, aliquots of 5 mL were measured. Bulk solutions were used directly from 
the initial vial container. Pool-to-pool variability was assessed by single measurements of six 
independent and identically prepared solutions, each obtained by pooling the content of 10 syringes 
manually.  
Resonant Mass Measurements (Archimedes) 
Resonant mass measurements were performed using Archimedes system (Affinity Biosensors, Santa 
Barbara, USA) equipped with a Hi-Q micro sensor. Prior to each sample, system was rinsed as 
follows: matrix sample solution for 2 minutes, PCC54 detergent solution (ThermoScientific, Illinois, 
USA) for 2 minutes and particle-free water for 10 minutes. A threshold of 0.04 Hz and 0.03 Hz for 
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protein and polystyrene standards was applied, respectively. The density of the fluid was 1.004 g/mL. 
The density of proteinaceous particles and silicon oil droplets was defined as 1.32 and 0.9 (vendor 
recommendation), respectively. Hence, positively buoyant particles (RMM (+)) were assigned as 
silicon oil like particles and negatively buoyant particles (RMM (-)) were assigned as protein like 
particles. Run time of 8 hours or 10000 collected particles was defined as termination type point to 
ensure sufficient volume sampled, high number of detected particles and hence sound statistics. Such 
long measurement time allowed for single runs only instead of triplicates. The frequency vs time chart 
obtained in real time as the measurement is running was used to monitor possible sensor clogging. 
When such trend showed strange gaps and/or irregularities in the points distribution, the run was 
disregarded, the sensor cleaned (or replaced) and the run repeated. The data was collected and 
analysed using software ParticleLab version 1.8.570 (Affinity Biosensors, USA). Intermediate 
precision and stability samples T3 w; T8 w and T13 w were prepared by pooling the content of 10 
syringes. From the final sample volume of 5 mL, single aliquots of 1 mL were prepared for the 
measurements. The actual measured volume varied among samples and was obtained from the .csv file 
(in general 7 – 10 µL). Bulk solutions were used directly from the initial vial container. 
Nanoparticle Tracking Analysis (NTA) 
The NTA measurements were performed with the Nanosight NS200, LM20 equipped with a 405 nm 
laser. Before measurements, the chamber was cleaned with 0.02 μm filtered (Anotop 25, Whatman, 
Glattbrugg, Switzerland) water and analysed to confirm the absence of particles. Samples were 
injected using 1 mL sterile syringes (Norm-Ject, HSW, Tuttlingen, Germany). First volume was used 
to rinse out the flushing water and with the remaining volume 3 videos of 90 s were recorded using 
replenished sample each time. Video recording settings were set so that clear and sharp particle images 
were obtained. During the measurement, the temperature was controlled and recorded by a 
temperature sensor contained in the viewing unit. The software used for capturing and analysing the 
samples was the NTA 2.2. In order to get statistically reliable results, a minimum of 300 completed 
tracks was required. Intermediate precision and stability samples were prepared by pooling the content 
of 6 syringes. From the final sample volume of 3 mL, aliquots of 1 mL were prepared for the 
measurements. Information from the supplier reports chamber sample dimensions of approximately 
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10x120x80 µm. Hence the measuring volume can be estimated as 9.6x10-8 mL. Bulk solutions were 
used directly from the initial vial container. 
Poisson distribution statistical simulations 
All simulations were performed using R 3.2.2 (R Foundation for Statistical Computing, Vienna, 
Austria).  To estimate the distribution and magnitude of CV based on simulation alone, 1000 
simulations runs were performed based on the expected number of particles λ. Three (for repeatability) 
or six (for intermediate precision) random values of the Poisson distribution were generated and their 
respective CV computed 
 
1.4 RESULTS  
In the present study, a number of particle measurement methods (Table 1.1) were compared in the 
context of an accelerated stability study. For the assessment of particles between 100-1000 nm size, 
Nanoparticle Tracking Analysis, (NTA), Resonant Mass Measurement (RMM) and the Coulter 
Counter (CC) instruments were included. These methods will be hereafter referred to as 
submicrometer methods. For the assessment of particles between 1-100 µm size, Flow Microscopy 
(Micro Flow imaging (MFI)), Coulter Counter (CC) and the compendial Light Obscuration (HIAC) 
were included. These methods will hereafter be referred to as micrometer methods. The methods were 
used to analyse a commercial protein, which was stored under accelerated stability conditions. 
Samples were analysed at T0 and 4, 8 and 13 weeks and protein particles in cumulative counts per mL 
were reported as presented in Table 1.2. Significant discrepancies between the different measurement 
methods were observed as well as inconsistent trends within different time points. For example: a) 
HIAC light obscuration method reported very similar quantities of particle of the samples stored at 5 
ºC and 25 ºC, while in the samples stored at 40 ºC there was an apparent increase in the particle count 
over time. An apparent increase in the spread between individual results for different replicates with 
the time of storage was also observed. b) The results from the RMM measurements showed an 
apparent increase of the overall counts with temperature, but an apparent decrease of counts with time 
within each condition. These inconsistent results and the large and unexpected deviations between the  
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Table 1.2 Number of particle per mL measured in a low-concentration therapeutic product in a prefilled syringe container at 5°C; 25°C and 40°C over the course of 4, 8 and 13 
weeks. Instruments are described in Table 1.1 
 
Size 
[um
] 
 
  5°C    
 
  25°C    
 
  40°C    
4 8 13 4 8 13 4 8 13 
H
IA
C
 
>1 19055 ± 133 13446 ± 481 14929 ± 4291 19584 ± 849 12370 ± 415 15933 ± 7673 12107 ± 400 19019 ± 657 20704 ± 7390 
>2 12352 ± 186 8119 ± 324 10701 ± 2213 10247 ± 406 6664 ± 214 8448 ± 4448 6257 ± 166 10503 ± 279 12620 ± 4967 
>5 6466 ± 94 3821 ± 167 5939 ± 849 2845 ± 282 2514 ± 58 2276 ± 1149 1933 ± 11 3425 ± 50 3961 ± 1210 
>10 1179 ± 50 691 ± 36 819 ± 449 310 ± 66 452 ± 25 254 ± 123 231 ± 4 573 ± 11 552 ± 69 
>25 6 ± 3 6 ± 0 1 ± 2 3 ± 2 2 ± 2 2 ± 2 2 ± 3 7 ± 2 10 ± 3 
M
F
I 
>1 19205 ± 699 40437 ± 215 16612 ± 8276 33813 ± 554 28067 ± 108 30830 ± 3996 32140 ± 692 62658 ± 847 41138 ± 1223 
>2 7547.8 ± 226 18054 ± 170 6872 ± 3520 9743 ± 170 9324 ± 107 9569 ± 275 9527 ± 82 22972 ± 228 14444 ± 782 
>5 2092 ± 185 5627 ± 235 1727 ± 496 1241 ± 46 1473 ± 28 793 ± 171 1269 ± 29 3989 ± 77 1763 ± 203 
>10 792 ± 154 1382 ± 101 427 ± 110 222 ± 22 224 ± 17 67 ± 27 139 ± 9 519 ± 52 182 ± 33 
>25 12 ± 5 12 ± 6 1 ± 1 4 ± 3 6 ± 6 1 ± 0 4 ± 2 7 ± 4 3 ± 4 
C
C
 
>0.4 740667 ±18595 434133 ± 16754 457167 ± 16292 815600 ± 14152 553933 ± 23150 625400 ± 37013 782800 ± 16008 899333 ± 36875 2014667 ± 42336 
>0.5 464967 ± 11918 297100 ± 10872 283400 ± 11663 525233 ± 9347 383667 ± 15292 405233 ± 26508 515767 ± 13639 559333 ± 22396 703500 ± 10835 
>0.8 137033 ± 2631 106300 ± 3851 91700 ± 4506 170700 ± 4949 141433 ± 4200 139533 ± 10995 179233 ± 4409 203000 ± 7234 214033 ± 4802 
>1 73200 ± 1837 59890 ± 2923 50887 ± 2728 88110 ± 3637 81990 ± 2330 75410 ± 7123 96063 ± 3403 113767 ± 4661 108433 ± 2150 
>2 14587 ± 500 13050 ± 920 10773 ± 670 13523 ± 613 16547 ± 304 12313 ± 705 13820 ± 512 19893 ± 935 12030 ± 318 
>5 1719 ± 159 1969 ± 44 1099 ± 26 1336 ± 115 1931 ± 123 895 ± 33 1014 ± 103 2760 ± 243 1256 ± 181 
>10 175 ± 34 229 ± 58 74 ± 42 107 ± 24 95 ± 30 65 ± 40 75 ± 34 147 ± 64 52 ± 20 
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Table 1.2 Continuation 
R
M
M
 (
+
) 
>0.3 236000 140000 99200 672000 202000 185000 1120000 322000 201000 
>0.4 236000 140000 10 672000 202000 185000 1120000 322000 201000 
>0.5 231000 138000 10 656000 198000 185000 1050000 317000 200000 
>0.8 15400 21000 13300 76300 28300 24100 122000 46000 32100 
>1 2130 6600 3010 18100 8420 7420 26900 9750 72400 
>2 0  309 0  0 213 102 106 0 0 
>5 0  0  0  0 0 0 0 0 0 
R
M
M
 (
-)
 
>0.3 138000 28100 7880 107000 24800 40700 197000 13600 62100 
>0.4 78000 13900 3010 58300 11100 31200 43100 5910 43100 
>0.5 28900 3090 726 23800 2240 22000 9350 1560 16900 
>0.8 2740 206 0 ± 0 1770 0 508 0 0 210 
>1 913 103 0 ± 0 417 0 0 0 0 0 
>2 0 ± 0 0 ± 0 0 ± 0 0 0 0 0 0 0 
>5 0 ± 0 0 ± 0 0 ± 0 0 0 0 0 0 0 
N
T
A
a
 
>0.0
5 
221 ± 34 279 ± 36 267 ± 24 250 ± 20 161 ± 33 183 ± 31 75 ± 4 63 ± 9 43 ± 6 
>0.2 61 ± 12 65 ± 8 75 ± 24 82 ± 5 37 ± 21 51 ±11 31 ± 5 27 ± 8 19 ± 12 
>0.3 18 ±13 16 ± 4 25 ± 7 24 ± 9 11 ± 7 14 ± 6 8 ± 3 11 ± 7 7 ± 9 
>0.4 9 ± 12 4 ± 1 13 ± 6 14 ± 6 5 ± 4 6 ± 4 3 ± 2 4 ± 5 2 ± 2 
>0.5 5 ± 8 1 ± 0 8 ± 8 10 ± 5 1 ± 0 4 ± 3 1 ± 1 3 ± 5 1 ± 1 
>0.8 2 ± 3 0 ± 0 1 ± 2 3 ± 2 0 ± 0 1 ± 1 0 ± 0 2 ± 3 0 ± 0 
>1 0 ± 0 0 ± 0 1 ± 1 1 ± 1 0 ± 0 0 ± 0 0 ± 0 1 ± 2 0 ± 0 
a
 E8 particles/mL 
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different instruments were indicative of analytical artefacts. In order to address this problem, the 
precision of the methods, the repeatability and intermediate precision were determined. 
Repeatability assessment 
The repeatability of all methods was assessed by measuring an identical sample repeatedly within a 
short interval of time (< 1 h) on the same instrument by the same analyst. The results from this 
assessment are summarized in Table 1.3A (See also Table S1.1 the complete dataset). In these 
experiments the micrometer methods HIAC; MFI and CC demonstrated very good repeatability (CV 
% in the range of 4 ± 3) except for the larger particle sizes of >10 µm and >25 µm (CV % 50 ± 69). In 
contrast, the submicrometer methods RMM and NTA exhibited relatively poor repeatability (CV % 84 
± 51) in all particle sizes except for 0.05 µm particles, where NTA measurements showed CV % of 7. 
Interestingly, the results for the positively buoyant particles (presumably silicone oil droplets 
originating from the lubricant layer of the syringes) were much more precise than the measurements of 
the negatively buoyant particles (presumably protein particles) with CV % 37 ± 10 for the former and 
CV % 136 ± 21 for the latter. 
In all methods, the precision of measurement for the larger particles within the same sample was 
 
Table 1.3 Precision assessments of subvisible particle measurements using a 
low-concentration protein therapeutic product in PFS. Data expressed as 
coefficient of variation % (CV%). Values bigger than 10% are marked in italics 
 A) Repeatability 
Size µm HIAC MFI CC   Size µm RMM(+) RMM(-) NTA 
>0.4 nd nd 6   >0.05 nd nd 7 
>0.5 nd nd 1   >0.2 nd nd 33 
>0.8 nd nd 3   >0.3 29 128 34 
>1 nd 2 5   >0.4 29 127 67 
>2 3 5 1   >0.5 30 132 122 
>5 3 12 5   >0.8 49 120 92 
>10 7 29 173   >1 47 173 134 
>25 17 25 nd       
B) Intermediate precision 
Size µm HIAC MFI CC   Size µm RMM(+) RMM(-) NTA 
>0.4 nd nd 6   >0.05 nd nd 20 
>0.5 nd nd 23   >0.2 nd nd 47 
>0.8 nd nd 39   >0.3 39 99 82 
>1 nd 51 44   >0.4 39 100 114 
>2 48 58 49   >0.5 39 107 101 
>5 51 61 56   >0.8 50 122 77 
>10 38 55 104   >1 48 127 118 
>25 27 46 nd       
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significantly poorer, compared to that of the small particles. This is a known phenomenon which is 
usually attributed to the very small number of particles from the larger sizes present in the sample, 
which results in very poor sampling. In order to assess this apparent discrepancy of the precision of 
measuring smaller and larger particles, an experiment using latex bead count standards of different 
nominal sizes (2 µm, 5 µm, 10 µm and 25 µm) was carried out. The used standard suspensions 
contained a known concentration of particles (3000 beads/mL). As expected, in all bead sizes the 
repeatability was nearly identical from size to size and very low in magnitude ~CV % 5 ± 4, (Table 
1.4A). 
Intermediate precision assessment 
The intermediate precision of all techniques was evaluated by measuring samples prepared and 
measured independently in different days by different analysts. The results of this assessment are 
presented in Table 1.3B. Contrary to the relatively high precision demonstrated in the repeatability 
study, the micrometer methods showed poor intermediate precision (CV% 50±18, except for 0.4 µm 
particles in CC with CV% of 6). On the other hand, the submicrometer methods, showed also poor 
performance with even larger variance (CV % 78 ± 35) as compared to the micrometer methods, 
which was expected considering the poor repeatability of the submicrometer techniques described 
above. This overall larger variance (all methods) in the intermediate precision experiments suggests 
the likely contribution of additional factors besides the ones influencing the repeatability of these 
measurements (typically, instrument-related). Such additional factors usually reflect the contribution 
of the analyst, i.e. factors related to sample preparation, as well as real differences from sample to 
sample. Similarly to the repeatability experiments, the intermediate precision also improved when 
 
Table 1.4 Precision assessment of subvisible particle measurements using 
count standards. Data expressed as coefficient of variation % (CV%). 
Values bigger than 10% are marked in italics 
 
A) Repeatability   B) Intermediate precision 
Size um HIAC MFI CC  HIAC MFI CC 
>2 1 4 10  2 3 23 
>5 1 1 10  2 12 7 
>10 3 4 10  4 13 7 
>25 5 2 11  4 7 11 
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standard suspension of known size and concentration was used (Table 1.4B). 
1.5 DISCUSSION  
At present due to concerns related to the immunogenic potential of subvisible protein particles, a 
growing number of new analytical tools for their characterization were introduced during the last 
years. 
They are often combined to characterize particles over the entire sub-visible size-range. Unfortunately, 
one difficulty associated with this approach is major discrepancies between analytical results from 
different methods. In particular, information on particle concentrations of identical samples may 
deviate considerably (this study and (1)). Such differences may originate from the different physical 
principles that some of the methods use, thus presenting inherent difficulties. Additional challenges 
may be posed by sample composition and the properties of the different types of particles present in 
the sample (for example, particles with refractive index values close to that of the medium may be 
difficult to detect accurately by either  light obscuration or flow microscopy measurements (2-4)). As 
we develop comprehensive understanding of the analytical performance of the various techniques for 
particle characterization available today, it is essential that we strive to grasp the complex factors 
governing their operation. 
In this study we present the results of a short term stability study using a low-concentration therapeutic 
protein product in a prefilled syringe. Despite the low protein particle burden that our model product 
depicted as compared to the amount of intrinsic silicon oil droplets; this model represents a worst case 
that clearly exposed the strengths and weaknesses of the instruments in scope. 
Factors governing method repeatability 
One striking outcome from the evaluation of method precision was the very poor repeatability of the 
submicrometer methods NTA and RMM. This observation is intriguing as it hints to a phenomenon 
that seemingly affects both methods, although they are based on completely different measurement 
principles. One such common feature is the very low measurement volumes that both methods utilize. 
In some cases, the volume measured is as low as 0.08 nL, which requires extrapolation of more than 
12 million fold in order to represent particle concentration in “particles per mL” units, as required for 
parenteral formulations. This is a serious problem, especially if the particle count in a given sample is 
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relatively low. This effect can be illustrated using the concept of statistical probabilities. In a 1 mL 
hypothetical sample containing a single particle, measurement of 0.1 mL portion of this sample will 
decrease the probability of detection of the single particle to 10 %, as compared to measuring the 
entire sample volume. In cases when measurement volumes as low as 1 nL are used (e.g. RMM 
measurements), the probability of detection of a single particle will be drastically reduced to just 
0.0001 %.  
As mentioned above, the sampling efficiency (the portion of 1 mL sample which is measured in each 
method) varies extensively from technique to technique and in some cases can be as low as 0.08 × 10-6 
%, (see Table 1.5). Interestingly, many submicrometer methods nevertheless seem to focus on low 
sampling volume, resulting in very large extrapolation factors used to calculate final particle 
concentrations and in turn poor precision. Thus, the sampling efficiency is perhaps the main factor 
governing the precision of particle submicrometer counting instruments. Figure 1.1 illustrates the 
correlation of high variability with the large extrapolation factor (due to the low sampling efficiency). 
Methods with extrapolation factors smaller than 20 fold (e.g. HIAC, MFI and CC) demonstrated far 
better repeatability as indicated by the CV % as compared to the methods with larger extrapolation 
factors (e.g. RMM and NTA).  
To further elaborate in this phenomenon, the CV experimental values were compared to simulated 
ones using a Poisson distribution model. That model describes the occurrence of successful events 
when the associated probability is low. For each combination of instrument and particle size bin, 1000 
simulation runs were performed to estimate the CV distribution. Based on the respective instrument 
 
Table 1.5 Sample volume and extrapolation factors of the different instruments. 
To report final protein concentrations normalized to 1 mL of sample volume, the 
indicated extrapolation factors are needed 
Instrument 
Measurement volume, V 
(mL) Extrapolation factor, 1/V (mL
-1
) 
HIAC > 1 1.0x 
MFI 0.6 1.6x 
CC 0.05 20x 
RMM 0.01     100x 
NTA 0.00000008 12500000x 
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Figure 1.1 Precision of subvisible particle methods in relation to the applied extrapolation 
factors. Syringes containing protein formulation stored for 2 months at 2-8 °C were used for 
precision assessment. Results, reported as CV% were plotted against the corresponding 
extrapolation factors. Factors used were <20x for HIAC, MFI and CC. 100x for RMM. 
12500000x for NTA 
 
specific measured volume as λ (e.g. for MFI λ is the actual number of particles found in the 0.6 mL 
volume sampled), three (for repeatability) or six (for intermediate precision) random values of the 
Poisson distribution were generated and their respective CV computed. The distribution of simulated
and observed CV is compared in Figure 1.2 by means of boxplots, separated by type of instrument and 
precision assessment. It can be observed that the computational estimates of repeatability CV% for all 
of the methods which we evaluated show similar or lower values as compared to the ones measured 
experimentally (see Figure 1.2). As the simulation process considers exclusively the effect of sampling 
volume, this result supports the conclusion that sampling efficiency is likely the major factor 
governing precision of submicroscopic methods. As expected, these results also demonstrate that in 
some cases additional experimental factors likely contribute as well. The corresponding statistical 
simulations for intermediate precision show values that are generally lower than the experimentally 
measured ones, which is also an expected result, considering the fact that additional experimental 
factors surely contribute to intermediate precision.   In a second simulation, the impact of the 
encountered particles in such small volumes was studied. In very small volumes, the number of 
particles n becomes very low too. For example, let us compare the volume under investigation in a 
given Instrument1 with V1 = 1 mL with the volume of another Instrument2 with V2 = 0.08 nL. In this 
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Figure 1.2 Comparison of the experimentally measured and simulated (using Poisson 
distribution) CV% values per instrument and type of precision analysis. For additional details, 
please refer to Materials and Methods Section 1.3 
 
hypothetical situation, V1 is about 10
8 larger than V2. Let us assume that in the sample n1 = 100’000 
particles were found. Then the expected was numbers of particles n2 in the investigated Volume V2 of 
Instrument2 would be  = n2 = n1 * V2/V1.  Using the Poisson distribution, we have simulated this 
situation with different numbers of originating particles n1 and ratios of V2/V1 resulting in different 
expected numbers of particle, .  Each setting simulated 1000 times, and the CV was estimated for 3 
random numbers. Figure S1.1 demonstrates, that the CV is highest for   = 1. Here a median CV of 
approximately 100 % is found. With   = 10 it already reduces down to a median CV of 25 %, and at  
= 100’000 this CV is already negligible. Figure S1.1 also demonstrates that the CV is not dependent 
on the total number of particles in the sample, n1. It is simply dependent on the number of expected 
particles in the volume under investigation. Moreover, it shows that the contribution of counting small 
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numbers to the overall loss of precision is highly considerable. The same phenomenon of poor 
precision due to very low number of particles is also reflected in the measurements of the larger 
particle sizes in both the micrometer and submicrometer ranges. The precision for these larger sizes 
was considerably decreased as compared to smaller size ranges. As can be seen in Table 1.3A, the CV 
% decreased from 173 to 6 for <10 µm and <0.04 µm particles, respectively, using the CC method. 
Thus, the precision of a given method is a function of particle number. To confirm this hypothesis, an 
additional experiment was performed using different polystyrene bead count-standards with identical 
and defined concentration in individual size-bins (i.e. 3000 particles/mL for particles sizes from 2 µm 
up to 25 µm). It is important to note that in contrast to polystyrene beads, protein particles are 
typically heterogeneous in shape, optically uneven, exhibit higher pliability and perhaps different 
refractive indexes along the entire size distribution. Such characteristics pose much higher challenge 
for particle detection and quantification as compared to polystyrene beads. The impact of these 
differences on the measurements has been studied and efforts to generate standard material that 
resembles better the characteristics of protein particles are also published. (25, 26) However, 
polystyrene standards are broadly used for the calibration and verification of particle counting 
instruments due to the easy handling and good stability of the particles. As expected the results from 
these measurements demonstrated that the precision in a given size-range was (at least partially) 
dependent on the number of particles present (Table 1.4). Good repeatability was confirmed for 
particles up to 5 µm, and notably, good repeatability was also found for particles >10 µm and >25 µm. 
This finding confirms that precision is independent of particle size but strongly influenced by particle 
number. An analysis of the size distribution of data corroborates these findings. For example, particles 
>25 µm in the HIAC represent in average less than 3 % of the total size distribution and therefore have 
a poor CV % of > 17. Particles between 0.05 and 0.2 µm in the NTA represent in average more than 70 
% of all particles and have a much better CV % of 6.5. Finally, additional support for the fundamental 
importance of sampling efficiency was provided by the apparent difference between the precision of 
measurement of the positively buoyant and negatively buoyant particles counted by RMM. The results 
for the former appear more precise than the results for the latter, which corresponds well to their 
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relative abundance (the more abundant positively buoyant particles were measured more precisely 
than the less abundant negatively buoyant particles). 
Our results suggest that the large discrepancies in repeatability from technique to technique are mainly 
due to the large differences in the measured volumes (sampling efficiency). Thus, one potential 
direction for future instrument development is improving sampling efficiency, particularly in the 
techniques which currently allow for measuring very low effective volumes only.  
Factors governing method intermediate precision  
The measured intermediate precision of all different subvisible measurement methods used in this 
study was relatively poor. As expected, the CV % values measured for each individual method were 
larger than the values for repeatability, likely indicating that additional factors may play a role. These 
potential factors include instrument-related (e.g. day-to-day instrument performance differences not 
reflected by routine suitability test runs) and sample-related effects (e.g. sample preparation, container-
to-container variability, etc.). To gain further insight into the relative contribution of these two types of 
factors, a set of experiments using different sample preparation procedures was carried out. Samples 
were prepared by pooling a different number of containers. These different pools were measured and 
the corresponding precision values were correlated to the size of each pool. Measurements of uniform 
samples (certified bead concentration standards) demonstrated very high intermediate precision in all 
size categories (in general CV % < 11, Table 1.4). Interestingly, the results from the pooling 
experiments (MFI measurements) indicate that the larger the pool size, the better the precision (Figure 
1.3). Similarly low variability for larger pools (N=10) was confirmed for HIAC and CC methods 
(Figure S1.1). These results indicate that the measured variance is likely sample-related – e.g. possible 
small differences in the siliconization level of individual syringes or minor variation in the sample 
preparation procedure (manual ejection of the syringe content is difficult to control). As the pool size 
increases such container-to-container differences presumably are averaged out.  Contribution from the 
instrument day-to-day variability was excluded, because the system suitability tests performed on each 
measurement day remained within acceptance limits (data not shown).  
The repeatability and intermediate precision data presented in this study highlight general principles  
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Figure 1.3 Protein particle concentration variability as a function of pool size Comparison of the 
variability of 6 independently prepared samples of commercial proteins. The content of a number 
N of prefilled syringes was pooled and analysed by MFI 
 
and factors influencing the performance of a new generation of particle counting methods. It should be 
emphasized, that the used analytical methods are not yet generic methods but need to be adapted to 
address specific needs of users. For example, assay parameters and instrument configurations need to 
be optimized to account for differences in sample properties (e.g. viscosity, turbidity, refractive index 
contaminants, buffer systems etc. As a final remark, it needs to be pointed out that the specific values 
of the method attributes measured in this study should not be taken outside of the context of these 
experimental conditions. These measured values should serve as examples/guides only in order to 
demonstrate the general factors in play. In other test systems the values of the method attributes will 
likely be different as these are dependent on the specific test system used. Surely, further case studies 
from different laboratories using other model systems will be valuable in shedding more light on the 
methods’ variability and the factors that affect it. However, the current study is meant to provide a 
systematic evaluation of the analytical performance of subvisible particle methods with the main goal 
to identify the principal factors controlling the precision of the methods assessed. 
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1.6 CONCLUSIONS 
To our knowledge, the current report is the first detailed and systematic comparative assessment of the 
precision of a broad array of subvisible particle measurement methods. A commercial pharmaceutical 
protein product was used as representative and realistic test system. In this specific frame, our study 
revealed serious shortcomings of all tested subvisible particle measurement methods with the 
exception of the compendial light obscuration method and other micrometer methods. Despite the fact 
that the exact precision numbers (CV % values) might vary for different drug products, intriguingly, 
the submicrometer particle measurement methods demonstrated particularly poor precision. This 
finding could be explained by the extremely small samples volumes utilized by these methods limiting 
the probability for particle detection and necessitating large extrapolation factors to calculate the 
measurement results. We conclude that the very low precision of the submicrometer particle 
measurement techniques is an inherent instrument problem which for the moment excludes them from 
use in routine or quality control setting. 
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1.8 SUPPLEMENTARY MATERIAL  
 
 
 
Figure S1.1 Boxplot of CV%, each estimated from 3 random values based on a Poisson distribution with expected 
number of particles λ and originating number of particles n1 
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Figure S1.2 Pool variability in HIAC and CC. Variability of six independent and identically prepared pools of 
10 units of PFS measured in HIAC (a) and CC (b). The large pool size originates low variability in the 
measurements 
 
Figure S1.3 Collage of randomly selected MFI image and larger than 5 μm of the protein product used in this 
study. Mainly silicon oil-like particles can be observed 
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Table S1.1 Precision assessment of subvisible particle measurements using a low-concentration protein therapeutic product in pre-filled syringe Data is expressed in particles per mL 
    
Size um 
  Analyst 11   Analyst 2   Overall2 
      run 1 run 2 run 3   average std CV%   run 1 run 2 run 3   average std CV%   average std CV% 
HIAC 
  >2   6.49E+03 6.37E+03 6.72E+03   6.53E+03 173.9234 3   2.58E+03 2.58E+03 2.50E+03   2.55E+03 51.09795 2   4.54E+03 2178.937 48 
  >5   2.40E+03 2.30E+03 2.26E+03   2.32E+03 70.46512 3   8.89E+02 8.52E+02 8.30E+02   8.57E+02 29.8161 3   1.59E+03 802.4135 51 
  >10   4.82E+02 4.49E+02 4.22E+02   4.51E+02 30.04996 7   2.36E+02 1.99E+02 2.23E+02   2.19E+02 18.77054 9   3.35E+02 128.8525 38 
  >25   1.20E+01 9.00E+00 9.00E+00   1.00E+01 1.732051 17   1.00E+01 6.00E+00 6.00E+00   7.33E+00 2.309401 31   8.67E+00 2.33809 27 
MFI 
  >1   4.11E+04 4.23E+04 4.27E+04   4.21E+04 844.6238 2   1.52E+04 1.57E+04 1.57E+04   1.55E+04 312.3694 2   2.88E+04 14542.05 50 
  >2   1.79E+04 1.92E+04 1.97E+04   1.89E+04 907.8044 5   5.88E+03 5.77E+03 5.85E+03   5.83E+03 60.56553 1   1.24E+04 7196.393 58 
  >5   3.25E+03 3.78E+03 4.18E+03   3.74E+03 464.1802 12   1.14E+03 1.03E+03 1.16E+03   1.11E+03 68.94632 6   2.42E+03 1469.382 61 
  >10   3.06E+02 5.37E+02 5.26E+02   4.56E+02 130.1428 29   1.61E+02 1.93E+02 1.79E+02   1.77E+02 16.40973 9   3.17E+02 173.8577 55 
  >25   3.28E+00 1.64E+00 1.64E+00   2.19E+00 0.946854 43   1.64E+00 1.64E+00 4.92E+00   2.73E+00 1.893709 69   2.46E+00 1.372122 56 
CC 
  >0.4   6.96E+05 6.24E+05 6.97E+05   6.72E+05 41895.39 6   6.05E+05 6.27E+05 6.22E+05   6.18E+05 11363.54 2   6.45E+05 40422.14 6 
  >0.5   2.70E+05 2.73E+05 2.75E+05   2.73E+05 2657.693 1   4.11E+05 4.27E+05 4.24E+05   4.21E+05 8337.266 2   3.47E+05 81324.5 23 
  >0.8   80150 82090 84830   8.24E+04 2351.368 3   1.69E+05 1.74E+05 1.73E+05   1.72E+05 2672.702 2   1.27E+05 49133.03 39 
  >1   42220 44200 46660   4.44E+04 2224.32 5   1.00E+05 1.04E+05 1.06E+05   1.03E+05 2793.445 3   7.37E+04 32270.6 44 
  >2   6273 6131 6276   6.23E+03 82.86334 1   16050 16540 16200   1.63E+04 251.0644 2   1.12E+04 5499.851 49 
  >5   420 388.9 380   3.96E+02 21.00167 5   1199 1279 1219   1.23E+03 41.63332 3   8.14E+02 458.863 56 
  >10   40 0 0   1.33E+01 23.09401 173   40 108.9 40   6.30E+01 39.77943 63   3.82E+01 39.81627 104 
1 Repeatability assessment                                         
2 Intermediate precision assessment                                      
3 E8 particles/mL                                         
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Table S1.1 (continuation) 
    
Size um 
  Analyst 11   Analyst 2   Overall2 
      run 1 run 2 run 3   average std CV%   run 1 run 2 run 3   average std CV%   average std CV% 
RMM (+) 
  >0.3   1.67E+05 9.65E+04 1.15E+05   1.26E+05 36552.47 29   1.10E+05 7.44E+04 2.08E+05   1.31E+05 69186.13 53   1.28E+05 49553.62 39 
  >0.4   1.67E+05 9.65E+04 1.15E+05   1.26E+05 36552.47 29   1.10E+05 7.44E+04 2.08E+05   1.31E+05 69186.13 53   1.28E+05 49553.62 39 
  >0.5   1.65E+05 9.56E+04 1.10E+05   1.24E+05 36625.86 30   1.09E+05 7.38E+04 2.07E+05   1.30E+05 69023.28 53   1.27E+05 49543.46 39 
  >0.8   2.47E+04 1.18E+04 1.09E+04   1.58E+04 7720.751 49   1.26E+04 1.05E+04 3.01E+04   1.77E+04 10761.2 61   1.68E+04 8443.143 50 
  >1   7.55E+03 4.41E+03 2.95E+03   4.97E+03 2350.574 47   4.24E+03 2.73E+03 8.71E+03   5.23E+03 3109.7 59   5.10E+03 2469.4 48 
RMM (-) 
  >0.3   1.01E+05 1.75E+04 4.58E+03   4.10E+04 52338.63 128   1.04E+05 1.77E+04 2.80E+04   4.99E+04 47134.17 94   4.55E+04 44810.78 99 
  >0.4   6.23E+04 1.06E+04 3.26E+03   2.54E+04 32177.86 127   5.82E+04 9.41E+03 1.51E+04   2.76E+04 26678.49 97   2.65E+04 26463.04 100 
  >0.5   2.51E+04 3.55E+03 1.22E+03   9.96E+03 13166.15 132   2.01E+04 2.93E+03 4.72E+03   9.25E+03 9438.904 102   9.60E+03 10253.1 107 
  >0.8   7.44E+02 2.15E+02 0.00E+00   3.20E+02 382.8842 120   3.20E+02 0.00E+00 1.05E+02   1.42E+02 163.1206 115   2.31E+02 280.6932 122 
  >1   3.19E+02 0.00E+00 0.00E+00   1.06E+02 184.1747 173   2.07E+02 0.00E+00 1.05E+02   1.04E+02 103.5036 100   1.05E+02 133.6225 127 
NTA3 
  >0.05   268.1198 246.736 280.991   2.65E+02 17.30289 7   343.3306 413.6359 314.6525   3.57E+02 50.92963 14   3.11E+02 60.76427 20 
  >0.2   79.92221 50.10522 100.6841   7.69E+01 25.42418 33   19.57352 81.48103 47.48463   4.95E+01 31.00356 63   6.32E+01 29.46388 47 
  >0.3   14.29503 9.372155 19.16112   1.43E+01 4.894508 34   2.340979 37.67165 7.930685   1.60E+01 18.99134 119   1.51E+01 12.43877 82 
  >0.4   6.605697 1.742749 2.946583   3.77E+00 2.532673 67   0.735303 15.88422 2.490145   6.37E+00 8.28624 130   5.07E+00 5.662694 112 
  >0.5   5.123745 0.455044 0.806469   2.13E+00 2.599972 122   0.482311 4.688885 1.295921   2.16E+00 2.231197 104   2.14E+00 2.166901 101 
  >0.8   0.518275 0 0.33719   2.85E-01 0.263027 92   0.17525 0.22539 0.139476   1.80E-01 0.043157 24   2.33E-01 0.178138 77 
  >1   0.036138 0 0.189032   7.51E-02 0.100346 134   0.049556 0.075002 0.004286   4.29E-02 0.035818 83   5.90E-02 0.069643 118 
1 Repeatability assessment                                         
2 Intermediate precision assessment                                      
3 E8 particles/mL                                         
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2.1 ABSTRACT  
A number of new techniques for particle characterization in biotechnological products 
have emerged in the last few decades. Although the pharmaceutical community is 
actively using them and many applications can be found in scientific literature, little is 
known about the analytical performance of these tools. With the aim of increasing our 
knowledge and understanding of said instruments, we have performed a systematic 
evaluation of the accuracy of the most commonly used particle counting instruments. 
Our results showed a marked, over-counting effect especially for low concentrated 
samples and particles fragile in nature. Furthermore, we established the relative 
sample size distribution as the most important contributor to an instrument’s 
performance in accuracy counting. The smaller the representation of a particle size 
within a solution, the more difficulty the instruments had in providing an accurate 
count. A more thorough understanding of the capabilities of the different particle 
counting methods here provided will help correct the applicability and the results 
interpretation in particle assessment studies. 
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2.2 INTRODUCTION 
Particulate matter is an important quality attribute of parenteral pharmaceutical formulations (1, 2). 
Lately, due to the new challenges that the emergence of biotechnological products have provoked, the 
assessment of particles in this type of products has received further attention (3-5). Specifically, 
concerns had been raised about the possible clinical relevance of protein particles in the submicron 
range (6-8). It is necessary to have analytical tools capable of the assessing and characterizing particles 
smaller than the current < 10 µm and < 25 µm limits established in the USP <788> and other 
harmonized compendial methods. 
In the last decade, several instruments have been developed (or adapted) to monitor particles and to 
possibly support pharmaceutical development or even quality control (9-11). The most popular 
technologies available to date are NanoSight (Nano Tracking Analysis) (12, 13); Archimedes 
(Resonant Mass Measurement) (14-17); Coulter Counter (Electro Zone Sensing) (18, 19); Micro Flow 
Imaging and Flow Cam (Flow Imaging Microscopy) (20-25). However, each one of those emerging 
techniques tracks and explores different properties of the particulate matter in order to provide size and 
count information. Consequently, the different technical principle of each methodology implies 
different outcomes, both in terms of analytical performance (this and Chapter 1) and particle 
assessments (11). For example, whereas NanoSight combines light scattering with video recording of 
the Brownian motion of single particles; Archimedes uses frequency shifts and particle density values 
to estimate the weight of each particle. For a given sample, a hypothetical increase in viscosity will 
produce an apparent increase in size in NanoSight (particles would move slower) whereas the same 
change will produce an apparent decrease in Archimedes (particles would produce a smaller frequency 
shift). Although both methodologies can possibly account for such artefacts, it is important to notice 
that each technique will be affected in a different extend by the same given properties of the sample 
and by specific artefacts. Even when those two methodologies share a similar size range, the particle 
assessment performed by various methods will not necessarily compare. The latter highlights the 
importance of constructing a complete understanding of the analytical performance abilities of particle 
counting methodologies. 
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Some partial attempts had been made trying to evaluate the individual methods performance (12, 13, 
17-19, 22-32), but to date no systematic analysis including a comparison between all the different 
methods using a number of different standard systems has been carried out. Recently, we reported “A 
Case Study With A Low-Concentration Therapeutic Protein Product In A Prefilled Syringe” (Chapter 
1) describing the precision of the previously mentioned analytical tool box. The aim of the present 
paper, in contrast, is to study their accuracy. For the first time we took a realistic and integrative 
approach to evaluate the accuracy performance of sub-micron methods in a detailed and systematic 
fashion. Due to concerns 
 
2.3 MATERIALS AND METHODS 
Particle generation  
Bovine serum albumin (BSA Sigma Aldrich; USA) MW ~67 kDa, formulated with phosphate buffer 
(DPBS 10x, GIBCO; UK) at 30 mg/mL as well as a monoclonal antibody (mAb) Roche Property 
calculated MW ~149 kDa, formulated with 51 mM sodium phosphate, 60 mg/ml trehalose dehydrate 
and 0.04% polysorbate 20 at ca 25 mg/mL were used as model proteins in our studies. Additionally, 
latex bead standards (Duke Standards; ThermoScientific, USA) were tested.    
To generate sufficient amounts of protein particles, proteins were artificially stressed.  
For the BSA particles, BSA formulation was initially filtered through a 0.22 µm filter membrane 
(Millex GB PVDF membrane, Millipore; Ireland). A 50 mL tube (SARSTEDT; Germany) with 30 mL 
of protein solution was heated to 73 °C for 30 minutes using a Thermostat station (Eppendorf, 
Germany). The resulting solution was diluted 1:10 to a total volume of 10 mL with PBS 1x (DPBS 1x, 
GIBCO; UK) and homogenized by vortexing (VWR; Belgium). After centrifugation (Centrifuge 
5810R, Eppendorf; Germany) at 1200G for one minute, the supernatant was collected and either the 
sample was used as initial micrometer-enriched stock or a nanometer-enriching procedure followed. 
For the mAb model A particles, mAb formulation was diluted 1:10 in PBS 10x (DPBS 10x, GIBCO; 
UK) followed by filtration through 0.22 um filter membrane (Millex GB PVDF membrane, Millipore; 
Ireland). Several 1.5 mL particle-free Eppendorf tubes (Biopure; Eppendorf; Germany) were filled 
with 1.3 mL of protein formulation using Eppendorf multippipete (Multippete stream, Eppendorf; 
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Germany) and 50 mL Combitips (Biopure, Eppendorf; Germany) at the slowest take-in and take-out 
speed. A Thermostat station (Eppendorf, Germany) was used to apply 73 °C heat stress for 7 minutes. 
A total of 24 tubes were pulled and either the sample was used as initial micrometer-enriched stock or 
a nanometer-enriching procedure followed. For the mAb model B particles, mAb formulation was 
initially filtered through 0.22 um filter membrane (0.22 µm PVDF Stericup, Millipore; USA). Several 
1.5 mL Eppendorf tubes (Biopure; Eppendorf; Germany) were filled with 1.0 mL of protein 
formulation using Eppendorf multippipete (Multippete stream, Eppendorf; Germany) and 50 mL 
Combitips (Biopure, Eppendorf; Germany) at the slowest take-in and take-out speed. A Thermomixer 
station (Eppendorf, Germany) was used to apply 80 °C heat and 1400 rpm shake stress for 3 minutes. 
Using a silicon oil free 5 mL syringe (Norm-Ject luer lock; HSW, Germany) and a 27 G x 1½ʺ needle 
(100 Sterican; Braun, Germany), the volume of each tube were sucked in and out 20 times and 
collected in 2 mL Eppendorf tubes (Biopure, Eppendorf; Germany). After centrifugation at 540 G for 
one minute, the supernatant fractions of 24 tubes were collected and a final centrifugation step of 1200 
G for 1 minute was applied. Either the sample was used as initial micrometer-enriched stock or a 
nanometer-enriching procedure followed. For the latex bead samples ThermoScientific size certified 
standards of different sizes were mixed in a proper ratio in water or isotone (Beckman Coulter Inc) to 
reach concentration and size distribution similar to that of the protein particles in the nano- and 
micrometer-enriched stocks. Depending on the size range specification for every instrument in the 
study, either a nano- or a micrometer-enriched stock was used.  
Stock characterization  
For the micrometer-enriched stock, samples were used in their original composition after the stress 
procedure. For the nanometer-enriched stock, filtration through 1.02 um filter (Acrodisc Versapor 
membrane; PALL Corp, USA) was combined with centrifugation steps until a suitable stock was 
produced not containing any large species. In all cases, the initial stocks were translucent solutions 
without visible particles. Vendor information of maximum concentration limits was considered to 
adjust initial instrument-specific stock counts. All the stocks were generated the day of analysis and 
were kept in lab conditions during each experiment. All the used material was extensively rinsed with 
particle free water (in house generated by several filtration (0.22 µm Millex GB PES membrane, 
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Millipore; Ireland) and degassing steps (Liquicel Membrane Contactors, Membrana; Germany) of 
bidestilated water)) and dried with filtered (0.22 um Millex GB PES membrane, Millipore; Ireland) 
air. For light obscuration (HIAC) and flow imaging instruments (MFI and FC), the micrometer 
enriched stock of the correspondent particle type was prepared. For electro zone sensing (Coulter 
Counter), resonant mass measurements (Archimedes) and nano tracking analysis (Nano Sight), a 
nanometer enriched stock was prepared.  
Dilution procedure 
Initial particle concentration of every stock was obtained measuring the stock in every single 
instrument per day of analysis. Several dilutions of the proper stock were prepared and measured in 
triplicate immediately after aliquoting that same day of stress. Dilutions were calculated in an 
instrument- and particle-specific way to achieve particle counts ranging from 101 to 108 particles per 
mL (with 4 target points per order of magnitude: 1.0, 2.5, 5.0 and 7.5) according to the specifications 
of each methodology. Final volumes of the dilutions were set considering: 1) minimum instrument 
requirements to assure at least triplicate measurements; 2) aliquot volume of at least 1 µL for easy 
handling with normal lab pipets; 3) dilution factor (DF) limits of 1.250 < DF > 50000.000 for the 
linearity experiments and 1.250 < DF < 500 for recovery experiments. Such dilution limits provided 
good profiles when non-stressed mAb formulation was diluted and protein in solution was then 
followed by UV-Vis absorption spectrometry as described later in the Results section. The assumption 
was applying the same handling procedure to the dilution of particles would lead to the isolation of 
particle- and instrument-related response, minimizing dilution artefacts. Dilutions were made and 
immediately measured in increasing concentration sequence. Aliquots were always taken from the 
initial stock. Stock stability was assessed by following the particle counts and size distribution at the 
beginning and at the end of each day’s experiment allowing CV variations <15 %. Diluent solution 
was the correspondent fresh, particle-free and non-stressed protein solution (or water in the case of 
latex beads). For a given instrument and target concentration, the proportion stock:diluent was kept 
comparable along the different particle types.  
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Accuracy assessment 
The average of the three experimental measurements was compared to the theoretical concentration 
and the ratio was expressed as a percentage. The recovery profile (one for each type of particle and 
analytical methodology) was built by plotting theoretical concentrations versus recovery percentage 
values. The initial approach considered all cumulative counts above the instrument’s lower size limit 
of detection as follows: >0.03 µm for NTA; >0.2 µm for Archimedes; >0.60 µm for CC; >1.00 µm for 
MFI and FC; and >2.00 µm for HIAC. Additionally, a size-wise analysis considered cumulative 
particle counts in certain bins as follows: >0.03 µm, >0.05 µm, >0.2 µm, >0.3 µm, >0.4 µm and >0.5 
µm for NTA; >0.2 µm, >0.3 µm, >0.4 µm and >0.5 µm >0.8 µm for RMM; >0.4 µm, >0.5 µm, >0.8 
µm and >1 µm >2 µm and >5µm for CC; >1.00 µm, >2 µm, >5 µm, >10 µm and >25µm for MFI and 
FC; and >2.00 µm, >5 µm, >10 µm and >25 µm for HIAC.  
Linearity assessment 
The average of the three experimental measurements was plotted against the theoretical concentration. 
Data points were fit using linear regression analysis. For detailed evaluation, the linearity of the 
corresponding method was assessed considering the full concentration range studied and also by order 
of magnitude. Data was plotted using radar representations. Each linear fit parameter is represented in 
one axis of the radar plot. Scales were adapted to be common for all the instruments so that the better 
linear fit is represented by the smaller radar plot depicted area pointing to the r2 axis. 
Light obscuration, HIAC 
A ROYCO System 9703, sensor HRLD400HC (Pacific scientific, New Jersey, USA) was used with a 
small volume method. Rinsing volume was set to 0.4 mL and 4 runs of 0.4 mL each were performed 
(sample volume was minimum 3 mL). Flow rate was set to 10 mL/min. The first run was discarded 
and the average ± standard deviation of the last three runs was reported. Blank measurements were 
performed at the beginning of the tests and in between family of samples (order of magnitude-based) 
using fresh particle-free water. The acceptance criterion for blanks was less than 5 particles > 1 µm. 
The suitability test per day of experiments consisted of the measurement of count standards of 2, 5 and 
10 µm (COUNT-CAL Count Precision Standards, ThermoScientific; USA) with acceptance limits of ± 
10% of the reported concentration for particles bigger than 1.3, 3.0 and 5 µm, respectively.  
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Micro flow imaging, MFI 
A DPA 4052 instrument from Protein Simple was used. Cleanness of the 100 um flow cell was 
achieved every day of measurement by rinsing with 1% Tergazyme (Alconox Inc.; USA) solution for 
two minutes at maximum speed, soaking for one minute and finally flushing with particle free water 
for five minutes. Method parameters were set to 1 mL sample volume as termination type, 0.2 mL as 
purge volume, with “edge particle rejection” as well as “fill particle” options activated. The light 
optimization step was performed with the correspondent filtrated sample matrix. Either single or three 
independent runs of the same dilution were performed for blanks and particle samples, respectively. 
Blank measurements were performed at the beginning of the measurements and in-between family of 
samples (order of magnitude-based) using either fresh particle-free water (for latex standards) or fresh 
unstressed formulations (for protein particles). Acceptance criteria for blanks was less than 100 
particles per mL > 1um. The suitability test per day of experiment involved 1) measurement of 5 µm 
count standards (COUNT-CAL Count Precision Standards, ThermoScientific; USA) with acceptance 
limits of ± 10% the reported concentration for particles >3 µm and 2) measurement of 5 µm size 
standard with acceptance limits of ECD mean of  ± 25% the reported size and standard deviation <0.4.  
FlowCam, FC 
A benchtop model from Fluid Imaging Technologies was used. Camera parameters with a 10x 
magnification objective were set to 14 and 25 as threshold values for the dark and bright pixels, 
respectively. Camera rate was set at 20 frames per second. Sample volume was 1 mL using 0.2 mL for 
manual initial purge and background measurement. Any other parameter for the system suitability test 
and blank measurements were kept as those described for MFI measurements.  
Coulter counter, CC 
A CC4 model of Beckman Coulter with a 30 um aperture tube was used. For mAb particles, stock 
conductivity was enhanced by adding 4 µl/mL of a saturated NaCl solution to final conductivity values 
of ~16 mS. Stocks of BSA and latex particles were used without further modification since their 
correspondent PBS and isotonic matrix, respectively, allowed for acceptable conductivity values ~18 
mS. The electrolyte jar was filled with the same buffer solution as that of sample’s matrix. Method 
parameters were set to volume analysed 50 µl, consecutive runs 3, current 600 and gain 4. Aperture 
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tube cleanness was verified in between every sample with blank measurements <1000 particles/mL of 
isoton and unstressed formulations. The instrument was calibrated using 5 um size standards in the 
correspondent buffer with no more than 1% change to the accepted Kd values, (average of 5 
independent determinations).  
Resonant mass measurement, RMM, Archimedes 
Resonant mass measurements were performed using Archimedes system (RMM0017 Generation 2) 
Affinity Biosensors, Santa Barbara, USA) equipped with a Hi-Q micro sensor. The sensor was 
calibrated using 1 μm Duke polystyrene size standards. The acceptance criterion was at least 90% 
of the particles within ± 10 % of the standard size. Prior to each sample, the system was rinsed as 
follows: matrix sample solution for two minutes, PCC54 detergent solution (ThermoScientific, 
Illinois, USA) for 2 minutes and particle-free water for ten minutes. A threshold of 0.04 Hz and 0.03 
Hz for protein and polystyrene standards was applied, respectively. The data was collected and 
analysed using the software program ParticleLab version 1.8.570 (Affinity Biosensors, USA). 
Nanoparticle Tracking Analysis, NTA 
A NS200 instrument model LM20 from NanoSight with a 405 nm laser was used. The chamber was 
extensively flushed with filtered water (0.02 um (Anotop, Whatman) and cleanness was visually 
assessed using instrument’s interface. Non-siliconized syringes (Norm-Ject, HSW, Tuttlingen, 
Germany) were used to load a 1 mL sample directly into the chamber. An initial volume of 0.6 mL was 
used to rinse out the flushing water, and with the remaining volume, three videos of 60 seconds were 
recorded using a replenished sample each time. Video recording settings were as follows: the best 
focus for a clear and sharp particle image was set. Starting from shutter equals to zero, this value was 
increased until no more new particles were visible on the screen. To avoid camera over exposition, the 
shutter was kept as low as possible. Starting for gain equals to zero, this value was increased until the 
contrast between the background and the particles was high and the actual particles were easily 
distinguished. To avoid the presence refractive rings, gain was kept as low as possible. A final slight 
adjustment of these three parameters together was made to obtain the best possible combination and 
the highest image quality. Among different runs of the same sample, strictly the same video-recording 
values were kept. Within series of samples, video-recording values were kept within narrow ranges but 
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higher importance was given to ensure all particles in a sample were tracked. The video analysis 
settings were as follows: the detection threshold value was set so that the software recognized every 
actual particle centre with a red cross. To avoid refractive rings interference, the blur value was set so 
that the area around every particle was clear and without the presence of noise particles (blue crosses). 
The applicability of these two settings was optimal throughout the video footage. The minimum track 
length was set to ten. The minimum expected particle size was set to automatic so that the software 
calculated it regarding the first 100 tracks. Considering all videos coming from the same sample were 
recorded under the same video quality settings, video analysis settings were also kept the same and 
batch analysis was performed. During measurement, temperature was recorded by a temperature 
sensor contained in the viewing unit. Sample viscosity was determined using a cone rheometer 
instrument (Anton Paar AG Switzerland, Zofingen, Switzerland) at 29 and 23 Celsius degrees. 
Viscosity values in steps of 0.1°C were interpolated and product-specific viscosity tables were loaded 
into the instrument’s software.  During video analysis, the proper viscosity values were automatically 
selected from previously loaded user viscosity tables 
 
2.4 RESULTS AND DISCUSSION  
Particle models 
To identify morphology-related factors that may influence instrument performance, different particle 
models were generated. Typically used latex beads standards were used in a mixture of different sizes 
to mimic the heterogeneity of actual protein particle samples. In the best effort to generate particles 
under lab conditions, the applied stress to BSA and mAb formulations was unrealistically high. 
However, the generated samples showed characteristics of particle heterogeneity, matrix, morphology 
and pliability similar to actual protein particles in representative samples – although significantly 
higher in number. Table 2.1 shows randomly selected MFI images of the different particle models. In 
general, latex particles exhibited the characteristic round and dark shape whereas protein particles 
were highly amorphous. BSA and mAb-model A were both highly translucent with the former having 
better defined particle edges. In contrast, the higher stress applied to generate mAb-model B originated 
darker particles. Such characteristics, helped to challenge each of the instruments included in the 
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study. For example, the differences in translucency became a critical aspect for light obscuration and 
flow imaging technologies.(33, 34) On the other hand, the different stress levels produced different 
particle pliability that became interesting factor when performing dilutions.  
Particle dilution 
To overcome the lack of count standards in all the appropriate size and concentration ranges, dilutions 
of well characterized samples had to be performed. To determine the best way to dilute particles, two 
different schemes were tested. Scheme number 1 involved various intermediate stocks (a different one 
per order of magnitude) and scheme number 2 used only one (so that all the aliquots were taken from  
 
Table 2.1 Randomly selected and representative MFI images of the particle models used. To generate latex 
samples, size standards were mixed. For the protein samples, different levels of heat stress were applied. In 
contrast with the high sphericity of latex particles, protein particles are amorphous 
Latex 
mixture 
 
BSA 
 
mAb 
model A 
 
mAb 
model B  
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the same initial preparation). Using Fluorescein (as a model of a non proteinaceous and chromophore 
small molecule) and a non-stressed monoclonal antibody (mAb) formulation, dilutions were calculated 
following both dilution schemes to generate a broad set of samples covering five orders of magnitude 
Absorbance was then followed by SoloVPE technology and the concentration in mg/mL was directly 
obtained from the instrument. Performance of both dilution schemes were compared in terms of linear 
fit (intercept b, slope m, coefficient of correlation, r2 and sum of squares total, SST) and confident 
intervals at 95%, with main focus in the lowest concentration ranges. Over the full concentration range 
both schemes correlated well with a linear fit (data not shown). However, a closer analysis per order of 
magnitude revealed for the lowest concentration range better m and r2 values for scheme 2. This 
approach could require aliquot volumes as small as 1 µL and dilution factors as large as 5000 for the 
highest diluted samples, however it reduces the noise that can be introduced using several intermediate 
stocks. Hence, scheme 2 was chosen to dilute all the protein particles in the study. It allowed us to 
directly attribute observations to an instrument’s performance, provided that dilution errors were 
shown to be minimized. Furthermore, several controls were also implemented (see also Materials and 
Methods): the size distribution of the stock solutions was noted at the beginning and at the end of the 
dilution series. Coefficients of variation values between initial and final concentration below 15% 
were considered as insignificant. This allowed for dilution set intra-comparability as all aliquots were 
taken from the same representative stock. This was the case for all the particles and instruments except 
for mAb-model A in MFI and FC; mAb-model B in MFI and FC; and latex beads in NTA (data not 
shown).  
Accuracy of counting 
In order to assess the factors governing the counting accuracy performance of different particle 
counting instruments, a highly integrative approach was taken. Important aspects like particle 
morphology, stability and size were considered. Dilutions of latex bead mixtures and artificially 
generated protein particles were prepared. That strategy helped to overcome the lack of count 
standards that i) covered the full concentration range of interest and ii) somewhat resembled the 
characteristics (morphology and size-wise) of relevant protein particle samples. Figure 2.1 shows the 
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Figure 2.1 Accuracy of particle counting. The accuracy of eight different instruments was 
studied by following the recovery of four different particle models with a dilution scheme 
approach. Rows represent instruments ordered from top to bottom in micron to submicron and 
nano size ranges. Columns represent particle models ordered from left to right in comparatively 
decreasing levels of applied stress for its generation. Horizontal axes represent the theoretical 
particle concentration per mL of each independent sample of the dilution set. Vertical axes 
represent the calculated recovery, (theoretical concentration/experimental concentration*100), 
considering all counts above the instrument lower size limit of detection as follows: >0.03 µm for 
NTA; >0.2 µm for Archimedes; >0.60 µm for CC; >1.00 µm for MFI and FC; and >2.00 µm for 
HIAC.  Ideal recovery of 100% is represented with the continuous horizontal line. For RMM, the 
vertical line indicates the lower limit of the concentration range studied and missing points 
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implies data not detected. For the rest of the instruments, missing points implies concentration 
not studied. Red symbols represent recoveries > 200%. 
 
percentage ratio between the theoretical and experimental concentrations of each particle model 
(columns) and instrument (rows) included in the study. The experimental setup used in this research 
allowed for the detection of interesting factors governing accuracy performance of sub-micron 
methods. Results showed that the different particle nature of the models produced different recovery 
profiles. In general, the recovery % of total particle counts was good in the upper concentration ranges 
whereas a strong over-counting effect –mainly for the mAb particles– occurred in the lower 
concentration ranges. A more detailed evaluation on the recovery profiles demonstrated that, in most 
of the cases, instrument accuracy varied depending on the type of particle. Latex beads showed the 
best recovery profiles with a large majority of the values smoothly distributed around 100 % recovery 
(except for NTA). This confirmed the already established good performance of the instruments when 
measuring these typically used standard particles. Interestingly, the picture was different when using 
actual protein particles. Poorer profiles (recoveries >>> than 100%) were found i) as the particle 
nature changed from a high (and hence high optical density and particle stability) to lower level (and 
hence high translucency and pliability) of applied stress and ii) as the sample concentration decreased 
(except for RMM). It is important to note that the over-counting was more severe for the model mAb-
A, which contained particles generated through the less severe stress level (as compare with model 
mAb-B and BSA). Since that model of particles is considered to be the most fragile the observed poor 
recovery can most likely be attributed to particle desintegration. In another interesting observation, for 
a given instrument, the starting concentration point of this striking over-counting effect varied 
depending on the particle model. That suggests that sample nature played an important role in the 
accuracy performance of the instrumentation. The over-counting here described, clearly reveals severe 
weaknesses in the accuracy performance of subvisible/submicron particle methods when realistic 
protein samples are measured (size-heterogeneous and proteinaceous samples). Most importantly, 
from a quality control point of view, this would lead to many false positive measurements. 
Although dilution-related artefacts cannot be completely excluded as likely contributors to the poor 
accuracy at low concentrations, the exhaustive controls that were implemented (see Materials and 
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Methods section and further data not shown) severely limited their presence. Furthermore, the dilution 
methodology here implemented had already been successful reported in a previous publication (35). In 
another control, a series of fake dilutions (on which the same mixture proportions of stock : diluent 
was reproduced using only diluent) showed random recoveries (data not shown), whereas the results 
showed a clear tendency to higher recoveries. Finally, controls to exclude 1) likely dilution-induced 
artefacts and 2) sample polydispersity (in the case of latex particles) effects were also implemented. 
For 1) when counts standards were available (i.e. for 2, 5, 10 and 25 µm) the accuracy of counting was 
also analysed using the customary commercial and fixed concentration of 3000 particles/mL. This was 
also limited to those instruments in the micron size range. Results indicate good (> 95%) recoveries 
(not shown). For 2) the accuracy profile of latex dilutions of single sizes was also analysed. In this 
case, the overestimation of the counts that increased with every consecutive dilution was also observed 
(data not shown). Interestingly, as the initial concentration of this type of sample was not limited by 
the applied stress level as in the case of protein samples, much higher concentrations were possible to 
test. Results showed an undercounting effect that can be explained by sensor saturation (data not 
shown). However, the initial concentrations of the bead suspensions were calculated using the dry 
content of the suspensions as declared by the manufacturers. Such estimation may result in additional 
errors and present another important caveat when using this single-size approach means of the 
assessment. In conclusion, both previously described control experiments were not representative of 
the morphology, concentration and heterogeneity characteristics of the particles likely present in 
biotechnological products. These results showed that dilutions of (protein) particle-containing 
solutions are not recommended, unless a sound understanding of any instrument-specific effect is 
achieved and has been specifically qualified. 
By visual assessment on plotted results, accuracy ranges can be defined per instrument and per particle 
type as shown in Table S2.1. However, these limits should not be considered as general. They just 
exemplify the application of a methodology that is useful in selecting, in a realistic product- and 
instrument-specific manner, the best accurate ranges for particle characterization. Below the indicated 
lower limits, all the instruments (except for RMM) demonstrated a propensity to over counting. This 
approach helps to overcome the difficulties that applying typical statistics would offer. For example, 
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there is little available data about the submicron particle burden of biotherapeutics. This is because of 
the limited application of subvisible particle analysis to the characterization and development stage not 
the routine quality control process. The former, in combination with the inherent product variability 
(1), can lead to unrealistically low control limits. The methodology here proposed is to define the 
lower limit of counting capabilities and also allow for the identification of important instrument-
specific effects that were also encountered and will be discussed later in the corresponding section. 
To further evaluate the root cause of the over-counting effect, in contrast with Figure 2.1 on which 
total particle counts were presented, a size-wise analysis was carried out to evaluate whether there was 
instrument accuracy (for a given particle model and instrument combination) bias towards specific 
size ranges (see Figure S2.1). Based on this representation, certain patters were identified and are 
presented in Figure 2.2 where both, stock concentration (left axis) and recovery percent (right axis) are 
plotted as a function of the particle size. Three different categories can be described: Case I. Good 
recovery along all the concentration ranges tested which do not vary with binned sizes. Case II. 
Recovery worsened as the sample concentration decreased and size bin increased. Case III. Poor 
recovery along all the concentration ranges tested, which did not vary with binned sizes. This 
important result highlights the impact that the relative size composition had on the method accuracy 
performance. Similarly, such an effect was already described in Chapter 1 on which the precision of 
particle counting instruments was also found to be sample-composition dependent. More importantly, 
as can be seen in Table 2.2, most of the recovery profiles described in Figure 2.1, fall into Case II (see 
also Figure S2.2) which implies that, not only instrument related artefacts, but also sample relative 
size composition has to be considered to interpret accuracy performance results. 
Accuracy of sizing 
The sizing accuracy of each method was evaluated using size standard polystyrene bead suspensions 
and is presented in Figure 2.3. The accuracy of sizing varied widely as a function of size, with all 
methods overestimating the size of the standards in their respective lower size range. For example, 
MFI overestimated the size of beads of 1 μm in diameter, CC overestimated the size of beads of 0.5 
μm diameter, RMM overestimated the size of beads of 0.5 μm diameter and NTA
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Figure 2.2 Identified categories that describe the relation between size distribution and method 
accuracy performance. The recovery profile presented in Figure 2.1 was analysed size wise and 
correlated with the size distribution of stocks from where dilutions were prepared. Horizontal 
axes represent cumulative size bins. Vertical left axes represent the particle concentration of the 
stock and error bars represent the related standard deviation of the measurements at the beginning 
and at the end of the experiment. Vertical right axes represent the recovery associated with each 
sample of the dilution set from high (black) to low concentration (red). Each panel exemplifies 
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typical encountered profiles that can describe the relation between accuracy and size distribution: 
Case I, accuracy is independent of particle concentration (ideal); Case II, better accuracy for 
those sizes with higher counts (inverse); Case III, poor accuracy 
 
overestimated the size of beads of 0.05 μm diameter. Conversely, most methods underestimated the 
size of standards with diameters in the larger size range. In addition, the sizing accuracy in those sizes 
ends varied substantially as a function of concentration. 
Linearity 
The linearity assessment was carried out using the same four particle models and dilution approach 
previously described for the evaluation of the accuracy of counting. Analysis of all linear fit 
parameters (slope (m); intercept (b); regression coefficient (r2) and sum of squares total (SST)) together 
in a radar plot representation offered a better insight on the instruments’ linear performance. Similarly 
to the counting accuracy profiles, linearity assessment also showed differences depending on the type 
of particle analysed. However, general observations can be made based on instrument type. As 
indicated in Figure 2.4, by the smaller radar plot area pointing to the r2 axis, the micron methods 
HIAC, MFI and FC showed better linearity performance than the submicron methods CC, RMM and 
NTA. With a more detailed evaluation of the linearity by order of magnitude, specific concentration 
ranges can be defined by each instrument and particle type. For example, while in the CC instrument 
the linear range for latex beads (considering r2 > 0.9 and m < 10) was from 103 to 105 particles/mL, the 
mAb-model A particles range appeared to be narrower covering just concentrations as high as 105 
particles/mL (see Figure S2.3a and Figure S2.3d). As already described for the accuracy assessment, 
poorer linear profiles were found i) as the particle nature changed from higher to lower levels of 
applied stress and ii) as the sample concentration decreased. As in the case of the accuracy lower limits 
proposed in Table S2.1, these linear ranges should not be interpreted as general but as the result of this 
specific experimental setup used to exemplify an integrative and realistic method evaluation approach.  
Use of the instruments as complementary analytical techniques 
All in all, not only the previously described accuracy and linear ranges of the instruments were 
different between particle types, but the particle measurements also displayed major discrepancies, as 
already observed in a previous stability study (see Chapter 1). These observed variations may have 
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different sources including instrument analytical deficiencies. The variety of methods investigated 
determined the reported particle size by assessing very different physical properties of the particle 
standards used for calibration. The accuracies of these methods are thus affected to varying degrees by 
the specific attributes of the polystyrene spheres. This difference is expected to affect the analysis of 
protein particles to an even greater degree, leading to substantial method-inherent differences in the 
total number of particles reported. Whilst the future availability of a protein or protein-like standard 
may allow different calibration procedures of these methods (possibly leading to an increase in 
accuracy), it is important to notice that sub visible particle instruments are frequently changing and 
both hardware and software- are constantly being updated. Aiming to improve analytical performance, 
there is currently a pump available for the NTA system (although in our experience it did not improve 
the performance of the method, see  
 
Table 2.2 Based on the cases presented in Figure 2.2, the 
size-dependent accuracy response of each particle model 
and instrument combination was categorized. 
Instrument Particle model Case I Case II Case III 
HIAC Latex X   
BSA  X  
mAb-model B  X  
mAb-model A   X 
MFI Latex X   
BSA  X  
mAb-model B  X  
mAb-model A  X  
FC Latex X   
BSA  X  
mAb-model B  X  
mAb-model A  X  
CC Latex  X  
BSA  X  
mAb-model B  X  
mAb-model A  X  
RMM Latex  X  
BSA  X  
mAb-model B  X  
mAb-model A  X  
NTA Latex  X  
BSA   X 
mAb-model B  X  
mAb-model A  X  
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Figure 2.3 Size accuracy of A) HIAC, B) MFI, C) CC, D) RMM and E) NTA instruments 
with polystyrene of different sizes as indicated in the header of every panel 
 
Chapter 4) and the incorporation of statistical tools for better particle classification using flow imaging 
technologies. Furthermore, although the “submicron gap” has been covered; a complete particle 
characterization (including micron and submicron size range) will synthesize the information coming 
from various instruments. Understanding their different principles, in addition to the assorted inherent 
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factors governing their performance, is essential if we are to fully understand to what extent they 
complement one another. To further this knowledge, Figure 2.5 shows the recovery percentage of four 
selected points of the dilution set of latex (Figure 2.5A) and mAb-model B (Figure 2.5B) particles 
plotted in a continuous size scale. Considering instrument’s (vendor recommended concentration and 
size ranges) and the stock’s limitations (dilution extend based on initial concentration as well as initial 
size distribution; see Materials and Methods) in regards to the specific setup of this experiment, a 
different combination of methodologies could provide information either in the nano (< 1 µm) or in 
the micron (> 1 µm) size range in a concentration dependent manner. Regardless of the considerations 
previously mentioned, these important observations should be considered: i) For a given particle size, 
particle counts varied depending on the methodology used as a reporter. However, comparable 
methodologies (i.e. MFI and FC) showed the closest recoveries. This highlights the impact of the 
different principles on the reported counts which will also lead to inherent differences in the precision 
(see Chapter 1) and accuracy of these measurements. ii) Variations described in i) followed a 
concentration dependent trend. For example, in the case of latex -at least in the upper size range- at 
7.5x106 particles per mL the discrepancies between RMM and NTA were significantly reduced as 
compared to the 7.5x105 particles per mL dilution point. For mAb-B particles even higher 
concentrations may be needed to reflect this effect. In general, better accuracy performance was found 
in the upper concentration range of each instrument. iii) For latex particles along the dilution set, a 
certain concentration was reached in which recovery for all instruments at most of the sizes was not 
only ~100% but also comparable between them. This is the case of micron-range particles at 7.5x103 
particles/mL and nano range particles at 7.5x106 particles/mL. However, for mAb-model A particles 
such consistency was not found at any concentration (neither for BSA and mAb-model B particles, 
data not shown). iv) There is lack of a suitable methodology than can accurately report low 
concentrations in the nano range and high concentrations in the micron range. For example, at 7.5x101 
particles per mL, the only instrument that reported particle counts both for latex and mAb particles in 
the micrometer range was HIAC, whereas in the nanometer range no methodology reported values at 
such a low concentration. In contrast, at 7.5x105 particles per mL, in the micrometer range only MFI.  
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Figure 2.4 Independent dilution series of each particle type were measured in each instrument. 
The linearity performance was evaluated and each linear fit parameter is represented by one axis 
of the radar plot. Scales were adapted to be common for all the instruments so that the better 
linear fit is represented by the smaller radar plot depicted area pointing to the r2 axis 
 
and FC reported information, whereas in the nanometer range RMM and NTA both did. This issue is 
something that will hopefully be assessed by further instrumentation developments. Interestingly, at 
this relatively high concentration, CC appeared in between the two size scales, however, a smooth 
transition was not observed. 
Instrument-specific considerations 
The use of identically prepared particle models for all the different techniques allowed for the 
identification of instrument-specific factors. This section will describe those observations. 
Interestingly, they revealed how the instrument fundament can bias count determinations as a result of 
different particle natures.  
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Figure 2.5 The recovery profile of 4 selected points (75; 7500; 750000 and 7500000 
particles/mL) within the dilution set of A, latex and B, mAb-model B particles is presented 
including all the instruments as follows:  HIAC;  MFI;  FC;  CC;  RMM;  NTA. 
This allows for data overlook in the complete size range (from >0.03 um (lower limit NTA) to 
>25 um (upper limit HIAC)). For a given concentration panel, only some of the instruments 
report data based on their specifications and sample composition. The horizontal axis represents 
the size of the particles and the vertical axis represents the recovery, 
(experimental/theoretical*100). At a given particle size and theoretical concentration, different 
instruments reported different experimental values hence different accuracy is associated. This 
effect is more severe for protein particles as compared with latex 
 
For the flow imaging technologies, a clear difference was found in the recovery profile of mAb and 
that of latex or BSA models. . Provided that the same dilution and handling procedure was applied to 
all four particle preparations, this observation suggests a likely influence of the more complex particle 
matrix on which the mAb particles are immersed. It seems that a final protein formulation with all the 
typical excipients included might represent a major challenge for the camera-based techniques. It has 
been suggested that protein formulations can trap very small air bubbles (~1-2 µm) which cannot be 
discerned using morphological parameters or available statistical filters. The size-wise analysis 
presented in Figure S2.1b suggests this hypothesis is applicable. In the case of mAb-model A particles, 
even at high concentrations, -where other instruments showed good accuracy profiles- a strong over 
counting effect can be observed for the smallest >1 µm bin.  
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Another example in which the effect of particle morphology/nature could be identified is the CC 
instrument. This methodology bases its determinations on volume displacement. Assuming a spherical 
diameter for all particles (equivalent circular diameter determinations) morphology should not play a 
role in the measurements. This was confirmed by comparing the recovery profiles of latex, BSA and 
mAb-model B particles (Figure 2.1). Those examples showed similar good recoveries in both latex 
and protein. However, mAb-model A was the only model which exhibited a different profile. One 
possible cause of this observation is the high pliability of this model (a consequence of the relative low 
stress level applied to its generation) that could not endure the mechanical stress of the particle 
pumping through the glass tube orifice. Such mechanical stress due to particle transit inside the 
instrument has been suggested for other techniques (31) and is probably also present during particle 
dilution. These observations are of the highest importance given that CC is a technique that often 
requires particle dilution to increase sample conductivity. Our results clearly show how detrimental 
this practice can be in terms of particle integrity and accuracy of results. 
The case of RMM exemplified a probabilistic effect already described in a previous publication of our 
group in which the precision assessment of particle counting instruments was carried out. In that study 
(Chapter 1) a poor precision for larger particle sizes was found to be rooted in a poor sampling effect 
due to low numbers of such particles whiting the entire sample size distribution. Similarly, in the 
present study, the tiny volumes that RMM uses challenged the limits of probabilistic detection (dashed 
lines Figure 2.1). Within our dilution study this effect is, of course, benchmarked by the initial 
concentration of the stock solutions. However, the same scenario would appear when measuring 
biotechnological products even without dilutions since their particle burden is generally low (2). 
Finally, NTA appeared to be the least effective methodology included in this experimental design. In 
contrast with all other methodologies, not even latex beads showed a good recovery profile. 
Interestingly, in another set of experiments in which single sizes instead of a mixture of latex standards 
was used, the accuracy profile was acceptable (data not shown). Such contrasting results perfectly 
exemplify how important is to assess instrument accuracy using a realistic experiment design. In this 
specific case, the use of size-wise polydisperse samples allowed for the unmasking of strong over 
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counting effects. This behaviour was found to be consistent and even more pronounced in the case of 
the proteinaceous particle models. 
Altogether, instrument-related artefacts were found to influence each one of the methodologies. 
Surely, particle characterization of biotechnological products constitutes a complex topic that offers 
many challenges. Some of them were illustrated by the different particle models used in this study. 
Despite the fact that only the Light Obscuration technology is currently considered in the regulatory 
frame; particle characterization at extended size ranges other than the >10 and >25 µm cut off values 
is recommended. In this regard, the careful use and interpretation of results when using any other 
techniques is strongly recommended. 
 
2.5 CONCLUSIONS 
The present study described the analytical assessment of the accuracy of subvisible and submicron 
particle counting instruments. We have shown that particle morphology and particle pliability are 
important factors that affect the performance of the instruments. The accuracy profiles appeared to be 
more different when measuring typically used latex beads standards than when measuring actual 
protein particles. Furthermore, a strong over-counting effect was found for the later especially at low 
concentration ranges and when particle stability was low. Among all the instruments tested, the nano 
tracking technology showed the strongest over-counting. For all techniques, the relative sample 
composition was found to be the most important factor, with improved accuracy for those particle 
sizes represented in the majority.  
Our study showed how the specific analytical principles can impact the response of the instruments 
and which considerations should frame the interpretation of the results. All in all, the here illustrated 
experimental design should help define the ranges of particle and instrument specific counting 
capabilities. This represents an important tool in the applicability of the subvisible particle counting 
instruments in the research and development pharmaceutical arena 
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Table S2.1 Lower limits of counting capabilities per instrument and particle type 
 
Latex BSA mAb1-B mAb1-A 
NTA 5.0x10
8
 2.5x10
9
 2.5x10
8
 7.5x10
8
 
RMM 2.5x10
5
 2.5x10
6
 2.5x10
5
 5.0x10
5
 
CC 2.5x10
3
  2.5x10
3
  7.5x10
4
 7.5x10
6
  
FC 2.5x10
2
 2.5x10
2
 2.5x10
4
 2.5x10
4
 
MFI 5.0x10
2
 5.0x10
2
 5.3x10
3
 1.0x10
4
 
HIAC 5.0x10
1
 5.0x10
1
 2.5x10
2
 5.0x10
2
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Figure S2.1a Examples of the recovery profile analyzed size-wise. Recovery profile of A) latex 
particles measured in HIAC; B) mAb-model B particles measured in MFI and C) BSA particles 
measured in NTA. Horizontal axes refer to the theoretical total particle concentration of each 
independent sample of the dilution set based on which the size-wise analysis was performed. Different 
panels represent the recovery profile of specific particle sizes in cumulative bins. 
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Figure S2.1b Recovery profile of all the counting instruments and particle models in scope analyzed 
per cumulative size bin. Horizontal axes refer to the theoretical total particle concentration of each 
independent sample of the dilution set based on which the size-wise analysis was performed. Vertical 
axes represents the calculated recovery, considering initial counts per bins as indicated by the different 
colors (theoretical concentration of a given bin/experimental concentration of the same bin*100). 
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Figure S2.2a. Recovery profile per particle size for HIAC instrument The recovery profile per total 
particle counts of A, latex; B, BSA, C, mAb-model B and D, mAb-model A particles was analyzed 
size wise and correlated with the size distribution of stocks from which dilutions were prepared. 
Horizontal axes represent cumulative size bins. Vertical left axes represent the particle concentration 
of the stock at the beginning (continue line) and at the end (dashed line) of the experiment. Vertical 
right axes represent the recovery associated with each specific size along the full dilution set (box 
plot). 
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Figure S2.2b Recovery profile per particle size for MFI instrument. See legend Figure S2a
 
Figure S2.2c Recovery profile per particle size for FC instrument. See legend Figure S2a 
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Figure S2.2d Recovery profile per particle size for CC instrument. See legend Figure S2a 
 
 
Figure S2.2e Recovery profile per particle size for RMM instrument. See legend Figure S2a 
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Figure S2.2f Recovery profile per particle size for NTA instrument See legend Figure S2a 
 
CHAPTER 2. Factors Governing The Accuracy Of Sub-Micrometer Particle Counting 
Methods 
85 
 
APPLICATION OF NOVEL TECHNIQUES FOR CHARACTERIZATION OF SUB-VISIBLE AND SUB-MICRON 
PARTICLES IN BIOPHARMACEUTICAL PREPARATIONS 
 
 
 
 
Figure S2.3a Linear assessment for latex particles A stock solution of the indicated type of particles 
was diluted to generate a broad set of samples benchmarked by instrument’s concentration capabilities 
to measure in each instrument. The linearity assessment was performed by following all linear fit 
parameters (slope (m); intercept (b); coefficient of determination (r2) and sum of squares total (SST)) 
together in a radar plot representation. Scales were adapted to be common for all the instruments so 
that the better linear fit is represented by the smaller radar plot area pointing to the r2 axis. Analysis 
was done considering the full size range (gray plots) and also per order of magnitude (color scale code 
from green=10 to red=100000000 particles/mL). Using internally defined criteria of m < 10 and r2 > 
0.9 optimal linear ranges are indicated by dotted boxes. 
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Figure S2.3b. Linear assessment for latex BSA particles See legend in Figure S2.3a 
 
Figure S2.3c. Linear assessment for latex mAb-B particles See legend in Figure S2.3a 
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Figure S2.3d Linear assessment for latex mAb-A particles See legend in Figure S2.3a 
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3.1 ABSTRACT 
Although light obscuration is the “gold standard” for subvisible particle 
measurements in biopharmaceutical products, the current technology has limitations 
with respect to the detection of translucent proteinaceous particles and particles of 
sizes smaller and around 2 µm. Here, we describe the evaluation of a modified light 
obscuration sensor utilizing a novel measuring mode. Whereas standard light 
obscuration methodology monitors the height (amplitude) of the signal, the new 
approach monitors its length (width). Experimental evaluation demonstrated that this 
new detection mode leads to improved detection of subvisible particles of sizes 
smaller than 2 µm, reduction of artefacts during measurements especially of low 
concentrations of translucent protein particles and higher counting accuracy as 
compared to flow imaging microscopy and standard light obscuration measurements. 
  
CHAPTER 3. Measuring Sub-Visible Particles in Protein Formulations Using a Modified 
Light Obscuration Sensor with Improved Detection Capabilities 
93 
 
APPLICATION OF NOVEL TECHNIQUES FOR CHARACTERIZATION OF SUB-VISIBLE AND SUB-MICRON 
PARTICLES IN BIOPHARMACEUTICAL PREPARATIONS 
 
3.2 INTRODUCTION 
Despite the introduction of multiple new methodologies for characterization of sub-visible particles in 
parenteral formulations during the last decades, the light obscuration method (as described in USP 
chapter <788> (1) and Ph.Eur. 2.9.19.) is still the most reliable method for subvisible particle 
quantification applied in the pharmaceutical industry. The broad use of this technique, included as a 
compendial method since 1986, is the result of proven robustness and well understood performance. 
The method is based on the blockage of a constant source of light illuminating a photo-diode by 
particles passing through the flow-cell and measuring of the consequential drop in voltage. The size of 
individual particles is determined by relating the registered signal to a calibration curve built using 
reference polystyrene particles of defined sizes.  
The light obscuration method was developed for measuring particles that are beyond the detection 
capabilities of visual inspection. The rationale for the introduction of measurement of sub-visible 
particles was the concern related to possible embolism or vein occlusion after intra venous (IV) 
administration. However, recently subvisible particle measurements have received further attention 
due to concerns that subvisible proteinaceous particles in protein therapeutics may have the potential 
to trigger immunological reactions (2-5). While the relevance of these concerns and the impact of 
subvisible particles on immunogenicity of biopharmaceuticals remain to be established, accurate and 
precise quantification of particles smaller than 10 µm is a major challenge to the current analytical 
methodology. 
Analysis of particles in formulations of therapeutic proteins, including biotechnological products 
intended for routes of administration other than IV may be challenging. Important sample 
characteristics such as high viscosities (>6 cP up to 120 cP), limited sample volume (in many cases 
<2.5 mL), appearance characteristics (e.g. translucency, optical density), and particle stability 
(agglomeration, aggregation and particle rearrangement) need to be considered. The USP <787> (6) 
(officially applicable since August 2014) attempts to address some of these considerations that were 
originally pointed out in research papers (7, 8). For example, the new chapter provides some guidance 
for sample handling relevant to biotech products – e.g. recommendation against sonication. 
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Nevertheless, a number of challenges still remain to be tackled. For example, one of the main 
limitations of the light obscuration method is related to the ability for detection and sizing of relatively 
translucent particles which are typically present in biotechnological products (9, 10). The basis of this 
potential limitation is the discrepancy between the nature of the particles used for calibration 
(polystyrene beads) and the particles actually measured (proteinaceous and others). Whereas the 
former are optically dense and spherical, the latter vary in shape and more importantly – in optical 
density. As a rule, proteinaceous particles are less optically dense and therefore, a larger total surface 
area of a protein particle may be required to generate a comparable voltage drop to that generated by a 
polystyrene bead of equal size. The difference between the translucency of calibration standards and 
that of the measured particles likely results in a certain undersizing effect (11). One direct approach to 
solve this issue would be to change the material used for calibration. However, both the production of 
protein particles that fit the requirements of a standard material and the production of synthetic 
particles that resemble the morphology and optical properties of actual protein particles present major 
technical challenges. Although the second approach had been focus of ongoing efforts and partial 
success has been achieved (12, 13), still a lot remains to be desired with regard to practical 
implementation of such solution. 
A methodology which claims to solve this quantification issue is the flow imaging microscopy 
technique. Despite the fact that in principle the detection of particles in this method should not be 
affected by particle morphology, it presents challenges of its own. For example, the detection of 
particles in flow imaging microscopy depends on the difference between the refractive indices of the 
medium and of the measured particles. Furthermore, in this technique the translucency of the 
measured particles affects the accuracy of particle sizing (9, 10, 14, 15). Because of these challenges, 
flow imaging microscopy does not necessarily present the best solution for particle quantification, 
although it remains a valuable tool for particle characterization. 
Light obscuration method adaptions, such as lower measuring volumes and sample pressurization have 
already been studied (8, 16, 17). It has been demonstrated that analytical performance of modified 
light obscuration method may produce reliable results as the large volume modality. Benefits  
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Figure 3.1 Schematic representation of the general principle of the Standard Light obscuration 
technique (SLO) in comparison with the Time resolved Light Obscuration prototype (TLO). 
Whereas SLO measures the height of the signal, TLO measures the width. For , despite the 
light blockage is weaker as compare to  given its higher translucency; when measured using 
TLO a correct bigger size will be reported.  
 
regarding improved counting accuracy, elimination of masking effects due to pooling procedures as 
well as comparisons with other counting techniques have also been described (1-3). However, some 
new opportunities still remain to be explored. 
This present study aimed to evaluate a prototype of an optimized version of the existing standard light 
obscuration method (hereafter referred to as SLO), which may allow the accurate monitoring of 
particles in the 1-2 µm size range and reduce the alleged undersizing effects of translucent (e.g. 
proteinaceous) particles (4-6). In addition to low volume and sample pressurization modifications, the 
new approach offers an improved light obscuration sensor with a novel instrument configuration and 
measurement mode represented in Figure 3.1. This new, time-resolved configuration (hereafter 
referred to as TLO) enabled i) higher accuracy for low voltage drop signals coming from small 
particles and ii) elimination of the influence of the morphology mismatch between standards used for 
calibration (latex beads) and protein particles on the accuracy of the measurements. Both by means of 
registering the width (time-resolved mode) instead of the height (standard mode) of the light 
obscuration signal. This represents a new and innovative technique that measures the time course on 
which the light is obscured rather than the intensity of this effect. Hence, particles resulting in very 
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low-intensity signals (e.g. translucent particles) can be sized more accurately by recording the time-
span of the light blockage. We present the results of the evaluation and verification of this approach. 
Special attention was given to the counting accuracy of particles below 2 µm with an uneven optical 
density. 
 
3.3 MATERIALS AND METHODS 
Counting accuracy 
Particle count standards (COUNT-CAL Count Precision Standards, ThermoScientific; USA) of 2, 5, 
10, 15 and 20 µm were used. Manufacturer’s reported concentration in particle/mL was 3000 ± 10 % 
for particles ≥1.3 µm; ≥3 µm; ≥7.5 µm; ≥10 µm and ≥15 µm; respectively.  
Linearity and recovery  
A broad set of dilutions was prepared using bovine serum albumin (BSA from Sigma Aldrich USA) 
particles generated as follows: a 30 mg/mL BSA formulation in PBS (DPBS, GIBCO UK) was 
initially filtered through a 0.22 µm filter membrane (Millex GB PVDF membrane, Millipore Ireland). 
A 50 mL tube (Sarstedt Germany) with 30 mL of protein solution was heated up to 73°C during 30 
minutes using a Thermostat station (Eppendorf Germany). The resulting solution was diluted 1:10 to a 
total volume of 10 mL with PBS 1x (DPBS 1x, GIBCO UK) and homogenized by vortexing (VWR 
Belgium). After centrifugation (Centrifuge 5810R, Eppendorf Germany) at 1200 x g for 1 minute, the 
supernatant was collected to generate the “BSA stock” solution. The dilution procedure was 
standardized as follows: unstressed 40 mg/mL monoclonal antibody (mAb) formulation (consisting of 
a Roche proprietary reference IgG monoclonal antibody) was diluted with the correspondent buffer to 
generate a broad set of dilutions. The protein concentration in solution was followed by UV absorption 
using a SOLO VPE (C. Technologies; USA) spectrophotometer. When good linearity and recovery 
profiles were obtained, the same handling procedure and dilution extend was applied for the dilution 
of protein particles. The absence of dilution artefacts was confirmed by the excellent linearity profiles 
as described later in the Results section. Initial concentration of the daily-prepared BSA stock was 
defined accordingly to every independent instrument. Dilutions were calculated to achieve particle 
counts ranging from 10 to 10000 particles per mL and were measured immediately after aliquoting and 
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during the same day of stress. Minimum sample volume was set accordingly to instrument 
requirements to assure at least triplicate measurements. Maximum sample volume was set as needed to 
ensure stock aliquot of at least 1 µL. The diluent solution was the corresponding fresh filtered (0.22 
µm PVDF Stericup, Millipore; USA) and non-stressed protein solution. All used material was 
extensively rinsed with particle free water (in house generated by several filtration and degassing steps 
(Liqui-cel Membrane Contactors, Membrana Germany) of bi-distilled water) and dried with 0.22 µm 
filtered (Millex GB PES membrane, Millipore Ireland) air prior use.  
Particle size distribution 
A stock solution of BSA particles prepared as described above was used. The same sample was 
measured in all the methods.  
Morphology evaluation  
The same preparations of mAb and ETFE (ethylene-tetrafluoroethylene) particles were measured in 
Flow imaging; Time resolved light obscuration and Standard light obscuration methods. mAb particles 
were generated as follows: a 25 mg/mL mAb formulation was diluted 1:10 in PBS (DPBS 10x, 
GIBCO UK) and filtrated through a 0.22 µm filter membrane (Millex GB PVDF membrane, Millipore 
Ireland). Formulation was subjected to heat stress (73°C for 7 minutes) using a Thermostat heat plate 
(Eppendorf, Hamburg Germany). ETFE particles were a gift from Dean Ripple (National Institute of 
Standards and Technology, Gaithersburg, Maryland USA).  
Concentration and size dependency experiment 
Two independently prepared stock solutions of mAb particles were used. Applying the dilution 
procedure already described independent dilution series were prepared and measured in Flow imaging 
and Time resolved light obscuration methods.  
Standard light obscuration (SLO) measurements 
A HIAC (ROYCO System 9703, sensor HRLD400HC, SKAN Basel, Switzerland) instrument with a 
small volume method was used as follows: rinsing volume was 0.2 mL and 4 runs of 0.4 mL each were 
performed at flow rate of 10 mL/min. The first run was discarded and the average ± standard deviation 
of the last 3 runs was reported. Cumulative particle counts per mL were obtained for sizes >2, >5, >10 
and >25 µm. Data of particles >1 µm was considered just informative. Blank measurements were 
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performed at the beginning of the measurements and in between family of samples (order of 
magnitude-based). Acceptance criterion for blanks was less than 5 particles >1 µm. Suitability test per 
day of measurements involved the measurement of count standards of 2, 5 and 10 µm 
(ThermoScientific; USA) with acceptance limits of ± 10 % the reported concentration for particles 
bigger than 1.3, 3.0 and 5 µm, respectively. All stock samples were measured at the beginning and at 
the end of each measurement day to compare the particle concentration and size distribution. For 
dilution samples, counts >2 µm were compared to the theoretical values and the percentage correlation 
was reported as % recovery, (theoretical concentration/experimental concentration*100). 
Time resolved light obscuration (TLO) measurements 
A modified version of the standard light obscuration principle was used to monitor time-resolved 
changes in light blockage. The instrument was manufactured and modified by Markus Klotz GmbH 
(Burgholz, Germany), so that width measurements of the voltage drop due to particle’s light 
obscuration effect could be measured. Additionally, as the sample was drawn at 40 mL per minute, the 
sample chamber was pressurized with nitrogen to avoid artefacts due to the presence of bubbles and/or 
air/liquid interface meniscus. Measurements were done accordingly with the small volume method 
described in the previous section. 
Flow imaging (FI) measurements 
An MFI instrument (DPA 4200 Brightwell Technologies Canada) equipped with a 100 µm flow cell 
was washed prior use with 1 % Tergazyme (Alconox Inc.; USA) solution during 2 minutes at 
maximum speed, soaking during 1 minute and finally flushing with particle free water during 5 
minutes. Method parameters were 0.6 mL sample volume as termination type and 0.2 mL as purge 
volume. “Edge particle rejection” as well as “fill particle” option was activated. Light optimization 
step was performed with the correspondent filtrated sample. Cumulative particle counts per mL were 
obtained for sizes >1, >2, >5, >10 and >25 µm. Blank measurements were performed at the beginning 
of the measurements and in-between family of samples (order of magnitude-based) using fresh 
particle-free water. Acceptance criterion for blanks was less than 100 particles per mL > 1 µm. 
Suitability test per day of experiment involved 1) measurement of 5 µm count standards 
(ThermoScientific, Count-Cal; USA) with acceptance limits of ± 10 % the reported concentration for 
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particles >3 µm and 2) measurement of 5 µm size standard (ThermoScientific Duke Standard) with 
acceptance limits of Equivalent Circular Diameter (ECD) mean of ± 25 % the reported size and 
standard deviation <0.4. For stock samples, measurements at the beginning and at the end of the day of 
experiment were done and particle concentration was compared in the following bins: 1-2, 2-5, 5-10 
and 10-25 µm. Size distribution in the 1 to 100 µm size range was also compared. For dilution 
samples, counts >1 µm were compared to the theoretical values and the percentage correlation was 
reported as % recovery, (theoretical concentration/experimental concentration*100). 
 
3.4 RESULTS AND DISCUSSION 
In order to evaluate the performance of the modifications made in the time-resolved light obscuration 
instrument (TLO), experiments to evaluate the count accuracy, linearity, recovery, size distribution, 
and morphology impact were carried out.  
Counting accuracy 
The counting accuracy of each instrument was evaluated by measuring the recovery of count standards 
of 2, 5, 10, 15 and 20 µm with a concentration of 3000 particles/mL (see Table S3.1). The SLO 
instrument configuration met supplier’s criteria (recovery of ± 10 %) for 5, 10, 15 and 20 µm 
standards. However, for 2 µm count standard, the accuracy was not satisfactory with only 53 % 
recovery. This is not surprising as size specification of particles >1.4 µm is outside the lower size limit 
of the sensor. Interestingly, TLO showed accuracy within specifications for all the sizes including the 
smallest 2 µm standard. This suggests a major improvement of the new measuring mode and 
demonstrates that measuring the width instead of the height of the drop in voltage peak offers better 
accuracy for the minor signals produced by small (< 2 µm) particles. The FI measurements showed 
accuracy within specifications for all sizes.  
Linearity and recovery 
Although the SLO measurements are well suited for the low particle counts that are frequently found 
in biotechnological therapeutic products, concentrations below 100 particles/mL might represent a 
challenge for the analytical performance of counting instruments due to a poor signal to noise ratio. To  
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Figure 3.2 Linearity profile Independent dilution series of BSA heat stressed particles were 
measured in A, SLO; B, FI and C, TLO methods. The linearity performance was evaluated for 
the full concentration range studied (101 to 103 particles/mL) and also per order of magnitude. 
Each linear fit parameter is represented in one axis of the radar plot. Scales were adapted to be 
common for all the instruments. The best linear profile was found in the case of TLO, with the 
smallest radar plot depicted area pointed to the r2 axis. 
 
evaluate the performance of the TLO method in this context, a stock solution of BSA protein particles 
was independently measured in SLO, TLO and FI instruments. Three different dilutions series were 
prepared using the initial stock concentration defined as per each respective technique   and the 
theoretical concentrations were compared to the experimentally measured ones (see Table S3.2). To 
analyse the data, a linear model was assumed and the descriptors of the fit (slope, m; intercept, b; 
coefficient of correlation, r2 and sum of squares total, SST) are presented in Figure 3.1 as radar plots 
(see also in Figure S3.1 and Table S3.3). Each axis have different scale (m 0-4; b 0-250; r2 0-1 and 
SST 301.5x106) adjusted so that the 12 representations displayed all the data. Thus, the smaller the 
plot area, the better the linear fit. Another advantage is that in contrast to other reports that consider 
only the coefficient of correlation value as reporter of the linear fit, this representation allows for a 
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Figure 3.3. Recovery profile. Independent dilution series of BSA heat stressed particles ranging 
from 10 to 10000 particles/mL were measured in A, SLO; B, FI and C, TLO methods. The 
horizontal axis represents the theoretical concentration (for all sizes present in sample) and the 
vertical axis represents the recovery (theoretical concentration/experimental concentration*100). 
An overestimation effect in the lower concentration range was found. TLO instrument however 
showed good recoveries over the full concentration range.  
 
stricter and more detailed evaluation of the linearity performance. For example, as can be seen in the 
case of FI measurements (Figure 3.2B), as the r2 improves from 101 to 103 particles/mL, (0.52 to 
0.88respectively), the SST worsens, (35000 to 1600000, respectively). It becomes also clear that at 
101 particles/mL not only the r2 is poor but also an overestimation of almost 4 fold should be expected 
(m = 3.92). Interestingly, for the TLO measurements at the three orders of magnitude tested, a good 
linear fit was found (as indicated by the single line pointing to the r2 axis of the radar plots, see Figure 
3.2C). Besides showing that sensor and instrument modifications in the new method improved the 
method linearity performance, this result also highlights that the dilution procedure and all the controls 
were successfully applied. Hence, this allowed us to exclude dilution artefacts and relate the observed 
response directly to instrumentation-related facts. 
The results of the recovery assessment (assessed as experimental concentration/theoretical 
concentration × 100) reported in Figure 3.2 also demonstrate exceptionally good performance of the 
TLO method. Whereas SLO and FI showed over counting effects (>150 %) around theoretical  
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Figure 3.4 Size distribution of protein particles. Size distribution of the same BSA stock sample 
measured in A, SLO; B, FI and C, TLO. FI reported the higher total counts followed by TLO and 
SLO. A typical protein particle size distribution skewed to the right can be seen. TLO reported a 
tailing effect towards larger species 
 
concentrations of 75 and 100 particles/mL, respectively, TLO showed good recoveries (85-130 %) 
along the entire dilution set. 
Size distribution 
A comparison between the particle size distribution measured by SLO, TLO and FI methods was 
carried out using BSA model particles. The results presented in Figure 3.4, showed some differences 
in the size distributions measured by the different instruments. Using SLO as a reference, counts for 
particles <5 µm were around 2 and 40 times higher for TLO and FI, respectively. On the other hand, 
for particles >5 µm, 120 and 9 fold times higher counts were found for TLO and FI, respectively.  
To further inquire if the tailing effect observed in TLO was related to possible instability of the BSA 
particles, the size distribution of the count standards measurements described in the counting accuracy 
section was analysed. As can be seen in each column of Figure S3.2, the reported size distribution for 
the same standard varied between instruments. Whereas SLO results showed the usual decay size 
distribution, certain tailing effect was confirmed for TLO and in a lower extent, also for FI. This 
suggests that the tailing effect is not related with particle instability or nature, but rather to intrinsic 
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Figure 3.5 Morphology impact. Comparison of the cumulative counts of A) mAb protein and B) 
protein-like ETFE particles measured with the SLO ; FI  and TLO  methods. For the 
ETFE model, similar results were found between TLO and FI for particles >5 µm 
 
method characteristics. The analysis of the proportion of the total size distribution within ± 10 % of 
the reported size revealed that the tailing effect was more pronounced as the particle size increases. 
For example, in the TLO measurement of 2 µm count standard that proportion was close to 90 % (low 
tailing effect) whereas for the 20 µm count standard it dropped down to only 40 % (severe tailing 
effect). One possible explanation for the tailing effect could be the increased flow rate that was 
implemented in this instrument modification (from 10 to 40 mL/min). Although the latter likely 
contributes to the better accuracy of TLO, perhaps lower/intermediate rates can be examined in the 
future. Taken together these results  demonstrate that despite the great improvements demonstrated by 
the excellent linearity and recovery profiles, the modified light obscuration method described here still 
presents challenges that remain to be addressed. Another interesting observation that can be made 
from the size distribution representation measured for the count standards is that although the same 
type of material was used in the three different measurements, only FI reported particles < ~2 µm for 
count standards of 5, 10, 15 and 20 µm, (see Figure S3.2). This can be explained by the detection of 
small, contaminating particles present in the standard solutions by FI. 
Particle morphology and concentration 
To further evaluate the instrument performance, morphology and concentration factors were 
considered. The goal was to understand if there were any attributes such as specific particle 
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Figure 3.6 Comparison of the particle counts reported by FI  and TLO  of 2 dilutions series 
of mAb particles independently prepared. The horizontal axis represents the different dilution 
samples from D1=7500 particles/mL to D12=10 particles/mL in steps of 2.5 increase fold 
(theoretical values). The vertical axis represents the experimental particle concentration for 
different bins as follows: A) 1-2 µm, B) 2-5 µm, C) 5-10 µm and D) 10-25 µm. A better 
agreement between the 2 methodologies was found for the lowest concentrations and largest 
sizes 
 
morphology, concentration and/or size range on which the TLO measurements showed a better 
agreement with the flow imaging technology. Such comparison would imply that implemented sensor 
and measurement’s modifications positively overcome the alleged drawbacks of the light obscuration-
based technique regarding the uneven optical density characteristic of protein particles. For the 
analysis of the morphology impact, mAb and ETFE (1) particle models were measured and the 
cumulative counts/mL was compared. The morphology characteristics of the particle models are 
described in Table S3.4. In general, mAb particles were less optically dense (more translucent) than 
the BSA particles used in this study. On the other hand, the ETFE particles presumably are highly 
stable (similar to latex beads) whilst retaining the typical morphology. The results of these 
measurements are presented in Figure 3.5. For both types of particles, FI reported the highest total 
counts of all three methods. This was also observed in the case of the BSA model particles (Figure 
3.4), implying morphology aspects do not impact the sensitivity of FI. However, the discrepancy 
between FI and TLO was far less pronounced in the case of ETFE particles (Figure 3.5B) than in the 
case of mAb particles (Figure 3.5A) with a ratio FI/TLO of 7 and 1158, respectively. This observation 
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can be attributed to the differences in the optical density between ETFE and proteinaceous particles 
smaller than 10 µm that still remain, although their shape is closely matched. (Figure S3.3).  
Finally, the concentration impact was evaluated using mAb particles and the dilution scheme approach 
previously described. In contrast to the experiment shown in Figure 3.3 (on which the recoveries of 
particle dilutions were also followed) in this part of the work the focus was not on the total counts > 1 
µm, but on defined size bins. Results are presented in Figure 3.6. The largest 10-25 µm particles, 
(Figure 3.6D), showed good agreement in all the concentration range tested. For the smallest particles 
1-2 µm (Figure 3.6A), such comparability was observed only at low concentrations (around samples 
D1 to D3). The discrepancies in the smallest size-ranges were not surprising considering the largest 
particle counts in these size-ranges and also the strong over counting effect already demonstrated by FI 
(Figure 3.2). One hint of the potential contribution of small contaminating particles to this effect is 
seen in Figure S3.2. Although the exact ranges might vary for a different particle model, the results 
presented in Figure 3.5 and Figure 3.6 demonstrate that good agreement between light obscuration and 
flow imaging can be achieved even when measuring highly translucent particles using the TLO 
instrument configuration when concentration and size ranges are considered.  
 
3.5 CONCLUSIONS 
We have evaluated a novel light obscuration sensor and measuring mode which minimizes the 
interference of particle morphology by means of changing the measuring configuration from 
“intensity” to “pulse”. The intended benefits of this approach were confirmed in terms of count 
accuracy, linearity and recovery as is indicated by the improved accuracy of counting polystyrene 
beads of 2 µm diameter and excellent linear and recovery response of protein particles in 
concentrations as low as 10 and up to 10000 particles/mL. Furthermore, it was demonstrated that 
despite the advantages that the flow-imaging technique offers, such as visualization of particles and 
characterization of particle morphology, an over counting effect is likely to be present. Thus, although 
flow imaging remains a valuable tool for particle characterization, its application to particle 
quantification remains to be evaluated. 
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 In contrast, the new modified light obscuration instrument demonstrated excellent accuracy, despite of 
the detected tailing which may need to be addressed in future instrument modifications (e.g. 
adjustments in the flow rate).  It was also shown that the time-resolved approach successfully 
diminishes the morphology and optical density influence in the particle detection by the light 
obscuration principle.  
Our work suggests that the pulse-width light obscuration-based approach offers major improvements 
for subvisible particle measurements in biotechnological therapeutic products by achieving a lower 
size limit of detection and elimination of particle morphology bias.  
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3.7 SUPPLEMENRATY MATERIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3.1 Several dilutions of BSA particles were prepared and measured in SLO ; FI  and TLO 
. Graphs show the scatter plots of the theoretical versus the experimental concentration. The dotted 
line represents the ideal case. TLO showed a good performance even in the very low concentration 
range. Different panel represent different theoretical concentration ranges (particles/mL) as follows: A, 
0-10000; B, 0-1000; C, 0-100. 
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Figure S3.2 The size distribution of the corresponding measurements displayed in Figure 2 is 
presented. Quantification limits to fit count (supplier recommendations as follows: >1.3 µm for 
2 µm; >3 µm for 5 µm; >7.5 µm for 10 µm and >10 µm for 15 µm and >15 µm for 20 µm) and 
size (authors’ recommendations: ±10 % of the reported size) specifications are displayed with 
continuous and dotted lines, respectively 
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Figure S3.3 Morphological analysis of the mAb and ETFE particles measured by FI. 
Comparison of the particle shape (Circularity, upper panel) and darkness/translucency (Intensity 
Min, lower panel) parameters measured by MFI or ETFE (light grey) and mAb (dark grey). The 
data distributions were summarized in bins of 2.5 micrometers 
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Table S3.1 Polystyrene count standards of different sizes and 3000 particles/mL were measured 
in SLO, FI, and TLO. The recoveries in particles/mL ± standard deviation of 3 independent 
measurements are presented. Supplier specifications are ±10% recovery. 
Standard 
Counting accuracy (recovery %) 
SLO FI TLO 
2 µm 1596 ± 97 2833 ± 101 2807 ± 142 
5 µm 2989 ± 75 3071 ± 58 2907 ± 36 
10 µm 3016 ± 19 3028 ± 67 3128 ± 129 
15 µm 2925 ± 24 2808 ± 27 3128 ± 129 
25 µm 2828 ± 53 2753 ± 68 3065 ± 13 
 
 
Table S3.2 Experimental concentrations of the dilution study. Theoretical and experimental 
concentration values of independent dilution sets of BSA particles measured in SLO, FI and 
TLO. For each dilution the mean and standard deviation of 3 measurements is presented 
 
 
 
 
 
 
 
 
 
 
 Experimental concentration* mean ± 
stdev of 3 measurements 
Theoretical concentration*  SLO FI TLO 
10 23 ± 6 435 ± 394 13 ± 173 
25 120 ± 61 174 ± 64 32 ± 99 
50 98 ± 16 408 ± 89 53 ± 103 
75 116 ± 16 563 ± 528 68 ± 9 
100 128 ± 26 387 ± 62 90 ± 47 
250 332 ± 27 420 ± 53 213 ± 25 
500 630 ± 72 478 ± 42 451 ± 28 
750 915 ± 64 664 ± 57 674 ± 5 
1000 1244 ± 75 832 ± 69 918 ± 15 
2500 2911 ± 140 1653 ± 177 2267 ± 9 
5000 5780 ± 124 5429 ± 2315 4546 ± 10 
7500 8363 ± 643 6116 ± 88 6825 ± 7 
10000 10339 ± 1350 7622 ± 248 8793 ± 4 
* particles/mL 
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Table S3.3 The response of the experimental versus the theoretical particle concentration was 
modelled to a linear fit. For each order of magnitude, 4 points were included, (full range 
included 12 points). The following output parameters of the linear fit are presented: slope (ideal 
m=1), intercept (ideal b=0), coefficient of correlation (ideal r2=1) and sum of squares total 
(ideal SST=0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrume
nt 
Linear fit 
parameter 
Full 
range 
10
1
 10
2
 10
3
 
SLO 
m 1.06 1.04 1.21 1.12 
b 112.29 47.95 19.00 81.16 
r2 1.00 0.43 1.00 1.00 
SST 420000 3500 410 16000 
FI 
m 0.58 3.92 0.32 0.70 
b 50.23 132.01 243.39 -32.01 
r2 1.00 0.52 0.90 0.88 
SST 12000000 35000 2900 1600000 
TLO 
m 0.89 0.84 0.91 0.91 
b 15.38 7.92 -5.75 1.09 
r2 1.00 0.98 1.00 1.00 
SST 42000 35 90 130 
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Table S3.4 Morphological characterization of the particle models used. Representative 
randomly selected FI images of the particle models used are presented. The first 100 particles 
detected in the run were analysed and mean ± standard deviation values of the morphological 
parameters are reported 
Size 
Morphological 
parameter 
BSA mAb ETFE 
 
  
   
1-2 µm 
ECD 1.24 ± 0.22 1.28 ± 0.25 1.27 ± 0.24 
Circularity 0.71 ± 0.08 0.78 ± 0.09 0.82 ± 0.06 
Aspect ratio 0.49 ± 0.15 0.65 ± 0.19 0.75 ± 0.14 
Intensity stdev. 9.53 ± 4.2 17.46 ± 11.36 18.73 ± 10.04 
 
 
 
 
 
 
 
2-5 µm 
ECD 2.93 ± 0.79 3.15 ± 0.86 3.08 ± 0.85 
Circularity 0.62 ± 0.08 0.73 ± 0.13 0.8 ± 0.09 
Aspect ratio 0.4 ± 0.13 0.62 ± 0.22 0.72 ± 0.16 
Intensity stdev. 17.68 ± 8.43 44.17 ± 31.83 58.72 ± 34.75 
 
 
 
 
 
 
 
  
5-10 µm 
ECD 6.82 ± 1.36 7.14 ± 1.42 7.08 ± 1.41 
Circularity 0.52 ± 0.1 0.69 ± 0.15 0.76 ± 0.11 
Aspect ratio 0.46 ± 0.2 0.61 ± 0.22 0.68 ± 0.16 
Intensity stdev. 26.28 ± 13.62 63.72 ± 44.04 89.56 ± 48.29 
 
 
 
 
 
 
 
  
10-25 µm 
ECD 14.12 ± 3.62 15.62 ± 4.22 14.26 ± 3.69 
Circularity 0.46 ± 0.14 0.59 ± 0.16 0.72 ± 0.11 
Aspect ratio 0.57 ± 0.22 0.49 ± 0.21 0.62 ± 0.16 
Intensity stdev. 43.53 ± 24.29 74.88 ± 46.39 127.57 ± 55.44 
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4.1 ABSTRACT 
Within the framework of particle characterization methods for Biotechnological 
products, the current study aimed to provide a description of the variables that affect 
the performance of the Nano Tracking Analysis technique. The method of tracking 
particles under Brownian motion as they interact with a laser beam was evaluated 
using a LM20 NTA instrument from NanoSight. Sample- and instrument-related 
variables were studied using different model protein formulations, polystyrene nano-
sized standards and one model of artificially generated protein particles. Experiments 
were designed to focus on dilution procedures, video recording settings and the 
precision of the size and concentration measurements. One of the study’s main 
findings is that high protein concentration, or high particle polydispersity (typical 
characteristics of a biotechnological therapeutic product), can compromise the 
interpretation of NTA results. Furthermore, this methodology demonstrated a high 
sensitivity towards slight changes in the user-defined parameters, leading to high 
variability of the measurements. Greater reliability was found in the size 
determinations. Finally, the uncertainty in the calculation of the sample volume that is 
analyzed was found to be the main downside of this technique. Several variables were 
found to interfere with the Nano Particle Tracking assessments. The proper inclusion 
of the considerations here outlined to the development of sample-specific methods 
will surely increase the understanding of the results and contribute to the better 
performance of the technique in the frame of research and development activities. 
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4.2 INTRODUCTION 
Nano Tracking Technology (NTA) is a technique capable of measuring single particles in solution and 
reporting size and concentration data. The basis of the technique is tracking of x, y coordinates of the 
particles’ Brownian motion for the calculation of the diffusivity (Dt) of individual particles: 
𝐷𝑡 =
(𝑥, 𝑦)2
4
 
NTA obtains the location of particles along the time (speed of the movements) using video recording. 
As signal enhancer, the instrument has a laser unit that applies light to the sample chamber that makes 
it interact with the surface of the suspended particles. When the light is scattered out of the particles, a 
charge-coupled device (CCD) (1) camera connected to a microscope objective generates a digital 
image. This image is then collected through many frames, creating a video of user-defined duration. 
Using an internal NTA algorithm, the tracking of each individual particle occurs, following user-
defined parameters: i) Detection threshold set to the minimum brightness as compared to the 
background, above which a pixel will be considered as a particle. The higher the value, the lower the 
number of particles detected for a given frame; ii) Blur set to the area in pixels around any detected 
particle centre in which changes in pixel intensity (as compared to the background) will be assumed to 
proceed from that specific particle centre. The higher the value, the lower the noisy particles detected; 
iii) Minimum expected particle size set to the distance in pixels in which a particle will be searched 
from frame to frame in order to construct its trajectory. Particle centres detected outside this area will 
be considered as independent centres. The higher the value, the smaller the search area; iv) Minimum 
track length set to the minimum number of consecutive frames, after which the tracked particle will be 
included in the analysis. The higher the value, the better the statistical robustness of the analysis. 
For size determinations, a hypothetical hard sphere that diffuses at the same speed of the tracked 
particles is assumed (2). Thus the hydrodynamic diameter (d) can be obtained according to a two-
dimensional modified version of the Stokes-Einstein equation by multiplying temperature (T) of the 
measurement by the Boltzmann constant (KB); and dividing by the product of pi (𝜋), sample viscosity 
(ɳ) and diffusivity (𝐷𝑡): 
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𝑑 =
𝑇𝐾𝐵
3𝜋ɳ𝐷𝑡
 
For count determinations the average particle abundance (average number of particles per frame) is 
divided by the sample volume analysed. 
In the field of Pharmaceutical Technology, NTA represents a potential methodology for the 
characterization of particulate matter in Biotechnological products. It has been used for several 
applications and summaries are available (3, 4).  Interesting examples of its use include the 
classification of aggregates in order to help develop protein formulation strategies (5); seeding studies 
that follow likely particle growth from nano to micron range (6); size characterization of particles 
immersed in biological fluid or in primary containers (7, 8).  
Although some partial evaluation studies have been published (9-13), the present paper aims for a 
guideline that can support the development of an adequate method for subvisible particle 
characterization using NTA. Two main aspects were considered: those inherent to the instrument itself 
and those imposed by the nature of the proteinaceous samples. Although our group has already 
conducted some research on this topic, (see Chapter 1 and Chapter 2), this present paper seeks to 
further explore specific effects and artefacts. 
 
4.3 MATERIALS AND METHODS 
Materials 
Different Roche-property proteins were used in the study as indicated in the text. Protein-1 is a low-
concentration 0.36 mg/mL pegylated protein of approximately 40 kDa. Protein-2 is a humanized 
monoclonal antibody of approximately 145 kDa, in a concentration of 180 mg/mL. Protein-3 is a 
humanized monoclonal antibody of approximately 149 kDa, in a concentration of 25 mg/mL. The final 
formulations were use freshly filtered through an 0.22 µm Millex GV PVDF Membrane (Merck 
Millipore Ltd, Ireland). Only for Protein-3 were two different stress models generated after filtration, 
as described later. National Institute of Standards and Technology (NIST) traceable polystyrene 
nanospheres size standards in an aqueous medium were purchased from Nanosphere Thermo 
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Scientific, Fremont, California USA. Particle free water was generated in house by filtration of 
degassed (Liqui-cel Membrane Contactors, Membrana; Germany) and bidestilated water through i) 
0.22 µm Millex GP PES Membrane (Merck Millipore Ltd, Ireland) and ii) 0.22 µm GP Stericup 
(Express Plus, Massachusetts, USA). 
Methods 
For the short-term stability studies, a recommended (5 °C), accelerated (25 °C/60% r.h.), and/or a 
stress condition (40 °C/75% r.h.) was used depending on the type of experiment and protein model. 
Total particle concentration and size distributions were analysed. For the dilution study using 
standards, nanoparticles of sizes 50 nm, 200 nm, 300 nm, 500 nm and 900 nm were used in a mixture 
of 10 %, 70 %, 12 %, 6 % and 2 % (v/v), respectively. This proportion was considered to be 
representative of what is typically found in polydisperse stressed protein samples (see Chapter 2). A 
final concentration of 1 x 109 particles/mL was adjusted assuming sphere volume for the particles and 
the solid content reported by the provider. From this stock, dilutions to achieve (7.5, 5.0, 2.5 and 1.0) x 
108 particles/mL were prepared using particle free water (0.02 um Anotop 25, Whatman, Glattbrugg, 
Switzerland). Each dilution was video recorded in 60 second triplicates i) keeping the shutter and gain 
parameters constant and  ii) making adjustments as needed according to the characteristics of each 
sample. The data was then analysed, comparing theoretical to experimental concentrations and that 
ratio was expressed as percentage. For the study of the video recording time and MES impact, 
artificially generated Protein-3 particles were used. Applied stress consisted of 2 h stirring a 5 mL 
sample in a 6 mL glass vial at 200 rpm in a magnetic multichannel stirring plate, using a Teflon bar of 
6 x 15 mm. The stock solution  along with 1:5; 1:10 and 1:80 dilutions (diluent was unstressed 
formulation 0.02 um Anotop 25, Whatman, Glattbrugg, Switzerland) were measured in triplicates at 4 
different video durations (10; 30; 60 and 90 s) and 8 different MES values (30; 50; 80; 100; 150; 200; 
250; 300 and 400). For the intermediate precision, 6x Protein-1 samples stored for 2 months at 5 °C 
were manually ejected into a Type I glass vial over a timespan of 20 to 25 seconds (s) each. Before 
measurements, pooled solutions were manually homogenized by repeated inversions of the vials. 
Intermediate precision was defined as the variance of the reported particle concentration values of 
triplicate consecutive measurements of identically prepared and independent samples performed by 
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different analysts on different days. For the video recording settings, 500 nm standard particles 
(Thermo Fisher Scientific) and the stressed model Protein-3 were used. Single measurements using all 
possible combinations of shutter (from 0 to 1000) and gain (from 0 to 400) in steps of approximately 
50 units were applied. The standard was properly diluted with water to achieve a final concentration of 
1 x 10 8 particles/mL, according to the solid content of the standard solutions given by the 
manufacturer, and density of 1.05 g/cm3 (according to the manufacturer’s certificate) for the 
polystyrene material. The stress condition on Protein-3 was applied by heating the formulation up to 
73 °C for 7minutes using a Thermostat station (Eppendorf, Germany).  
Nanoparticle Tracking Analysis (NTA) 
The Nanosight NS200, LM20 equipped with a 405 nm laser and the NTA 2.2 version was used. Video 
images were collected at 37.8 frames per second. The detailed instrument handling has already been 
reported (see Chapter 2). Briefly, before each measurement, chamber cleanness was verified using 
0.02 μm filtered water (Anotop 25, Whatman, Glattbrugg, Switzerland). Samples were injected using 1 
mL sterile syringes (Norm-Ject, HSW, Tuttlingen, Germany). The first volume was used to rinse out 
the flushing water, and with the remaining volume, one to three videos (as indicated in the text) of 60 
seconds were recorded using a replenished sample each time. Video recording parameters of shutter 
and gain were set to ensure that clear and sharp particle images were obtained. Initial gross focus was 
manually adjusted. Starting from shutter equals to zero, this value was increased until there were no 
new particles visible on the screen. Then, starting for gain equals to zero, this value was increased 
until the best possible contrast between the background and the particles was achieved. Final 
adjustments were done to find the best focus, shutter and gain combinations for the best screen 
visualization of particles. During the measurements, the temperature was recorded by a temperature 
sensor housed within the viewing unit of the instrument. Sample viscosity was determined using a 
cone rheometer instrument (Anton Paar AG Switzerland, Zofingen, Switzerland) at 29 and 23 Celsius 
degrees. Viscosity values in steps of 0.1°C were interpolated and product-specific viscosity tables were 
loaded in the instrument’s software. Video analysis settings were set as follows: detection threshold 
value was set so that the software recognized every actual particle centre with a red cross. The blur 
value was set so that the area around every particle was clear and without the presence of noise 
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particles (blue crosses). The applicability of these 2 settings was optimal for all video frames. The 
minimum track length was set to 10. The minimum expected particle size was set to automatic, so that 
the software calculated it based on the first 100 tracks. When video recording settings were similar, 
videos were analysed as batch, otherwise analysis parameters were optimized for each independent 
video. The summary data as .csv file as well as the 10 s video were generated for analysis. 
 
4.4 RESULTS  
Sample related considerations 
Scatter of oligomeric species The applicability of NTA to the analysis of proteinaceous particles 
frequently offers the challenge of high scatter species of sizes smaller than the lower 30 nm limit of 
detection. To demonstrate this effect, a Protein-1 sample was stored for one week at 40 °C. As can be 
observed in Figure 4.1, the quality of the video was poorer when compared with the non-stress control 
sample. Horizontal stripes appeared, resembling an “old-TV” effect. This compromised the clear 
visibility of all the particles present (see also Video 4.1 and Video 4.2). To a lesser extent, this 
phenomenon was also observed in a short-term stability study when a different Protein-2 was stored 
for two months at 5 °C and 25 °C (see Video 4.3 and Video 4.4). The analysis of those samples 
reported a total concentration of (16.3 ± 4.9 and 4.5 ± 3.2) x 106 particles/mL, respectively (Figure 
4.2A).  
Trying to improve the quality of the videos and reduce the signal of oligomeric species (see Figure 
S4.1), a 1:10 dilution with unstressed formulation was performed. Such treatment positively impacted 
the video recording step (see Video 4.5 and Video 4.6) with better image quality. Furthermore, the 
inconsistent trend of lower counts at higher temperatures was reversed with a total concentration of 
(122.13 ± 82 and 247.6 ± 58.7) x 106 particles/mL for the 5 °C and 25 °C storage conditions, 
respectively (Figure 4.2B). Although this could suggest an unmasking effect of actual present 
particles, our group’s recent publication had shown the likely over counting artefact that particle 
dilution can include in the analysis (see Chapter 2).  
The effect of particle dilution was further studied using a mixture of latex beads and a previously 
reported dilution protocol (see Chapter 2). From a stock solution containing a mixture of different  
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Figure 4.1 High scattering of oligomeric species. A low-concentration Protein-1 sample was 
stored for a week at A) 5 °C (control) and B) 40 °C (stress condition). The first frames of the 
NTA videos are presented. The old-TV effect in B) possibly compromises the good visibility of 
all the actual particles present. 
 
nanoparticles, four independent dilutions were prepared. Each sample was then analysed i) using 
shutter and gain parameters accordingly to the best adjustments as per each independent sample and ii) 
using the same shutter and gain parameters as the ones used to define the initial concentration of the 
stock. Interestingly, it was possible to achieve acceptable recoveries around 100% only when the 
camera level was kept constant and equal to the one t used for the analysis of the undiluted sample 
(open symbols in Figure 4.3C). By contrast, when the camera level was adjusted to be optimal for each 
sample, the expected over counting effect was confirmed (closed symbols in Figure 4.3C). This would 
suggest that shutter and gain parameters should be kept constant among family of samples. However, 
the comparison of the first recorded frame, when the camera level was optimized (Figure 4.3A), with 
the frames in which the camera level was kept constant (Figure 4.3B), showed that some actual 
particles present were missed. On the other hand, following vendor recommendations of 20 to 100 
centres per frame and more than 200 valid tracks to consider the analysis valid, both practices would 
be accepted (Figure 4.3E and Figure 4.3F). Notably, the size determinations remained stable 
independent of the recording adjustments (Figure 4.3D). 
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Figure.4.2 A Protein 2 formulation was stored for two months at 5 °C () and 25 °C (). 
Samples were measured directly (A) and after 1:10 dilution (B). Fresh and 0.02 µm filtered 
formulation was used as diluent (). An apparent unmasking effect can be observed after 
dilution. 
 
Video recording time and minimum expected particle size Video duration can be adjusted 
depending on sample concentration. For a low particle burden, the longest video length is 
recommended. By increasing the recording time, the number of possibly completed tracks also 
increases and enough statistical information is then collected to determine particle size and 
concentration. This aspect of the NTA system was challenged in terms of repeatability by using a 
highly concentrated sample and varying the video recording time from 10; 30; 60 and 90 seconds. 
Dilutions of 5; 10 and 80 fold were also measured.  
Results indicated that the video duration had a smaller impact on the size determinations (overall CV 
of 15 %), (Figure S4.2A) but strong impact on the concentration determination factors (overall CV of 
174 %). There was a tendency to apparent higher concentrations as the recording time increased, 
especially at higher dilution factors (Figure 4.4).  
The effect of the minimum expected particle size as a function of the video duration was also studied. 
Each sample was recorded at MES values of 30; 50; 80; 100; 150; 200; 250; 300 and 400. This is 
represented in the box plots of Figure 4.4. Concentration assessment was mostly independent of the 
MES value as indicated by the low variability of the assessments (except for the longest video duration  
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Figure 4.3 Video recording settings and accuracy of counting. Comparison of a mixture of latex 
particle beads measured in NTA when the video recording settings were adjusted for each 
independent sample (B, ) and when they were kept constant for all sample sets (A, ). Images 
show the first frame of the video per each dilution, in a decreasing concentration from left to 
right. Although both video recording modalities report the dilution tendency, very noticeable 
discrepancies can be observed in terms of recovery (C). Size determination (D) as well as the 
control parameters centres/frame (E) and valid tracks (F) were less sensitive to the adjustments. 
 
at the highest dilution factors). However, the size assessments, showed less robustness in front of MES 
changes. 
Instrument related considerations 
Precision In order to evaluate NTA robustness, two identically prepared Protein-1 samples stored for 
two months at 5 °C were measured independently on different days by different people. The quality of 
the videos recorded by each analyst was different (see Video 4.7 and Video 4.8) as well as the particle 
size distribution (see Figure S4.2). When a given video was analysed 
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Figure 4.4 Effects of different video recording durations on the concentration determinations of a 
stressed protein model measured undiluted and at 5; 10 and 80 fold diluted with unstressed 
formulation. Numbers from 1 to 9 indicate single independent measurements of the same sample 
at the following different Minimum Expected particle Size (MES) values: 30; 50; 80; 100; 150; 
200; 250; 300 and 400, respectively. 
 
either by Analyst 1 (A1) or Analyst 2 (A2), the variability associated with the particle count 
determinations was lower as compared to the opposite scenario in which either A1 or A2 analysed a 
self-recorded video or a video recorded by another(Figure 4.5 and Table 4.1). Although both the video 
recording and video analysis are important steps, this experiment demonstrates that video recording is 
the more critical. These results also show that, even with highly experienced analysts, the intermediate 
precision of the technique is poor. It is important to notice that the analytical software appeared to be 
powerful and capable enough to account for the video differences in terms of size determinations (CV 
between A1 and A2, 1 %). Interestingly, the operator manipulation includes high variability to the 
measurements mainly to the concentration determination (CV between A1 and A2, 20 %).  
Video recording settings From the previous experiments, it was found that choosing the right camera 
level is a sensitive parameter that can significantly vary the outcome of NTA measurements. Despite 
that, there is no clear guidance on how to select it and even highly experienced analyst have no 
standard optimal value settings. This becomes a critical point, especially when samples are not part of 
a stability study in which the unstressed material or the initial time point could serve as a reference. 
Consequently, a large scanning experiment was performed in which all possible combinations of  
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Figure 4.5 Intermediate precision – concentration assessment. The particle concentration of a 
protein sample independently assessed by two experienced analysts is presented.  X axis follows 
the nomenclature: “Analyst who performed the video recording/Analyst who performed the 
video analysis”. The variability of the measurements when a given video was analysed by 
different analysts (e.g. A1/A1 vs A1/A2) and the variability of the measurements when a 
designated person analysed either a self-recorded video or a video recorded by someone else (e.g. 
A1/A1 vs A2/A1) is presented as CV % values. More variability was found between videos 
recorded by different people. 
 
shutter (from 0 to 1000) and gain (from 0 to 400) were applied to the analysis of a 500 nm polystyrene 
sample at a concentration of 1 x 108 particles/mL. In Figure 4.6 the results in particles/mL and mean 
size are presented. The mean values of all tested combinations were sample concentration of (6.8 ± 
1.7)x 108 particles/mL and particle size of 432 ± 34 nm showing severe overestimation of the 
concentration and an undersizing by 13 % (Table 4.2).There was a broad range of possible shutter and 
gain combinations that fit the criteria of more than 200 completed tracks and 20-100 centres/frame for 
the analysis to be considered valid (black symbols in Figure 4.6). Interestingly, for a given gain value, 
small changes of 50 units in shutter consistently produced changes in the particle concentration (CV 
range 15-40 %) to a lesser degree, in the size determination as well (CV range 3-9 %) (Table 4.2). This 
effect was more pronounced in the largest gain values in which the number of invalid analysis also 
increased (grey symbols in Figure 4.6). Only around gain = 100 a certain stability was found in the 
concentration results. However, at this gain level the size results showed high variability. The opposite 
situation of stable results in terms of size, but high variability for the particle concentration assessment 
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was found at gain = 50. The same experiment was carried out using a model of artificially generated 
protein particles. In that case, the acceptance criteria for valid tracks and centres per frame constrained 
the possible adjustments to a much narrower window than that of the polystyrene measurements 
(Figure S4.6). Although in that range the concentration assessment was stable, the size determinations 
presented a much higher variability when compared to latex beads.  
Camera field of view To further investigate in the possible reasons for the results variability due to 
the video recording settings, the sample volume was analysed in greater detail. The sample chamber 
dimensions were 80 x 100 x 10 µm which gives a field of view of 8 x 10-8 mL. The consequences of 
measuring of such a small volume have been already discussed (see Chapter 1). One attempt to correct 
for this shortcoming was the injection of the sample using a pump to increase the amount of volume 
sampled. However, in our experience this was not enough to correct the low accuracy (Figure S4.3). 
Given the average counts of particles/frame and the equivalent particle concentration in the analysis 
report, it is possible to reverse calculate the volume that was assumed for each measurement. For 
example, in the case of the 500 nm particles measured at gain = 0 and shutter = 24, the average 
number of particles/frame was 7 and the reported concentration was 0.94 x 108. Thus a sample volume 
of 7.4 x 10-8 mL was estimated. In contrast, when gain = 0 and shutter = 1004, average number of 
particles/frame was 35 and the reported concentration was 5.49 x 108. Thus a sample volume of 6.5 x 
10-8 mL was estimated. This trend of lower apparent volumes as the shutter value increase was also 
found for the larger gain values (Figure 4.7 and Table S4.1). 
 
Table 4.1 Intermediate precision assessment. Video recording and video analysis parameters of the measurement 
of a protein sample identically prepared and independently measured by two different analysts on different days.  
Video recording 
 Analyst 1 (A1)  
 
Analyst 2 (A2) 
Video 1  Video 2  Video 3 Video 1  Video 2  Video 3 
Shutter 1265 
 
1265 
 
1265 299 
 
299 
 
299 
Gain  253  283  268  299  377  377 
Video analysis  A1 A2 
 
A1 A2 
 
A1 A2 
 
A1 A2 
 
A1 A2 
 
A1 A2 
Blur 7 7 7 7 7 7  7 9 7 9 7 9 
Detection Threshold  7 9 
 
8 11 
 
8 10  14 12 
 
14 13 
 
14 11 
Min Track Length  10 10 
 
10 10 
 
10 10 
 
10 10 
 
10 10 
 
10 10 
Min Expected Size  50 100 
 
50 100 
 
50 100  
 
100 50 
 
100 50 
 
100 100 
Results Mean Stdesv Mean Stdesv 
Concentration 2.66E+08 1.72E+07 3.58E+08 5.09E+07 
Size  139 30   141 28 
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Figure 4.6 Scanning of the video recording settings using latex beads. A 500 nm latex solution 
with a concentration of 1 x 10
8
 particles/mL was measured in NTA. Different video recording 
settings were applied to cover a broad combination of shutter and gain values. Each panel 
represents a fixed gain from 0 to 350 in steps of 50 units. The X axis represents a fixed shutter 
value from 0 to 1004 in steps of 50 units. The Y axis represents the concentration (upper row) 
and the size results (lower row). Considering limits of 20-100 centres/frame and more than 200 
completed tracks, valid  and invalid  tracks are presented.  
 
4.5 DISCUSSION  
Particle characterization in biotherapeutics covers a broad range of sizes from visible particulate 
matter (> 150 µm) down to oligomers or soluble aggregates (< 100 nm) (1). The Nanoparticle 
Tracking Technology (NTA) by NanoSight is capable of covering parts of the lower size range of 
interest (30 nm up to 1 µm) that before was only partially covered by other techniques like SEC or 
DLS. The theoretical basis of Brownian particle motion applied to size determinations has been 
broadly studied (2). Unpublished data from our lab suggests, however, that given the irregular shape of 
protein particles, the same estimations may be different when working with non-sphere and uneven 
optically dense particles. Furthermore, despite the great potentiality of NTA and the importance of 
collecting particle information in the nanometre range, in this study we explored specific effects that 
can influence the accuracy of the results. Such effects were divided in sample- and instrument-related. 
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The first part focused on the likely incompatibility of biotechnological samples analysed by NTA. The 
later in turn, describes a more in-depth analysis of the technique’s drawbacks that were outlined in 
recent publications (Chapter 1 and Chapter 2). The main sample-related issue appeared to be the 
typically high concentration of biotherapeutic samples. Although the monomer signal cannot be 
individually resolved, this weak scatter light can interfere with the resolution of other particles present. 
This phenomenon is normally accompanied with an increase in the percentage of oligomers detected 
by SEC (Figure S4.1) and produces the “old-TV” effect illustrated in Figure 4.1. This can be attributed 
to the noisy signal of these species resulting in poor video quality (Video 3 and Video 4). Furthermore, 
an apparent decrease in counts of around 70 % after two months storage at 25 °C could be detected 
(Figure 4.2A). This finding is in line with a previously reported stability study in which a different 
protein model showed a decrease in the particle concentration of 40 % and 80 % after two months 
storage at 25 °C and 40 °C, respectively (see Chapter 1). One common practice to improve the 
analysis of this type of samples is dilution with unstressed material (3, 4). By these means, soluble 
aggregates (oligomeric species) return to solution and the video recording improves. This step did, 
however, i) make particles appear sharper (Video 5 and Video 6) and ii) reverted the particle 
concentration assessment to the expected trend of higher counts at higher temperatures (Figure 4.2B). 
This unmasking effect is likely to add other artefacts. It is important to note that, besides particle 
dilution, this effect is also present within the stability studies in which any changes in the particle 
 
Table 4.2 Size and concentration results of the scanning experiment. 
Dispersion descriptors at fixed gain values of the size and concentration 
assessments of a latex bead sample measured at different shutter values 
ranging from 0 to 1006 in steps of 50 units. 
Gain 
 Size (nm)   Concentration (E8 particles/ml) 
 Mean Stdesv CV% Range
1 
  Mean Stdesv CV% Range
1 
0  470.6 15.7 3 58.6 
 
4.4 0.9 20 2.9 
50  453.5 16.6 4 66.4 
 
5.8 1.2 21 4.3 
100  458.3 20.7 5 83.6 
 
5.9 0.9 15 3.3 
150  455.2 11.5 3 40.2 
 
5.4 1.1 21 4.4 
200  434.6 25.5 6 106.4 
 
6.9 1.7 24 6.1 
250  412.1 35.4 9 112.8 
 
7.7 1.5 20 5.6 
300  406.3 24.3 6 67.4 
 
8.6 1.7 20 4.6 
350  371.3 34.4 9 86.8 
 
9.5 3.8 40 10.0 
1
 Max-Min 
 
134 4.5 DISCUSSION  
 
APPLICATION OF NOVEL TECHNIQUES FOR CHARACTERIZATION OF SUB-VISIBLE AND SUB-MICRON 
PARTICLES IN BIOPHARMACEUTICAL PREPARATIONS 
 
 
Figure 4.7 Sample volume as a function of gain and shutter. From the experiment reported in 
Figure 6 the ratio: (average number of centres per frame)/(concentration) was calculated to obtain 
the related sample volume (Y axis) as a function of all possible combinations of shutter (X axis) 
and gain (increasing from 0  to 350 in steps of 50 units) values. All values were inferior to 
the actual chamber volume of 0.08 nL (chamber dimensions: 80 µm x 100 µm x 10 µm). 
 
population will force the camera level to be adjusted. Furthermore, given the narrow concentration 
range in which NTA optimally works, some samples require dilution even without the oligomer scatter 
issue. One such artefact is the over counting that appears as the dilution factor increases. This 
detrimental effect in the counting accuracy of the technique was already described in Chapter 2. 
Another related artefact is the video recording parameters that diluted samples require as compared 
with the original, undiluted ones. As dilution makes the background clearer, higher shutter and gain 
values are generally needed to visualize all the particles present. This change in the camera level 
potentially compromise sample comparability. When a given sample was video-recorded by applying 
the shutter and gain settings that were optimal for the undiluted sample or by applying the new camera 
level necessary for the optimal visibility after dilution, the variability in the particle concentration 
assessment was higher than 30 %, with better accuracy for the former settings (Figure 4.3C). 
Interestingly, in terms of size the variability was lower than 8 % (Figure 4.3D). This suggests higher 
robustness in particle sizing rather than in particle counting for the NTA methodology. This statement 
is also supported by the lower variability obtained in the scanning experiment for the mean size values 
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(CV < 9 %) as compared to the particle concentration ones (CV > 15 %) (Figure 4.6 and Table 4.2). 
From this experiment, it becomes clear that the better practice is to keep the camera level unmodified 
and equal to that of the undiluted original sample. Despite the risk of missing actual present particles 
(Figure 4.3A-B), this will ensure a camera level comparability and thus comparability of the results as 
well.  
Both previously described effects, the over counting and the incomparable camera levels, are related to 
the field of view resulting from specific shutter and gain combinations. This was studied in the second 
part of this research paper where the focus was the instrument-related artefacts. To calculate sample 
volume, the X and Y axis are fixed by the dimensions of the sample chamber. However, the Z axis is 
defined by the depth of the laser beam and, thus, influenced by the magnitude of the video recording 
settings. As shown in Figure 4.6, NTA assumes a different volume per sample according to the shutter 
and gain values. That generates a specific apparent volume that can be as low as 0.005 nL (Table 
S4.1). However, the chamber dimensions (80 µm x 10 µm x 100 µm) are unchangeable and so is the 
0.08nL volume of the sample to be analysed. As the instrument does not correct for this, the detected 
number of particles is related to an erroneous lower volume which partially contributes to the over 
counting effect. Furthermore, it has to be considered that for a heterogeneous sample, the apparent 
volume in which a small particle is immersed is larger than that for a larger particle. This estimation is 
difficult to assess, though.  
One of the most generalized perceptions when working with NTA is the highly experienced analysts 
that the technique requires. However, the intermediate precision evaluation showed that, even for 
experienced analysts, the technique produces highly variable results. The fact that the methodology 
lacks of controls capable of guiding users to a standardized video recording procedure resulted in 
particle concentration differences of 21 % between the two Analysts (Table 4.1). (Interestingly, the 
impact on size determinations was minimal with a CV between Analyst 1 and Analyst 2 of only 1%. 
This result is in accordance with previously discussed results on which size showed also better 
robustness). The main difference was the shutter level that each analyst assigned (Analyst 1 = 1265 
and Analyst 2 = 299). After discussion with both analysts about the criteria they used to perform the 
video recording, we learned that Analyst 1 prioritized the contrast of the major particle population. 
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Analyst 2, on the other hand, paid greater attention to clear visibility and good recordings of all actual 
particles. Although the image quality of both sets of videos was highly similar (see Video 7 and Video 
8 as examples), the slightly brighter background obtained using a lower shutter value may have 
allowed the dimmest particles to be better recorded. This is reflected in the higher concentration and 
narrower size distribution obtained by Analyst 2 (Figure S4.2C) as compared to Analyst 1 (Figure 
S4.2A). Finally, this intermediate precision experiment showed that the NTA software has a good 
performance. Given a video, regardless of who performed the analysis, the results had low variability 
in terms of particle concentration with CV < 6 % (Figure 4.4). However, when a given person analysed 
a self-recorded video or a video recorded by another, the variability was much larger (CV > 20 %). 
This suggests that video recording is the most critical and user-dependent step. The same observations 
were also done for the size assessment (Figure S4.5). 
The experiments about the video recording settings (Figure 4.3) and the intermediate precision (Figure 
4.4) showed the importance of the right shutter and gain parameters selection. This will allow for good 
accuracy of counting, sample to sample comparability and high intermediate precision as 
demonstrated in the previously described experiments. To define the video recording parameters, a 
methodology comprising many variations was utilized in a scanning experiment (Figure 4.5 and 
Figure S4.3). This allowed all possible shutter and gain combinations to be tested. Although some 
combinations were clearly inappropriate and produced over exposed images (Figure S4.6), this 
approach defined a range in which shutter and gain changes produced no change in the concentration 
and size determinations. Such a range could be then defined as a range to limit all the possibilities for 
the comparable analysis of a family of samples (different time points, different dilutions, different 
analyst etc.). Surprisingly, the range that was identified to obtain relatively constant concentrations 
was different than the range needed to obtain constant size values. This means that although NTA is 
capable of giving both types of information, a different optimal setting is required for each one. In 
contrast to the experiment using polystyrene nanoparticles, the experiment with artificially generated 
protein showed a much narrower range for achieving a valid analysis. This can be attributed to 
differences in the refractive index of the protein particles and heterogeneity of the sample. This is also 
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consistent with other studies that reported different instrument performance depending on the particle 
nature (see Chapter 2). 
One of the most notable facts about the NanoSight Company is the number of NTA generations 
available on the market. Although the present evaluation was done using one of the first models, it is 
possible that some labs still work with the LM20 version. Maintaining an up-to-date particle 
laboratory requires a costly investment that, in some cases, is not easy to justify provided the 
immaturity of most of the incoming techniques. We are aware, however, that important improvements 
have been made to the NTA newest generation, e.g. automatic focus is now available.  
 
4.6 CONCLUSIONS 
The evaluation presented here demonstrates that NTA measurements are highly dependent on user-
selected settings. Therefore, the real meaning of any measurement has to be analysed in  a number of 
sample, instrument and analyst-related contexts. This may eclipse the relevance of the outcomes and, 
more importantly, the applicability of the technique in quality control environments. However, this 
technique offers flexibility in line with current research tasks. In this regard, the experimental 
evaluation of this technique might be useful in developing product-specific methods to support further 
nanoparticle characterization studies 
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Figure S4.1 Chromatograms of Protein-1 °C at 5 and 40 °C showing increase in high molecular 
weight species after stress. SE-HPLC is run on silica-based size exclusion column (TOSOHaas 
TSKgel G4000SWXL 7.8mm ID, 30 cm length) using isocratic elution with sodium phosphate 
buffer containing sodium chloride, diethylene glycol and ethanol. (0.02M sodium phosphate, 
0.15M sodium chloride, 1% V/V diethylene glycol, 10% ethanol v/v, pH 6.8). Chromatography 
was performed using a Waters 2695 HPLC Alliance System equipped with a Waters PDA 2996 
detector or with a Waters Dual Absorbance Detector 2487. The detection wavelength was set at 
210 nm with a flow rate of 0.4 mL/min 
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Figure S4.2 Size distribution of the intermediate precision assessment. The size distribution of a 
Protein-2 sample independently assessed by two experienced analysts is presented. Panel labels follow 
the nomenclature: “Analyst who performed the video recording/Analyst who performed the video 
analysis”. When two different people analyzed the same video, the size distribution showed small 
variations. By comparison, when the same person analyzed two different videos, major differences 
were observed. This experiment suggests that video recording is the most critical step to ensure 
measurement comparability.  
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Figure S4.3 Scanning of the video recording parameters using protein particles. The same sample of 
artificially generated protein particles of unknown concentration and size was measured several times 
in NTA. Different video recording settings were applied to cover a broad combination of shutter and 
gain values. Each panel represents a fixed gain from 0 to 350 in steps of 50 units. The X axis 
represents a fixed shutter value from 0 to 1004 in steps of 50 units. The Y axis represents the 
concentration (upper row) and the size results (lower row). Considering limits of 20-100 centers/frame 
and more than 200 completed tracks, valid  and invalid  tracks are presented. 
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Figure S4.4 NTA performance using pump. The accuracy of NTA was studied by following the 
recovery of artificially generated A) Protein-3 and B) BSA particles with the dilution scheme 
previously reported in Chapter 2. X axes represents the theoretical particle concentration per mL of 
each independent sample of the dilution set. Y axes represents the calculated recovery, (theoretical 
concentration/experimental concentration*100). Ideal recovery of 100% is represented with the 
continuous horizontal line. Video duration was 60 seconds. Samples were loaded into the chamber 
manually (), using a pump (). For the manual loading, the sample volume was limited by the 
chamber dimensions of 80 µm x 100 µm x 10 µm; a volume of 0.08 nL was analyzed. For the pump 
(Harvard apparatus catalog 98-4730, model B-57187) the loading speed was set to 20 units (1.1 x 10 -3 
mL/min); a volume of 110 nL was analyzed. Despite the increased volume that the use of the pump 
allows, severely overestimated counts (recoveries >>100%) were obtained regardless of the particle 
model and the loading method used. 
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Figure S4.5 Intermediate precision-size assessment. The particle mean size of a protein sample 
independently assessed by two experienced analysts is presented. X axis follows the nomenclature: 
“Analyst who performed the video recording/Analyst who performed the video analysis”. As in the 
case of the particle concentration assessment, the variability of the measurements when a given video 
was analyzed by different analysts (e.g. A1/A1 vs A1/A2) was lower than when a designated person 
analyzed either a self-recorded video or a video recorded by somebody else (e.g. A1/A1 vs A2/A1). 
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Figure S4.6 Scanning of the video recording settings using latex beads - examples of the first frame of the recorded videos. A latex solution was measured in NTA applying different video settings to 
cover a broad combination of shutter (from 0 to 1004 in steps of 50 units) and gain (from 0 to 350 in steps of 50 units) values. Images show the first frame of each of the collected videos.  
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Table S4.1 The sample volume which was measured as a function of the gain and shutter video recording parameters is reported. This calculated volume is the ratio 
between the reported number of particles per frame and the reported particles per mL.  A lower corrected concentration is obtained when a fixed measured volume of 0.08 
nL is assumed. 
Shutter  
Gain = 0 
 
Gain = 50 
 
Gain = 100 
 
Gain = 150 
 
#/frame 
#/mL1 
Vol4 
 
#/frame 
#/mL1 
Vol4 
 
#/frame 
#/mL1 
Vol4 
 
#/frame 
#/mL1 
Vol4 
Rep2 Corr3 Rep2 Corr3 Rep2 Corr3 Rep2 Corr3 
24 
 
7.000 0.940 0.875 0.074 
 
8.470 1.140 1.059 0.074 
 
20.140 2.720 2.518 0.074 
 
17.660 2.390 2.208 0.074 
56 
 
12.170 1.650 1.521 0.074 
 
17.450 2.370 2.181 0.074 
 
22.670 3.100 2.834 0.073 
 
27.030 3.700 3.379 0.073 
106 
 
15.000 2.040 1.875 0.074 
 
17.760 2.420 2.220 0.073 
 
34.040 4.740 4.255 0.072 
 
36.160 5.070 4.520 0.071 
156 
 
22.970 3.160 2.871 0.073 
 
19.310 2.660 2.414 0.073 
 
33.170 4.630 4.146 0.072 
 
22.730 3.210 2.841 0.071 
206 
 
27.960 3.900 3.495 0.072 
 
22.200 3.070 2.775 0.072 
 
31.300 4.440 3.913 0.071 
 
29.080 4.200 3.635 0.069 
256 
 
23.350 3.290 2.919 0.071 
 
29.480 4.260 3.685 0.069 
 
27.730 3.970 3.466 0.070 
 
35.020 5.240 4.378 0.067 
306 
 
22.740 3.200 2.843 0.071 
 
25.170 3.520 3.146 0.072 
 
37.800 5.630 4.725 0.067 
 
38.390 5.960 4.799 0.064 
356 
 
26.160 3.770 3.270 0.069 
 
32.980 4.840 4.123 0.068 
 
38.760 5.800 4.845 0.067 
 
31.660 4.730 3.958 0.067 
406 
 
23.680 3.340 2.960 0.071 
 
37.520 5.700 4.690 0.066 
 
42.370 6.580 5.296 0.064 
 
34.360 5.250 4.295 0.065 
456 
 
26.170 3.830 3.271 0.068 
 
30.240 4.480 3.780 0.068 
 
41.720 6.450 5.215 0.065 
 
34.880 5.330 4.360 0.065 
506 
 
29.130 4.340 3.641 0.067 
 
36.010 5.380 4.501 0.067 
 
39.950 6.360 4.994 0.063 
 
31.480 4.830 3.935 0.065 
556 
 
33.550 5.180 4.194 0.065 
 
38.820 6.070 4.853 0.064 
 
32.990 5.200 4.124 0.063 
 
32.470 5.180 4.059 0.063 
606 
 
29.180 4.390 3.648 0.066 
 
35.850 5.460 4.481 0.066 
 
40.100 6.580 5.013 0.061 
 
40.680 6.760 5.085 0.060 
656 
 
32.050 4.810 4.006 0.067 
 
35.710 5.620 4.464 0.064 
 
35.250 5.530 4.406 0.064 
 
35.370 5.780 4.421 0.061 
706 
 
38.760 6.130 4.845 0.063 
 
37.140 5.880 4.643 0.063 
 
38.060 6.020 4.758 0.063 
 
27.440 4.290 3.430 0.064 
756 
 
35.790 5.670 4.474 0.063 
 
40.420 6.580 5.053 0.061 
 
42.930 7.260 5.366 0.059 
 
29.940 4.690 3.743 0.064 
804 
 
29.270 4.480 3.659 0.065 
 
37.900 6.340 4.738 0.060 
 
38.950 6.640 4.869 0.059 
 
35.270 5.690 4.409 0.062 
854 
 
27.850 4.260 3.481 0.065 
 
42.180 7.450 5.273 0.057 
 
39.310 6.540 4.914 0.060 
 
37.310 6.350 4.664 0.059 
904 
 
28.700 4.470 3.588 0.064 
 
39.050 6.550 4.881 0.060 
 
36.310 5.930 4.539 0.061 
 
43.160 7.580 5.395 0.057 
954 
 
24.180 3.650 3.023 0.066 
 
42.900 7.380 5.363 0.058 
 
39.220 6.500 4.903 0.060 
 
41.330 7.120 5.166 0.058 
1004 
 
35.430 5.490 4.429 0.065 
 
45.620 7.860 5.703 0.058 
 
37.730 6.470 4.716 0.058 
 
36.050 6.370 4.506 0.057 
1 Concentration in (# of particles per mL) x 108    
2 Reported concentration 
3 Corrected concentration = (#/frame) / 0.08 nL 
4 Assumed volume in nL = (#/frame) / (reported concentration) 
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Table S4.1 continuation 
Shutter  
Gain = 200 
 
Gain = 253 
 
Gain = 300 
 
Gain = 350 
 
#/frame 
#/mL1 
Vol4 
 
#/frame 
#/mL1 
Vol4 
 
#/frame 
#/mL1 
Vol4 
 
#/frame 
#/mL1 
Vol4 
Rep2 Corr3 Rep2 Corr3 Rep2 Corr3 Rep2 Corr3 
24 
 
17.470 2.370 2.184 0.074 
 
21.290 2.900 2.661 0.073 
 
37.950 5.330 4.744 0.071 
 
7.560 5.330 0.945 0.014 
56 
 
25.570 3.520 3.196 0.073 
 
28.470 3.950 3.559 0.072 
 
46.580 6.930 5.823 0.067 
 
11.310 6.930 1.414 0.016 
106 
 
29.430 4.110 3.679 0.072 
 
40.380 5.850 5.048 0.069 
 
50.760 8.270 6.345 0.061 
 
14.800 8.270 1.850 0.018 
156 
 
30.100 4.270 3.763 0.070 
 
49.130 7.660 6.141 0.064 
 
51.720 9.150 6.465 0.057 
 
8.850 9.150 1.106 0.010 
206 
 
38.520 5.740 4.815 0.067 
 
46.540 7.530 5.818 0.062 
 
55.090 9.930 6.886 0.055 
 
4.800 9.930 0.600 0.005 
256 
 
42.620 6.640 5.328 0.064 
 
46.390 7.530 5.799 0.062 
 
55.120 9.900 6.890 0.056 
     306 
 
41.110 6.370 5.139 0.065 
 
52.400 9.040 6.550 0.058 
 
52.250 9.580 6.531 0.055 
     356 
 
39.660 6.260 4.958 0.063 
 
48.260 8.190 6.033 0.059 
 
47.910 9.830 5.989 0.049 
     406 
 
40.270 6.450 5.034 0.062 
 
51.320 9.140 6.415 0.056 
 
50.460 7.560 6.308 0.067 
     456 
 
36.320 5.950 4.540 0.061 
 
45.340 8.320 5.668 0.055 
 
67.500 11.310 8.438 0.060 
     506 
 
38.970 6.480 4.871 0.060 
 
47.320 8.800 5.915 0.054 
          556 
 
45.920 7.620 5.740 0.060 
 
50.580 9.540 6.323 0.053 
          606 
 
48.310 8.420 6.039 0.057 
 
43.000 8.180 5.375 0.053 
          656 
 
48.660 8.580 6.083 0.057 
 
40.360 7.910 5.045 0.051 
          706 
 
45.840 7.970 5.730 0.058 
 
44.380 9.020 5.548 0.049 
          756 
 
52.110 9.570 6.514 0.054 
 
36.370 7.550 4.546 0.048 
          804 
 
48.680 9.020 6.085 0.054 
 
39.380 7.800 4.923 0.050 
          854 
 
46.010 8.330 5.751 0.055 
 
26.840 4.790 3.355 0.056 
          904 
 
44.450 8.580 5.556 0.052 
               954 
 
38.440 7.530 4.805 0.051 
               1004 
 
35.220 6.780 4.403 0.052 
               1 Concentration in (# of particles per mL) x 108    
2 Reported concentration 
3 Corrected concentration = (#/frame) / 0.08 nL 
4 Assumed volume in nL = (#/frame) / (reported concentration) 
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III DISCUSSION 
Importance of a critical evaluation of subvisible particle counting techniques 
Particle profile in injections is an important quality attribute that involves a broad size range from tens 
of nanometers up to hundreds of micrometers (1, 2). Whilst visible particles (approx. > 100 µm) might 
represent a risk of capillary occlusion; subvisible particles (1 - 100 µm); submicrometer particles (100 
nm - 1 µm) and even nanometer particles (< 100 nm) are thought to be possible immunogenic 
enhancers (3). Hence, it is of the highest importance to have analytical tools to characterize particulate 
matter in liquid formulations. The visible range is much more developed and instruments to detect this 
particle sizes as well as compendial aspects (USP regulations (4)) are well established. However, the 
interest in the subvisible range is rather new and expanding. The likely biological consequences 
previously mentioned together with the emergence of analytical tools able to characterize subvisible 
particles smaller than 10 µm have motivated a great interest in extending the particle characterization 
to smaller sizes than the currently stipulated in the USP (5, 6). This tendency is mainly driven by 
health authorities. In practice, however, little was known about the suitability and added value of such 
extended studies when analysing biotechnological products. What is more, little was known about the 
analytical performance of the emerging instruments. Considerable research needs to be conducted 
before a complete understanding of the technique is achieved. 
The aforementioned necessity constituted the objective of the present dissertation. Besides the real 
clinical meaningfulness of proteinaceous sub visible particles, which is still to be clarified, the 
availability of new techniques offers interesting and challenging opportunities from the method 
development point of view. The present thesis was focused on increasing our understanding of basic 
principles and the likely applicability of the new techniques to the characterization of sub visible 
particles present in protein-based formulations. Over the course of this research, despite the fact that 
some strengths of the analytical toolbox under evaluation were confirmed, remaining challenges were 
also uncovered. On top of that, the collected knowledge can be applied to support better method 
development in the future. These aspects will be discussed in the following sections (see also Table 
III.a). 
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Analytical performance  
In order to provide a sound basis for analytical evaluation, general analytical method qualification 
principles were applied to the study of the new methods. They were classified in micron (assessment 
of particles between 1-100 µm) and submicron (assessment of particles between 100-1000 nm) 
methods. The thesis included light obscuration, and flow imaging for the first group and electro zone 
sensing, resonant mass frequency measurement and nano tracking analysis for the second group. 
Chapter 1 and Chapter 2 describe the pros and coins of every technique. Unlike other analytical 
techniques that have a narrow range of variability, particle counting instruments have many factors had 
to be considered as likely contributors to artefacts (particularly when used with protein solutions). The 
unstable nature of protein particles itself is one example. Hence, to include a broad and complete 
scenario, polystyrene beads -the most frequently used standard models- were complemented with and 
3 models of protein particles generated though different stress levels (therefore of different 
morphologies) were used. Although the experiments were designed so that the instrument response 
was independent of the sample handling (i.e. highly standardized procedures were implemented) some 
challenges were posed by the nature of the instruments and samples to evaluate. In the case of the 
precision evaluation, the small volume that some instruments required compromised the good 
representativeness of the sample. On the other hand, it was impossible to eliminate container to 
container variability, despite best sampling and pooling practices. For accuracy of sizing, although 
polystyrene standards are available at a broad range of sizes, they do not represent the morphological 
characteristics of protein particles. The generation of protein fractions sufficiently enriched to be used 
as size standards offers practical difficulties especially from stability aspects. The assessment of 
accuracy of counting and linearity offer the same difficulties with the additional issue that nano count 
standards made of polystyrene are not commercially available.  
Precision (Chapter 1) as well as accuracy (Chapter 2) results showed a bias towards particle nature 
with better results for homogeneous, spherical and optically dense material. Importantly, a statistical 
component was found to impact both performance parameters. Better precision and accuracy was 
found for those particle sizes mainly represented in the sample. Poor sampling procedures explained 
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Table III.a Summary of the main finding of this Doctoral research 
    Sizing   Counting   Linearity   Precision   Comments 
H
IA
C
 
 
* Oversizing effect for the 
lower size range covered 
by the technique. In the 
upper size range, an 
undersizing effect was 
found (see Figure 2.3)  
 
Remarkable performance 
at concentration bellow 
100 particles/mL 
 
Performance varied with 
respect to the particle 
type. In general acceptable 
at concentration higher 
than 1E2 particles/mL (see 
Figure S2.3) 
 
Acceptable for all sizes 
when particles are present 
at concentrations of at 
least  3000 particles/mL as 
verified using polystyrene 
standards (see Table 1.4) 
 
a) Precision at lower concentrations than 3000 
particles/mL not tested as such count standards 
are not available.  
b) Typical positive skewed particle size 
distributions of biotechnological samples 
suppose poor performance for the largest 
particles 
c) Improved performance when measuring the 
width of the signal (see Figure 3.1). Possible to 
lower size limit of detection (see Table S3.1) 
and increase accuracy of counting at 
concentrations as low as 10 particles/mL (see 
Figure 3.2 and Table S3.2) 
M
F
I 
 
 
Likely high method 
sensitivity towards small 
sizes (see Figure S3.2) 
   
a) For precision improvements method 
modifications (e.g. .increase of the sample 
volume) are possible 
See also comment a) and b) for HIAC 
C
C
 
 
 
  
 
Poorer performance as 
compared with micron 
methods. Except for 
polystyrene particles at the 
highest concentration 
range (see Figure S2.3) 
  
a) Likely mechanical stress when measuring 
highly fragile particles 
See also comment a) and b) for HIAC 
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Table III.a continuation 
 
 Sizing   Counting   Linearity   Precision   Comments 
R
M
M
 
  
Severe undersizing effect 
at all size and 
concentration levels 
  
Self limitant lower limit 
of detection (see Figure 
2.1) due to probabilistic 
effects (see Figure S1.1) 
and tiny sampling 
volume (see Table 1.5)   
  
 
Poorer performance as 
compared with micron 
methods. Except for 
polystyrene particles at 
the highest concentration 
range (see Figure S2.3) 
 
** Poor performance at 
all sizes  (see Table 1.3)  
a) Due to the probabilistic effect described in 
Figure 1.2 possible to improve precision 
performance if sample allows for long 
measurement time and hence high number of 
events is recorded. Not nanometer counts 
standards are available to test hypothesis. 
N
T
A
 
See * 
Acceptable only for 
highly concentrated 
(particles/mL > 1E8) 
samples (see Figure 2.1). 
For accurate count 
assessments, video 
recording settings should 
keep constant among 
family of samples (see 
Figure 4.3C) 
  
Video recording process 
is the main source of 
variability (see Figure 
4.5) 
See also ** 
  
a) Recommended as sizing rather than 
counting technique (see Figure 4.3) 
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Table III.a continuation 
  
  
  
Sizing 
  
  
Counting 
  
  
Linearity 
  
  
Precision 
  
  
Comments 
C
o
m
m
en
ts
 
  
A) Overcounting effect 
at the lower 
concentration range of 
each instrument 
especially for highly 
pliable particle (see 
Figure 2.1) and for the 
smallest sizes (see Figure 
S2.1b).   
B) Different accuracy 
profiles depending on 
particle characteristics 
(see Figure 2.1)  
C) In contrast to 
comment b) for HIAC 
and depending on 
particle type (see Table 
2.2), possible to obtain 
excellent recoveries (see 
Figure 2.2)  
D)  Discrete agreement 
between instruments 
when comparing upper 
concentration ranges of 
overlapping size range 
(see Figure 2.5) 
A) Similar to comment 
A) for the counting 
assessment, poor linear 
profiles at the lower 
concentration range of 
each instrument, 
especially for highly 
pliable particles (see 
Figure 2.4) 
B) For a given 
instrument, the linear 
range differ among 
different particle types 
(see Figure 2.4) 
A) Acceptable when 
extrapolation factors to 
report counts per mililiter 
of sample is 20x or 
smaller (Figure 1.1) 
B) Remarkable improve 
when sample-related 
variability (like 
differences between 
containers (Figure 1.3)) 
can be cross out by 
appropriate sampling 
methodologies 
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the effect – in the case of precision due to the tiny volume that the instruments measure and in the case 
of the accuracy due to the relative size distribution of the sample which in general is right skewed 
(larger sizes are poorly represented). Given that those two aspects are inherent characteristics of the 
instruments and samples, for the user, little is possible to do in order to improve analytical 
performance. As discussed in Chapter 1, increasing the measuring volume increases the measuring 
time to impractical durations. On the other hand, in Chapter 2, it was clearly shown that even with the 
use of latex beads the polydispersity of the sample will always represent a challenge for the instrument 
in terms of accuracy. The challenge that the typically low particle burden represents for the counting 
methods was also evident in terms of linearity (Chapter 2). Apart from the light obscuration method 
on which a sensor modification successfully improved the performance of the technique at 
concentration as low as 10 particles/mL (Chapter 3), all methods showed poor linearity in the 
respective lower concentration range. In some cases, a minimum concentration as high as 10^7 
particles/mL was required (Chapter 4). 
As single techniques cannot cover the full size range and provided that these techniques actually 
measure different properties, an inherent miscorrelation has to be accepted when combining different 
techniques. This was studied in Chapter 2 where not only different morphologies and instruments 
were compared but also a concentration gradient in particles/mL was evaluated. It was already 
reported that the size transition from technique to technique is not smooth (7). However, this can be 
modified depending on the amount of particles to be analysed. In general, better correlation was found 
between instruments when the higher concentration ranges of each one were into comparison. 
Biopharmaceutical products, however will exhibit low particle burden as exemplified in Chapter 1. 
The methodology that was applied to study the setup of specific instruments (e.g. the use of real 
products, artificially generated particle models, as well as bead standards) provides a highly 
integrative example on how to design such experiments and which variables to consider. However, 
from results in Chapters 1 and 2 it became evident that sample-specific method development is 
required. The implication is that general limits of quantification cannot be provided based on 
instrument performance alone, we have to consider the instrument to sample compatibility. Hence, the 
meaningfulness of such limits should be benchmarked not only in the historical values for the specific 
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product, but also in the evaluation of the instrument performance in front of the specific sample setup. 
This would imply exhaustive method development (as demonstrated in Chapter 4) that in a quality 
control environment is difficult to implement.  
Together with the number of particles, it is also important to define their nature and likely source. 
Particle characterization becomes a critical issue: whereas protein particles can be a trace of product 
instability, the presence of particles other than protein (e.g. silicon oil) might represent a container 
interaction which might or might not compromise the quality of the product when the source is well 
identified. That is the case of silicon oil particles that come from the inner coating layer that syringes 
have. The amount of silicon oil that can enter solutions depends on the speed of syringe ejection. Thus, 
this can represent an artefact if the speed is not kept constant throughout any particle characterization 
experiment (Chapter 1). In this frame, flow imaging technologies become highly important analytical 
tools. Their major strength is that these methods do not translate any particle property into a secondary 
signal to follow in order to provide particle counts by size. On the contrary, flow imaging technologies 
directly image particles. Limits of the technique are related to the optic capabilities of the camera set 
up. Consequently, particles smaller than 5 µm, although imaged, cannot be visually identified because 
the camera resolution is too low. In these cases the use of statistical filters that work with 
morphological descriptors are the option to improve particle identification (8-12). However, all those 
filters rely entirely on general particle descriptors. For example, intensity or aspect ratio values that do 
not take into account the effect of the media on the optical properties of the particles and hence the 
way they are imaged.  
The lack of adequate standards 
One of the main findings of this study is the description of how different the instrument performance 
can be depending on the type of particle to analyse. It was shown that the recovery and linear profiles 
appeared to be different depending on the use of polystyrene beads or the use of proteinaceous 
particles (Chapter 2). Furthermore, the artificially generated protein models that in turn showed 
different morphologies helped to establish that the latex beads standards can only reproduce protein 
profiles when the latter come from unrealistic high stress conditions. Provided that protein particles do 
not exist in a standard configuration, polystyrene beads represent the best option for normalized and 
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reproducible results when qualifying particle counting methods. However, the morphological 
differences existing between latex and protein particles will interfere in different degrees with the 
results depending on the method principle. Hence, deviations between size and count determinations 
of standards and proteinaceous material can be expected. The light obscuration principle is an example 
of this where the consequence is an undersizing effect (Chapter 3). Whereas the registered drop in 
voltage in the calibration curve comes from an optically dense and round particle (polystyrene beads), 
the same response in the case of a protein sample comes from an optically uneven and amorphous 
particle. The drop in voltage of those 2 particle types can only be equivalent when sphere morphology 
is assumed for the latter. Concomitantly with that assumption a “shrink” effect also occurs so that the 
optical density can be compared. A larger total surface area of a protein particle is required to generate 
a comparable voltage drop to that of a polystyrene bead with a comparable hydrodynamic radius. 
Another example is the coulter principle. There, not only morphology but particle pliability becomes a 
critical factor (Chapter 2). The technique is based on a pump that moves particles through an orifice. 
The response that is measured is the displaced volume that in turn originates resistivity changes. 
Whereas polystyrene standards are less affected by mechanical stress, protein particles may suffer 
from extended distortion. This was clearly shown when particles produced by relatively low stress 
level were measured in the coulter instrument. Similarly to the light obscuration principle, a 
discrepancy between standards and protein samples can be expected. 
Estimating the error due to standards-to-sample mismatching is difficult to assess. Some of the main 
complications come from the fact that proteinaceous particles exhibit a broad variety of morphologies. 
However, in some cases like in the light obscuration method, instrument modifications could improve 
this situation (Chapter 3). In a case in which that is not possible, the present research demonstrated 
that a particle- and instrument-specific analysis should be conducted to expose the likely misleading 
effects (Chapter 1-2). Another tool here exemplified is the use of dilutions series to generate samples 
of proper and meaningful concentrations (Chapter 2). Although it was also shown that dilutions are 
not recommended due to possible particle instability, when artefacts are well understood and dilutions 
carefully prepared, they help to study the performance of the instruments. 
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Recommended use of emerging orthogonal techniques  
The availability of new instruments have strongly motivated the interest in particles of sizes other 
(smaller) than >10 µm and >25 µm. However, over the course of this research, inherent instrument 
weaknesses were identified. Such characteristics will likely exclude these methods from integration 
into typical quality control systems. For example, some methods do not offer the possibility of 
performing daily suitability test or, when suitability tests are established, they may not completely 
reflect artefacts that are related with the nature of the sample (see section about standards). In other 
cases, blank measurements can overlap the historical values that are reported for the sample to 
measure (Chapter 1-2). On the other hand, as some instruments overlapped, major complications 
appeared when different instruments reported different numbers for the same particle sizes (Chapter 
1). Defining what the right values are is not useful as each instrument examines different 
characteristics of the particles that are then translated into size and counts results. Thus, outcomes will 
differ among each technique and assessments will not be interchangeable. The immaturity of the 
methods, however, was also exposed when in a stability study (Chapter 1) when some of them 
reported inconsistent trends along time and storage conditions. Some of the sources of error were 
identified (Chapters 1-2 and 4) and can be corrected. It was also possible to appreciate parallel trends 
between the compendial light obscuration method and e.g. flow imaging microscopy techniques. The 
real added value of implementing all the orthogonal methods then can still be topic of research. At the 
moment, their use constitutes an excellent tool for particle research and characterization. 
Light obscuration is the method of choice as it is for the USP. Although it also has some limitations, 
this technique is well understood. Such sound knowledge allows for instruments modifications that 
directly correct for some known downsides of the technique. For example, the accuracy of the 
technique for particles around 1-2 µm was improved by means of changing the measuring mode from 
height to width of the voltage pulse (Chapter 3). This result shows that despite how long light 
obscuration has been used; some opportunity for improvement remains. Those that are described in the 
present Thesis build upon the already solid foundation of using and understanding this particular 
technique. Furthermore, as i) studies had already stated the likely transition of submicron to micron 
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particles and ii) a clinical relevance of submicron particles is not defined yet, the assessment of micron 
particles by means of the compendial light obscuration technique might be sufficient. 
Future directions  
Instruments for particle counting are changing on a regular base. Within the timeframe of this doctoral 
thesis, three generations of nano tracking analysis systems and were available. In this specific 
example, the newer generations correct for some operator adjustments that before increased the 
variability of the measurements. Flow imaging technologies have also made changes pointing towards 
sample automation. Those examples show the great potential that particle counting instruments have 
and how actively the community is using them. Scientific conferences can also confirm this as today it 
is more and more frequently the inclusion of particle-expert panels. However it is also possible to 
sense the diverging opinions about the new methodologies. Whilst academic institutions (and 
manufactures) are continuously finding many applications, industry is reluctant to include them as 
regular analytical tools. The results presented in this doctoral thesis can verify both viewpoints. The 
technical options and flexibility of the instruments certainly offer exciting opportunities, yet in 
practice they lack the automated, straightforward implementation and the functional robustness that 
quality control tasks require. Surely, further studies on the use of the instruments as complementary 
analytical techniques, more case studies more technical development from manufacturing companies, 
will add illuminate the field. On the other hand; even before the real added value of the assessment of 
< 10 µm particles is defined, i.e. the biological role of such particles is completely understood, 
interesting studies can still be implemented. For example, besides sizing and counting, particle nature 
is an important attribute that can be further researched and implemented to support the identification 
of likely degradation or stress conditions that originate in the particulate matter. One good approach 
can be found in the resonant mass measurements. Differences in the density values between the types 
of particles which are present in the sample and also with respect to the media on which they are 
suspended allow their discrimination due to the consequent differences in buoyancy. However, a rather 
large minimum density difference has to be met to achieve proper population segregation and that is 
only possible for no more than 2 particle types. Perhaps further technical improvements could allow a 
higher number of density-base sorting channels. To date, the flow imaging technologies offer a similar 
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possibility by means of particle morphological descriptors and actual images. Discrimination between 
several populations is possible e.g. silicon oil droplets, air bubbles protein or glass particles. However, 
below 5 µm the visual judgment of the images is difficult due to the actual camera pixel resolution and 
even morphological filters that fail for the smallest particles. Improvements in the optical system will 
certainly help and a better particle differentiation can be obtained in combination with mathematical 
models. Using morphological descriptors it is possible to define boundaries between populations of 
particles. Although some statistical filters have been developed, the possibility of protein particle 
differentiation base on the specific stress condition that generated them (instead of simply from other 
particle nature) is an exciting opportunity.  
Another interesting area of research is the deeper understanding on the roots of instruments 
divergences. In the course of this dissertation it became clear that each particle counting instrument 
will report different concentration numbers for a given sample. Furthermore, several cases were 
presented suggesting that despite that fact, similar trends will be observed. Hence, finding possible 
correlations between the different instruments might shed light on how many and which analytical 
tools can characterize the particle content sufficiently. Such studies need to thoroughly examine the 
physical principles of each technique. That knowledge in combination with the analytical evaluation 
presented in this thesis will surely help the decision making process when defining strategies for 
particle characterization in biotechnological products. 
Finally, the present status of particle counting instrumentation only allows for encouraging their 
careful use and data interpretation as guidance for formulation-related development activities.  
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IV CONCLUSIONS 
Several new techniques for the research and characterization of sub visible particulate matter in 
parenteral formulations have been recently developed. The present work has outlined the 
complications that can be faced when using the new methodologies without a deep understanding of 
the specific sample and instrument configuration. A systematic evaluation of the applicability of such 
instruments was accomplished. The analytical performance was assessed considering particle 
morphologies; size ranges; concentration ranges and heterogeneity aspects that are likely present in 
protein therapeutic samples. As a result, a highly integrative overview was explored.  
Main findings pointed towards immaturity of most of the systems for inclusion as general tools for 
routine characterization.  On the one hand they do not correlate due to their different fundaments, but 
on the other hand they cannot be used independently as single techniques do not cover the full size 
range of interest. Importantly, particle detection was found to be biased towards probabilistic aspects 
with better analytical performance for those particles of sizes mainly represented in the sample. Both, 
low sampling volumes as well as the typically left skewed size distribution of protein particles were 
detected as main constraints for acceptable precision and accuracy performance. Low particle burden 
was also found to be challenging as over-counting effects were found in the lower concentration 
ranges of each method.  
Altogether, this research highlights the importance of exhaustive product specific method development 
before the implementation of any of the techniques. The analytical approach described here should 
serve as basis for further assessments on which the strengths and weaknesses here unveiled are 
considered. 
Once a deeper understanding of the different techniques was achieved, it was possible to develop tools 
to improve the applicability of the light obscuration and nano tracking analysis techniques. Light 
obscuration showed the better performance in comparison with the other techniques, thus an effort to 
lower the size and the concentration range of the technique was tested. Successfully, a time resolved 
measuring mode was implemented. In contrast, nano tracking analysis, showed the highest variability 
as a consequence of user-defined parameters, thus experiments were designed to guide the proper 
method development tasks when working with this technique.  
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Biotechnological products will continue their incursion into the pharmaceutical market. Several 
studies are ongoing to understand better the alleged immunogenicity of sub visible protein particles 
present in this type of formulations. While this particular research comes to concise findings, it is clear 
that any outcome should be accompanied with a sound analytical toolbox that allows for an accurate 
particle characterization. The general results of this research indicate that at the moment, however, 
only research activities can be supported with extensive method development studies.  
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